

Prof. Murat Terzi



Personal Information

Office Phone: [+90 0362 312 1919](tel:+9003623121919) Extension: 3077

Email: mterzi@omu.edu.tr

Web: <https://avesis.omu.edu.tr/mterzi>



International Researcher IDs

ScholarID: 0yHyABAAAAAJ

ORCID: 0000-0002-3586-9115

Publons / Web Of Science ResearcherID: AAA-1284-2021

ScopusID: 23062131200

Yoksis Researcher ID: 119309

Education Information

Doctorate, Ondokuz Mayıs University, Lisansüstü Eğitim Enstitüsü, Klinik Sinir Bilimleri (Dr), Turkey 2015 - 2020

Expertise In Medicine, Ondokuz Mayıs University, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Turkey 2000 - 2005

Undergraduate, Ondokuz Mayıs University, Tıp Fakültesi, Tıp Pr., Turkey 1994 - 2000

Biography

Born in 1976 in Trabzon, he completed his primary and secondary education at Samsun İlkadım Primary School and his high school education at Samsun 19 Mayıs High School. He started his higher education at Samsun Ondokuz Mayıs University Faculty of Medicine in October 1994. He completed his medical school education in Samsun Ondokuz Mayıs University Faculty of Medicine in 2000, neurology specialty education in 2005 and Clinical Neurosciences doctorate education in 2022. On March 14, 2006, he was promoted to Assistant Professor, on March 14, 2012 to Associate Professor and in March 2018 to Professor. He served his military service at Ankara Gülhane Military Medical Academy between 2007-2008. Since March 14, 2006, he has been a faculty member at Ondokuz Mayıs University Faculty of Medicine, Department of Neurology and since June 2018, he has been working as the Head of the Department of Neurology. He took part in different boards and commissions of our university and Faculty of Medicine in the fields of education, R&D and project development. Between 2017 and 2020, he served as Ondokuz Mayıs University Rector consultant and Clinical Research Ethics Committee member. Since 2019, he has been the Dean of Ondokuz Mayıs University Faculty of Health Sciences, since 2016 he has been the head of the Department of Neurosciences at Ondokuz Mayıs University Graduate Institute, since 2014 he has been responsible for the Faculty of Medicine Clinical Research Unit and University Education Commission membership, since 2017 he has been responsible for Ondokuz Mayıs University Neuroimmunology Laboratory. Since 2020, he has been on the board of directors of the Turkish Neurology Association and continues to serve as vice president. He is a member of Turkey Multiple Sclerosis Study Group, Turkey Neuroimmunology Study Group, Turkey Environmental Health and Occupational Diseases in Neurology Study Group and Turkey Quality of Life Study Group. He has worked as a primary investigator in more than 50 international projects. He has been involved in many domestic and international articles, book authorship and book chapter authorship, and papers presented in national and international congresses and scientific meetings, especially in the fields of multiple sclerosis, neuroimmunology, artificial intelligence and neuroscience, and his h index is 22. He worked as a consultant in

4 specialty theses completed in the field of neurology, 20 master's and 9 doctoral theses completed in the field of neurosciences. He is married and has two children.

Foreign Languages

English, B2 Upper Intermediate

Dissertations

Doctorate, Multipl skleroz ön tanısı ile izlenen hastalarda gözyaşı sıvısında oligoklonal bant varlığı, Ondokuz Mayıs University, 2022

Expertise In Medicine, Multipl skleroz hastalarında beyin omurilik sıvısı total tau protein düzeyi ve diffüzyon ağırlıklı beyin magnetik rezonans f  r  nt  leme ile olan iliřkisi, Ondokuz Mayıs University, Tıp Fak  ltesi, Dahili Tıp Bilimleri B  l  m  , 2005

Research Areas

Medicine, Neurology, Immunology, Neurosystems

Academic Titles / Tasks

Professor, Ondokuz Mayıs University, Tıp Fak  ltesi, Dahili Tıp Bilimleri B  l  m  , 2018 - Continues

Associate Professor, Ondokuz Mayıs University, Tıp Fak  ltesi, Dahili Tıp Bilimleri B  l  m  , 2012 - 2018

Assistant Professor, Ondokuz Mayıs University, Tıp Fak  ltesi, Dahili Tıp Bilimleri B  l  m  , 2006 - 2012

Research Assistant, Ondokuz Mayıs University, Tıp Fak  ltesi, Dahili Tıp Bilimleri B  l  m  , 2000 - 2005

Academic and Administrative Experience

Vice Rector, Ondokuz Mayıs University, 2023 - Continues

Ondokuz Mayıs University, 2019 - Continues

Ondokuz Mayıs University, 2018 - Continues

Ondokuz Mayıs University, 2017 - Continues

Ondokuz Mayıs University, 2017 - Continues

Ondokuz Mayıs University, 2016 - Continues

Ondokuz Mayıs University, 2016 - Continues

Courses

DEMYELİNATİNG DİSEASE OF CNTRAL NERVOUS SYSTEM, Undergraduate, 2019 - 2020, 2018 - 2019, 2017 - 2018, 2016 - 2017, 2015 - 2016

SANTRAL G  ÇS  ZL  K, Undergraduate, 2019 - 2020

SEREBRAL KORTEK VE BEYNİN ENTELEKT  EL İřLEVLERİ, Postgraduate, 2019 - 2020, 2018 - 2019, 2017 - 2018, 2016 - 2017

BRAİN STEAM, Undergraduate, 2019 - 2020, 2018 - 2019, 2017 - 2018, 2016 - 2017, 2015 - 2016, 2014 - 2015, 2013 - 2014

UZMANLIK ALAN DERSİ, Postgraduate, 2019 - 2020, 2018 - 2019, 2017 - 2018
TIBBİ ETİK, Undergraduate, 2019 - 2020, 2018 - 2019
MULTİPLE SCLEROSİS, Undergraduate, 2019 - 2020, 2018 - 2019, 2017 - 2018, 2016 - 2017, 2015 - 2016
DAHİLİ TIP BİLİMLERİ, Undergraduate, 2019 - 2020, 2018 - 2019, 2017 - 2018, 2016 - 2017, 2015 - 2016
BİLİŞSEL PSİKOLOJİDE SİSTEMLER VE MODELLER, Doctorate, 2019 - 2020, 2018 - 2019, 2017 - 2018, 2016 - 2017
BİLİMSEL ARAŞTIRMA YÖNTEMLERİ VE ETİK, Postgraduate, 2019 - 2020, 2018 - 2019, 2017 - 2018
BEYİN SAPI, Undergraduate, 2019 - 2020, 2018 - 2019, 2017 - 2018, 2016 - 2017, 2015 - 2016, 2014 - 2015, 2013 - 2014, 2012 - 2013, 2011 - 2012, 2010 - 2011, 2009 - 2010
KORTİKAL DUYULAR, Undergraduate, 2019 - 2020, 2018 - 2019, 2017 - 2018, 2016 - 2017, 2015 - 2016, 2014 - 2015, 2013 - 2014, 2011 - 2012, 2009 - 2010
MULTİPL SKLEROZ, Undergraduate, 2019 - 2020, 2018 - 2019, 2017 - 2018, 2016 - 2017, 2015 - 2016, 2014 - 2015, 2013 - 2014, 2012 - 2013, 2010 - 2011, 2009 - 2010, 2006 - 2007
TIP VE MEDYA, Undergraduate, 2019 - 2020, 2018 - 2019, 2017 - 2018, 2016 - 2017, 2015 - 2016, 2014 - 2015, 2013 - 2014
DENEYİM Mİ? KANIT MI?, Undergraduate, 2019 - 2020, 2018 - 2019
SANTRAL SİNİR SİSTEMİ DEMİYELİNİZAN HASTALIKLARI, Undergraduate, 2019 - 2020, 2018 - 2019, 2017 - 2018, 2016 - 2017, 2015 - 2016, 2014 - 2015, 2013 - 2014, 2012 - 2013
UZMANLIK ALAN DERSİ, Doctorate, 2019 - 2020, 2018 - 2019, 2017 - 2018
SANTRAL VERTİGOYA YAKLAŞIM, Undergraduate, 2019 - 2020, 2018 - 2019, 2017 - 2018, 2016 - 2017, 2015 - 2016
CORTİCAL SENSATION, Undergraduate, 2019 - 2020, 2018 - 2019, 2017 - 2018, 2016 - 2017, 2015 - 2016, 2014 - 2015, 2013 - 2014
SANTAL GÜÇSÜZLÜK, Undergraduate, 2018 - 2019, 2017 - 2018, 2016 - 2017, 2015 - 2016, 2014 - 2015, 2013 - 2014
Spinal Deney Yöntemler, Postgraduate, 2016 - 2017
Sinirbilimde Araştırma Yöntemleri, Doctorate, 2016 - 2017
Motor Kontrol Fizyolojisi, Postgraduate, 2016 - 2017
Santral Sinir Sistemi Nöroanatomisi, Postgraduate, 2016 - 2017, 2015 - 2016, 2014 - 2015
Spinal Deneyisel Modeller, Doctorate, 2016 - 2017, 2015 - 2016, 2014 - 2015
Santral sinir sistemi Nöroanatomisi, Doctorate, 2014 - 2015
Central nervous system immunology, Undergraduate, 2013 - 2014
status epileptikus, Undergraduate, 2013 - 2014, 2011 - 2012, 2010 - 2011, 2008 - 2009
parsiyel epileptik nöbet, Undergraduate, 2013 - 2014, 2012 - 2013, 2011 - 2012, 2010 - 2011
Sinir sistemi hastalıklarında tetkikler, Doctorate, 2013 - 2014
Santral sinir sistemi İmmünolojisi, Undergraduate, 2013 - 2014
Sinir sistemi deneysel yöntemleri, Postgraduate, 2013 - 2014, 2012 - 2013
Sinir sistemi Anatomisi, Postgraduate, 2012 - 2013
Sinir sistemi Anatomisi, Doctorate, 2012 - 2013

Published journal articles indexed by SCI, SSCI, and AHCI

- I. **Comparing dysphonia severity index, objective, subjective, and perceptual analysis of voice in patients with multiple sclerosis and healthy controls**
Yaşar Ö., Tahir E., Erensoy İ., Terzi M.
MULTIPLE SCLEROSIS AND RELATED DISORDERS, vol.82, 2024 (SCI-Expanded)
- II. **Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom**
Spelman T., Herring W. L., Acosta C., Hyde R., Jokubaitis V. G., Pucci E., Lugaresi A., Laureys G., Havrdova E. K., Horakova D., et al.
JOURNAL OF MEDICAL ECONOMICS, vol.27, no.1, pp.109-125, 2024 (SCI-Expanded)
- III. **The effect of sleep disorders on quality of life in patients with epilepsy: A multicenter study from Turkey**

Akdağ G., Canbaz Kabay S., Bican Demir A., Ergin Bakar E., Koç G., Üstün Özek S., Küçük A., Ünsal M. A., Neyal A., Florentina Ateş M., et al.

Epilepsy and Behavior, vol.150, 2024 (SCI-Expanded)

- IV. **Risk of secondary progressive multiple sclerosis after early worsening of disability**
Dzau W., Sharmin S., Patti F., Izquierdo G., Eichau S., Prat A., Girard M., Duquette P., Onofrj M., Lugaesi A., et al.
Journal of Neurology, Neurosurgery and Psychiatry, vol.94, no.12, pp.984-991, 2023 (SCI-Expanded)
- V. **Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial**
Diouf I., Malpas C. B., Sharmin S., Roos I., Horakova D., Kubala Havrdova E., Patti F., Shaygannejad V., Ozakbas S., Eichau S., et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, vol.94, pp.1004-1011, 2023 (SCI-Expanded)
- VI. **Severe disease reactivation in seropositive neuromyelitis optica spectrum disorders patients after stopping eculizumab treatment**
Şen S., Tuncer A., Terzi M., BÜNÜL S. D., Ozen-Acar P., Altunrende B., ÖZAKBAŞ S., TÜTÜNCÜ M., UYGUNOĞLU U., Akman-Demir G., et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS, vol.79, 2023 (SCI-Expanded)
- VII. **The risk of secondary progressive multiple sclerosis is geographically determined but modifiable**
Sharmin S., Roos I., Simpson-Yap S., Malpes C., Sanchez M. M., Ozakbas S., Horakova D., Havrdova E. K., Patti F., Alroughani R., et al.
BRAIN, vol.146, no.11, pp.4633-4644, 2023 (SCI-Expanded)
- VIII. **Teriflunomide and Time to Clinical Multiple Sclerosis in Patients with Radiologically Isolated Syndrome: The TERIS Randomized Clinical Trial**
Lebrun-Fréney C., Siva A., Sormani M. P., Landes-Chateau C., Mondot L., Bovis F., Vermersch P., Papeix C., Thouvenot E., Labauge P., et al.
JAMA Neurology, vol.80, no.10, pp.1080-1088, 2023 (SCI-Expanded)
- IX. **Dietary Inflammatory Index score and its association with body mass index, body fat percentage, body fat mass, and lipid profile in patients with multiple sclerosis**
KAYA S., UZDİL Z., Shivappa N., HEBERT J. R., SOKÜLMEZ KAYA P., Terzi M.
Turkish Journal of Medical Sciences, vol.53, no.5, pp.1155-1165, 2023 (SCI-Expanded)
- X. **Disability accrual in primary and secondary progressive multiple sclerosis**
Harding-Forrester S., Roos I., Nguyen A., Malpas C. B., Diouf I., Moradi N., Sharmin S., Izquierdo G., Eichau S., Patti F., et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, vol.94, no.9, pp.707-717, 2023 (SCI-Expanded)
- XI. **Newly Diagnosed Tumefactive Demyelinating Lesion and Multiple Sclerosis After COVID-19 Infection**
ERDOĞAN T., Kocer B., Şen S., Balci B. P., Terzi M.
NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY, vol.60, no.3, pp.223-230, 2023 (SCI-Expanded)
- XII. **Use of follow-on fingolimod for multiple sclerosis: Analysis of effectiveness and patient reported outcomes in a real-world clinical setting**
Altunan B., Ünal A., EFENDİ H., Köseoğlu M., Terzi M., Kotan D., Tamam Y., BOZ C., GÜLER S., TURAN Ö. F., et al.
Multiple Sclerosis and Related Disorders, vol.77, 2023 (SCI-Expanded)
- XIII. **Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis**
Roos I., Hughes S., McDonnell G., Malpas C. B., Sharmin S., BOZ C., Alroughani R., Ozakbas S., Buzzard K., Skibina O., et al.
JAMA NEUROLOGY, vol.80, no.8, pp.789-797, 2023 (SCI-Expanded)
- XIV. **Impact of COVID-19 vaccination or infection on disease activity in a radiologically isolated syndrome cohort: The VaxiRIS study**
Cohen M., Thomel-Rocchi O., SIVA A., Okuda D. T., Karabudak R., EFENDİ H., Terzi M., Carra-Dalliere C., Durand-Dubief F., Thouvenot E., et al.
Multiple Sclerosis Journal, vol.29, no.9, pp.1099-1106, 2023 (SCI-Expanded)
- XV. **Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation**
Zhu C., Kalincik T., Horakova D., Zhou Z., Buzzard K., Skibina O., Alroughani R., Izquierdo G., Eichau S., Kuhle J., et al.

JAMA Neurology, vol.80, no.7, pp.739-748, 2023 (SCI-Expanded)

- XVI. **mRNA versus inactivated virus COVID-19 vaccines in multiple sclerosis: Humoral responses and protectivity—Does it matter?**
Tütüncü M., Demir S., Arslan G., Dinç Ö., Şen S., GÜNDÜZ T., Uzunköprü C., Gümüş H., Tütüncü M., Akçin R., et al.
Multiple Sclerosis and Related Disorders, vol.75, 2023 (SCI-Expanded)
- XVII. **The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis**
BOZ C., ÖZAKBAŞ S., Terzi M., Karabudak R., Sevim S., Turkoglu R., Soysal A., Balci B. P., EFENDİ H., TURAN Ö. F., et al.
NEUROLOGICAL SCIENCES, vol.44, pp.2121-2129, 2023 (SCI-Expanded)
- XVIII. **Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis**
Diouf I., Malpas C. B., Sharmin S., Roos I., Horakova D., Havrdova E. K., Patti F., Shaygannejad V., ÖZAKBAŞ S., Izquierdo G., et al.
EUROPEAN JOURNAL OF NEUROLOGY, vol.30, no.4, pp.1014-1024, 2023 (SCI-Expanded)
- XIX. **Is Mediterranean diet associated with multiple sclerosis related symptoms and fatigue severity?**
Ertaş Öztürk Y., Helvacı E. M., Sökülmez Kaya P., Terzi M.
NUTRITIONAL NEUROSCIENCE, vol.26, no.3, pp.228-234, 2023 (SCI-Expanded)
- XX. **Clinical and Demographic Characteristics and Two-Year Efficacy and Safety Data of 508 Multiple Sclerosis Patients with Fingolimod Treatment**
Terzi M., Helvacı E. M., Şen S., Boz C., Cilingir V., Akçalı A., Beckmann Y., Uzunköprü C., Turkoglu R., Yüceyar N., et al.
Noropsikiyatri Arsivi, vol.60, no.1, pp.23-27, 2023 (SCI-Expanded)
- XXI. **Ublituximab: A new FDA-approved anti-CD20 mAb for relapsing forms of multiple sclerosis**
Terzi M.
MULTIPLE SCLEROSIS AND RELATED DISORDERS, no.2211-0348, pp.1-4, 2023 (SCI-Expanded)
- XXII. **Comparative effectiveness in multiple sclerosis: A methodological comparison**
Roos I., Diouf I., Sharmin S., Horakova D., Havrdova E. K., Patti F., Shaygannejad V., ÖZAKBAŞ S., Izquierdo G., Eichau S., et al.
Multiple Sclerosis Journal, vol.29, no.3, pp.326-332, 2023 (SCI-Expanded)
- XXIII. **External validation of a clinical prediction model in multiple sclerosis**
Moradi N., Sharmin S., Malpas C. B., Shaygannejad V., Terzi M., BOZ C., Yamout B., Khoury S. J., Turkoglu R., Karabudak R., et al.
MULTIPLE SCLEROSIS JOURNAL, vol.29, no.2, pp.261-269, 2023 (SCI-Expanded)
- XXIV. **Switching to natalizumab or fingolimod in multiple sclerosis: Comparative effectiveness and effect of pre-switch disease activity**
Spelman T., Horakova D., ÖZAKBAŞ S., Alroughani R., Onofrij M., Kalincik T., Prat A., Terzi M., Grammond P., Patti F., et al.
Multiple Sclerosis and Related Disorders, vol.70, 2023 (SCI-Expanded)
- XXV. **Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry**
Spelman T., ÖZAKBAŞ S., Alroughani R., Terzi M., Hodgkinson S., Laureys G., Kalincik T., Van Der Walt A., Yamout B., Lechner-Scott J., et al.
Multiple Sclerosis Journal, vol.29, no.2, pp.221-235, 2023 (SCI-Expanded)
- XXVI. **Relationship between stigma and symptom burden in patients with multiple sclerosis**
YENİ K., Özdelikara A., Terzi M.
Neurology Asia, vol.28, no.2, pp.359-366, 2023 (SCI-Expanded)
- XXVII. **Reliability and validity of the Turkish version of speech pathology-specific questionnaire for persons with multiple sclerosis (SMS-TR)**
Erensoy İ., Yaşar Ö., Şahvelioğlu Ö., İnan K., Terzi M.
INTERNATIONAL JOURNAL OF SPEECH-LANGUAGE PATHOLOGY, vol.25, no.6, pp.841-848, 2023 (SCI-Expanded)
- XXVIII. **Heterogeneity on long-term disability trajectories in patients with secondary progressive MS: a latent class analysis from Big MS Data network**

Signori A, Lorscheider J, Vukusic S, Trojano M, Iaffaldano P, Hillert J, Hyde R, Pellegrini F, Magyari M, Koch-Henriksen N, et al.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, vol.94, no.1, pp.23-30, 2023 (SCI-Expanded)

- XXIX. **The Effect of Smoking on Inactivated and mRNA Vaccine Responses Applied to Prevent COVID-19 in Multiple Sclerosis**

Şen S, Arslan G, TÛTÛNCÛ M, Demir S, DİNÇ H. Ö, Gunduz T, Uzunkopru C, GÛMÛŞ H, Tutuncu M, Akcin R, et al. NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY, vol.60, no.3, pp.252-256, 2023 (SCI-Expanded)

- XXX. **Retrospective analysis of effectiveness of fingolimod in real life setting in Turkey (REFINE)**

TUNCER A., KÛRTÛNCÛ M., TERZİ H. M., UYGUNOĞLU U., GÖNCÛOĞLU C., YÛCEYAR N., EKMEKÇİ Ö., Turkoglu R., SOSYAL A., KÖSEOĞLU M., et al.

Turkish Journal of Medical Sciences, vol.53, no.1, pp.323-332, 2023 (SCI-Expanded)

- XXXI. **Early onset multiple sclerosis and the effect of disease onset age on neurological disability in multiple sclerosis**

Usta N. C., BOZ C., Terzi M.

CLINICAL NEUROLOGY AND NEUROSURGERY, vol.224, 2023 (SCI-Expanded)

- XXXII. **Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis**

Lefort M., Sharmin S., Andersen J., Vukusic S., Casey R., Debouverie M., Edan G., Ciron J., Ruet A., De Sèze J., et al. BMC Medical Research Methodology, vol.22, no.1, 2022 (SCI-Expanded)

- XXXIII. **Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis**

Roos I., Malpas C., Leray E., Casey R., Horakova D., Havrdova E. K., Debouverie M., Patti F., De Seze J., Izquierdo G., et al.

Neurology, vol.99, no.17, 2022 (SCI-Expanded)

- XXXIV. **Stereological and comparative evaluation of the carpal tunnel in patients with carpal tunnel syndrome using magnetic resonance images**

Ak Güven G., Emirzeoğlu M., Terzi M., Selcuk M. B., Şahin B.

JOURNAL OF THE ANATOMICAL SOCIETY OF INDIA, vol.71, no.4, pp.272-278, 2022 (SCI-Expanded)

- XXXV. **The effect of a psychoeducation program based on the rational emotional behavioral approach in individuals with multiple sclerosis diagnosis: A randomized controlled trial**

Sahin E., Güleç Keskin S., Terzi M.

PERSPECTIVES IN PSYCHIATRIC CARE, vol.58, no.4, pp.1449-1459, 2022 (SCI-Expanded)

- XXXVI. **Early predictors of disability in paediatric multiple sclerosis: evidence from a multi-national registry**
- Sharmin S., Malpas C. B., Roos I., Diouf I., Alroughani R., ÖZAKBAŞ S., Izquierdo G., Eichau S., Horakova D., Havrdova E. K., et al.

Journal of Neurology, Neurosurgery and Psychiatry, vol.93, no.12, pp.1322-1329, 2022 (SCI-Expanded)

- XXXVII. **Machine-learning-based prediction of disability progression in multiple sclerosis: an observational, international, multi-center study**

Terzi M.

medRxiv, no.1, pp.1-53, 2022 (SCI-Expanded)

- XXXVIII. **Confirmed disability progression as a marker of permanent disability in multiple sclerosis**

Sharmin S., Bovis F., Malpas C., Horakova D., Havrdova E. K., Izquierdo G., Eichau S., Trojano M., Prat A., Girard M., et al.

European Journal of Neurology, vol.29, no.8, pp.2321-2334, 2022 (SCI-Expanded)

- XXXIX. **Association of Latitude and Exposure to Ultraviolet B Radiation With Severity of Multiple Sclerosis An International Registry Study**

Vitkova M., Diouf I., Malpas C., Horakova D., Havrdova E. K., Patti F., ÖZAKBAŞ S., Izquierdo G., Eichau S., Shaygannejad V., et al.

NEUROLOGY, vol.98, no.24, 2022 (SCI-Expanded)

- XL. **Effect of self-acupressure on fatigue in patients with multiple sclerosis**

YENİ K., TÛLEK Z., Terzi M.

- XLII. **10.1016/j.cmpb.2021.106479**
Terzi M.
Computer Methods and Programs in Biomedicine, pp.1-3, 2022 (SCI-Expanded)
- XLIII. **Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom**
Herring W. L., Zhang Y., Tempest M., Pearson I., Freudensprung U., Acosta C., Dort T., Hyde R., Horakova D., Trojano M., et al.
PharmacoEconomics, vol.40, no.3, pp.323-339, 2022 (SCI-Expanded)
- XLIV. **The Turkish experience of COVID-19 infection in people with NMOSD and MOGAD: A milder course?**
Şen S., Tuncer A., ÖZAKBAŞ S., Uzunkopru C., Baba C., Demir S., BECKMANN Y., GÜMÜŞ H., Arslan G., Kilic A. K., et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS, vol.58, 2022 (SCI-Expanded)
- XLV. **Coexistence of restless legs syndrome and multiple sclerosis aggravates anxiety and depression A coexistência da síndrome das pernas inquietas e esclerose múltipla agrava ansiedade e depressão**
Sevim S., DEMİRKIRAN D. M., Terzi M., Yüceyar N., Taşdelen B., İDiman E., KÜRTÜNCÜ M., BOZ C., Tuncel D., Karabudak R., et al.
Arquivos de Neuro-Psiquiatria, vol.80, no.2, pp.168-172, 2022 (SCI-Expanded)
- XLVI. **Effects of nutrition education given to persons with multiple sclerosis and their families on diet quality and anthropometric and biochemical measurements**
Uzdil Z., TÜRKER P. F., Terzi M.
REVISTA DE NUTRICAÇÃO-BRAZILIAN JOURNAL OF NUTRITION, vol.35, 2022 (SCI-Expanded)
- XLVII. **A year with the fear of COVID-19 in multiple sclerosis patients: Examination of depression, sleep quality and quality of life before and after the pandemic**
YENİ K., TÜLEK Z., Terzi M.
MULTIPLE SCLEROSIS AND RELATED DISORDERS, vol.57, 2022 (SCI-Expanded)
- XLVIII. **Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS**
Kalincik T., Kister I., Bacon T. E., Malpas C. B., Sharmin S., Horakova D., Kubala-Havrdova E., Patti F., Izquierdo G., Eichau S., et al.
Multiple Sclerosis Journal, 2022 (SCI-Expanded)
- XLIX. **Evaluation of the relationship between anxiety and nutritional habits in Turkish patients with multiple sclerosis during the Covid-19 outbreak**
KAYA S., Uzdil Z., ZARARSIZ G., Sökülmez Kaya P., Terzi M.
REVISTA DE NUTRICAÇÃO-BRAZILIAN JOURNAL OF NUTRITION, vol.35, 2022 (SCI-Expanded)
- L. **Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab: subgroup analysis of REGAIN and its extension study**
Siddiqi Z. A., Nowak R. J., Mozaffar T., O'Brien F., Yountz M., Patti F., Mazia C. G., Wilken M., Wilken M., Barroso F., et al.
Muscle and Nerve, vol.64, no.6, pp.662-669, 2021 (SCI-Expanded)
- LI. **Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts**
Sharmin S., Lefort M., Andersen J. B., Leray E., Horakova D., Havrdova E. K., Alroughani R., Izquierdo G., ÖZAKBAŞ S., Patti F., et al.
CNS Drugs, vol.35, no.11, pp.1217-1232, 2021 (SCI-Expanded)
- LII. **Long-term outcomes in patients presenting with optic neuritis: Analyses of the MSBase registry**
Kenney R., Liu M., Patil S., Alroughani R., Ampapa R., Bergamaschi R., BOZ C., Butzkueven H., Gomez J. C., Cartechini E., et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES, vol.430, 2021 (SCI-Expanded)
- LIII. **Tofacitinib enhances remyelination and improves myelin integrity in cuprizone-induced mice**
Gunaydin C., Önger M. E., Avci B., Bozkurt A., Terzi M., Bilge S. S.
IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY, vol.43, no.6, pp.790-798, 2021 (SCI-Expanded)

- LIII. Utilization of Multiple Sclerosis Therapies in the Middle East Over a Decade: 2009–2018**
Moradi N, Sharmin S, Malpas C, ÖZAKBAŞ S, Shaygannejad V, Terzi M, BOZ C, Yamout B, Turkoglu R, Karabudak R, et al.
CNS Drugs, vol.35, no.10, pp.1097-1106, 2021 (SCI-Expanded)
- LIV. Determinants of therapeutic lag in multiple sclerosis**
Roos I, Leray E, Frascoli F, Casey R, Brown J. W. L., Horakova D., Havrdova E. K., Debouverie M., Trojano M., Patti F., et al.
Multiple Sclerosis Journal, vol.27, no.12, pp.1838-1851, 2021 (SCI-Expanded)
- LV. Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression**
De Brouwer E., Becker T., Moreau Y., Havrdova E. K., Trojano M., Eichau S., ÖZAKBAŞ S., Onofrij M., Grammond P., Kuhle J., et al.
Computer Methods and Programs in Biomedicine, vol.208, 2021 (SCI-Expanded)
- LVI. The effectiveness of natalizumab vs fingolimod—A comparison of international registry studies**
Andersen J. B., Sharmin S., Lefort M., Koch-Henriksen N., Sellebjerg F., Sørensen P. S., Hilt Christensen C. C., Rasmussen P. V., Jensen M. B., Frederiksen J. L., et al.
Multiple Sclerosis and Related Disorders, vol.53, 2021 (SCI-Expanded)
- LVII. The outcome of a national MS-Covid-19 study: What the Turkish MS cohort reveals?**
Sen S., Karabudak R., Schiavetti I., Demir S., ÖZAKBAŞ S., Tutuncu M., Balci B. P., Turan O. F., Uzunkopru C., Koseoglu M., et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS, vol.52, 2021 (SCI-Expanded)
- LVIII. The efficacy of rituximab in patients with neuromyelitis optica spectrum disorder: A real-world study from Turkey**
Uzunköprü C., Tütüncü M., GÜNDÜZ T., Gümüş H., Şen S., Demir S., Çınar B. P., Türe H. S., UYGUNOĞLU U., Toğrol R. E., et al.
International Journal of Clinical Practice, vol.75, no.7, 2021 (SCI-Expanded)
- LIX. Natalizumab, Fingolimod, and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis**
Yeh W. Z., Widyastuti P. A., Van der Walt A., Stankovich J., Havrdova E., Horakova D., Vodehnalova K., ÖZAKBAŞ S., Eichau S., Duquette P., et al.
Neurology, vol.96, no.24, 2021 (SCI-Expanded)
- LX. Long-Term Safety and Efficacy of Eculizumab in Aquaporin-4 IgG-Positive NMOSD**
Wingerchuk D. M., Fujihara K., Palace J., Berthele A., Levy M., Kim H. J., Nakashima I., Oreja-Guevara C., Wang K., Miller L., et al.
Annals of Neurology, vol.89, no.6, pp.1088-1098, 2021 (SCI-Expanded)
- LXI. Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis**
Le M., Malpas C., Sharmin S., Horáková D., Havrdova E., Trojano M., Izquierdo G., Eichau S., ÖZAKBAŞ S., Lugaresi A., et al.
Multiple Sclerosis Journal, vol.27, no.5, pp.755-766, 2021 (SCI-Expanded)
- LXII. Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years**
Kalincik T., Diouf I., Sharmin S., Malpas C., Spelman T., Horakova D., Havrdova E. K., Trojano M., Izquierdo G., Lugaresi A., et al.
Neurology, vol.96, no.5, 2021 (SCI-Expanded)
- LXIII. Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension**
Mantegazza R., Wolfe G. I., Muppidi S., Wiendl H., Fujita K. P., O'Brien F. L., Booth H. D., Howard J. F., Mazia C. G., Wilken M., et al.
Neurology, vol.96, no.4, 2021 (SCI-Expanded)
- LXIV. Treatment Response Score to Glatiramer Acetate or Interferon Beta-1a**
Bovis F., Kalincik T., Lublin F., Cutter G., Malpas C., Horakova D., Havrdova E. K., Trojano M., Prat A., Girard M., et al.

NEUROLOGY, vol.96, no.2, 2021 (SCI-Expanded)

- LXV. **Benefits of eculizumab in AQP4+neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial**
Palace J., Wingerchuk D. M., Fujihara K., Berthele A., Oreja-Guevara C., Kim H. J., Nakashima I., Levy M., Terzi M., Totolyan N., et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS, vol.47, 2021 (SCI-Expanded)
- LXVI. **Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial**
Cree B. A. C., Cutter G., Wolinsky J. S., Freedman M. S., Comi G., Giovannoni G., Hartung H., Arnold D., Kuhle J., Block V., et al.
The Lancet Neurology, vol.19, no.12, pp.988-997, 2020 (SCI-Expanded)
- LXVII. **Association of Sustained Immunotherapy with Disability Outcomes in Patients with Active Secondary Progressive Multiple Sclerosis**
Kalincik T., Lizak N., Malpas C. B., Sharmin S., Havrdova E. K., Horakova D., Izquierdo G., Eichau S., Lugaresi A., Duquette P., et al.
JAMA Neurology, vol.77, no.11, pp.1398-1407, 2020 (SCI-Expanded)
- LXVIII. **Screening of dysphagia by DYMUS (Dysphagia in multiple sclerosis) and SWALQoL (Swallowing quality of life) surveys in patients with multiple sclerosis**
Tahir E., Kavaz Uştu E., Kemal Ö., Şen S., Terzi M.
MULTIPLE SCLEROSIS AND RELATED DISORDERS, vol.45, 2020 (SCI-Expanded)
- LXIX. **Methylprednisolone Concentrations in Breast Milk and Serum of Patients with Multiple Sclerosis Treated with IV Pulse Methylprednisolone**
Karahan S. Z., BOZ C., Terzi M., Aktoz G., Şen S., Ozbudun B., Caglar A., Sener M.
CLINICAL NEUROLOGY AND NEUROSURGERY, vol.197, 2020 (SCI-Expanded)
- LXX. **Delay from treatment start to full effect of immunotherapies for multiple sclerosis**
Roos I., Leray E., Frascoli F., Casey R., Brown W. J., Horakova D., Havrdova E. K., Trojano M., Patti F., Izquierdo G., et al.
Brain, vol.143, no.9, pp.2742-2756, 2020 (SCI-Expanded)
- LXXI. **Ofatumumab versus Teriflunomide in Multiple Sclerosis**
Terzi M.
The new england journal of medicine, pp.546-557, 2020 (SCI-Expanded)
- LXXII. **The Effectiveness of New Adiposity Indices on Plasma Lipid Profile in Patients with Multiple Sclerosis: A Cross-Sectional Study with A Body Shape Index, Body Roundness Index, and Visceral Adiposity Index**
Uzdil Z., KAYA S., Sökülmez Kaya P., Terzi M., Dunder E.
MULTIPLE SCLEROSIS AND RELATED DISORDERS, vol.43, 2020 (SCI-Expanded)
- LXXIII. **Consistent improvement with eculizumab across muscle groups in myasthenia gravis**
Mantegazza R., O'Brien F. L., Yountz M., Howard J. F., Gabriel Mazia C., Wilken M., Barroso F., Saba J., Rugiero M., Bettini M., et al.
Annals of Clinical and Translational Neurology, vol.7, no.8, pp.1327-1339, 2020 (SCI-Expanded)
- LXXIV. **'Minimal symptom expression' in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab**
Jacob S., Fujita K. P., O'Brien F., Howard J. F., Mazia C. G., Wilken M., Barroso F., Saba J., Rugiero M., Bettini M., et al.
Journal of Neurology, vol.267, no.7, pp.1991-2001, 2020 (SCI-Expanded)
- LXXV. **'Is RLS a harbinger and consequence of MS?: Striking results of the 'RELOMS-T' study'**
Sevim S., DEMİRKIRAN D. M., Terzi M., YÜCEYAR A. N., Tasdelen B., Idiman E., Kurtuncu M., BOZ C., TUNCEL D., Karabudak R., et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS, vol.42, 2020 (SCI-Expanded)
- LXXVI. **Early clinical markers of aggressive multiple sclerosis**
Malpas C. B., Manouchehrinia A., Sharmin S., Roos I., Horakova D., Havrdova E. K., Trojano M., Izquierdo G., Eichau S., Bergamaschi R., et al.

Brain, vol.143, no.5, pp.1400-1413, 2020 (SCI-Expanded)

- LXXXVII. **Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder**
Kunchok A., Malpas C., Nytrova P., Havrdova E. K., Alroughani R., Terzi M., Yamout B., Hor J. Y., Karabudak R., BOZ C., et al.
Multiple Sclerosis and Related Disorders, vol.38, 2020 (SCI-Expanded)
- LXXXVIII. **Risk of secondary progressive multiple sclerosis: A longitudinal study**
Fambiatos A., Jokubaitis V., Horakova D., Havrdova E. K., Trojano M., Prat A., Girard M., Duquette P., Lugaresi A., Izquierdo G., et al.
MULTIPLE SCLEROSIS JOURNAL, vol.26, no.1, pp.79-90, 2020 (SCI-Expanded)
- LXXXIX. **A Multicenter International Study to Evaluate Different Aspects of Relationship Between MS and Pregnancy**
Terzi M.
Multiple Sclerosis and Related Disorders, pp.1-2, 2020 (SCI-Expanded)
- LXXX. **A 12-month, Open Label, Multicenter Pilot Study Evaluating Fingolimod Treatment in terms of Patient Satisfaction in Relapsing Remitting Multiple Sclerosis Patients FINE Trial**
Akman Demir G., Turkoglu R., SAİP S., YÜCEYAR A. N., EFENDİ H., TURAN Ö. F., AĞAN YILDIRIM K., Terzi M., BOZ C., Tuncer A., et al.
NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY, vol.56, no.4, pp.253-257, 2019 (SCI-Expanded)
- LXXXI. **Differences Between General Neurologists and Multiple Sclerosis Specialists in the Management of Multiple Sclerosis Patients: A National Survey**
Kurtuncu M., Tuncer A., UYGUNOĞLU U., Caliskan Z., Kokenli Paksoy A., EFENDİ H., SAĞDUYU KOCAMAN A., Ozcan C., Terzi M., TURAN Ö. F., et al.
NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY, vol.56, no.4, pp.269-272, 2019 (SCI-Expanded)
- LXXXII. **Comparative analysis of fingolimod versus teriflunomide in relapsing-remitting multiple sclerosis**
BOZ C., Terzi M., Ozer B., Turkoglu R., Karabudak R., EFENDİ H., Soysal A., Sevim S., Altintas A., Kurne A., et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS, vol.36, 2019 (SCI-Expanded)
- LXXXIII. **Ecilizumab improves fatigue in refractory generalized myasthenia gravis**
Andersen H., Mantegazza R., Wang J. J., O'Brien F., Patra K., Howard J. F., Mazia C. G., Wilken M., Barroso F., Saba J., et al.
Quality of Life Research, vol.28, no.8, pp.2247-2254, 2019 (SCI-Expanded)
- LXXXIV. **Ecilizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder**
Pittock S. J., Berthele A., Fujihara K., Kim H. J., Levy M., Palace J., Nakashima I., Terzi M., Totolyan N., Viswanathan S., et al.
NEW ENGLAND JOURNAL OF MEDICINE, vol.381, no.7, pp.614-625, 2019 (SCI-Expanded)
- LXXXV. **Susac Syndrome: Clinical characteristics, diagnostic findings and treatment in 19 cases**
ZENGİN KAZANCI S., BOZ C., Saip S., Kale N., Demirkaya S., Celik Y., Demir S., Kurne A., ÖZBEK S., Terzi M.
Multiple Sclerosis and Related Disorders, vol.33, pp.94-99, 2019 (SCI-Expanded)
- LXXXVI. **Long-term safety and efficacy of ecilizumab in generalized myasthenia gravis**
Muppidi S., Utsugisawa K., Benatar M., Murai H., Barohn R. J., Illa I., Jacob S., Vissing J., Burns T. M., Kissel J. T., et al.
Muscle and Nerve, vol.60, no.1, pp.14-24, 2019 (SCI-Expanded)
- LXXXVII. **Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis**
Kalincik T., Kubala Havrdova E., Horakova D., Izquierdo G., Prat A., Girard M., Duquette P., Grammond P., Onofrj M., Lugaresi A., et al.
Journal of Neurology, Neurosurgery and Psychiatry, vol.90, no.4, pp.458-468, 2019 (SCI-Expanded)
- LXXXVIII. **Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study**
Nguyen A., Havrdova E. K., Horakova D., Izquierdo G., Kalincik T., van der Walt A., Terzi M., Alroughani R., Duquette P., Girard M., et al.
Multiple Sclerosis and Related Disorders, vol.28, pp.235-243, 2019 (SCI-Expanded)
- LXXXIX. **Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive**

Multiple Sclerosis

Brown J. W. L., Coles A., Horakova D., Havrdova E., Izquierdo G., Prat A., Girard M., Duquette P., Trojano M., Lugaresi A., et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, vol.321, no.2, pp.175-187, 2019 (SCI-Expanded)

- XC. **Association of Inflammation and Disability Accrual in Patients with Progressive-Onset Multiple Sclerosis**
Hughes J., Jokubaitis V., Lugaresi A., Hupperts R., Izquierdo G., Prat A., Girard M., Duquette P., Grand'Maison F., Grammond P., et al.
JAMA Neurology, vol.75, no.11, pp.1407-1415, 2018 (SCI-Expanded)
- XCI. **Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis**
Kalincik T., Jokubaitis V., Spelman T., Horakova D., Havrdova E., Trojano M., Lechner-Scott J., Lugaresi A., Prat A., Girard M., et al.
Multiple Sclerosis Journal, vol.24, no.12, pp.1617-1626, 2018 (SCI-Expanded)
- XCII. **Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis**
Terzi M.
the new england journal of medicine, pp.1017-1027, 2018 (SCI-Expanded)
- XCIII. **Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy**
Kister I., Spelman T., Patti F., Duquette P., Trojano M., Izquierdo G., Lugaresi A., Grammond P., Sola P., Ferraro D., et al.
Journal of the Neurological Sciences, vol.391, pp.72-76, 2018 (SCI-Expanded)
- XCIV. **Safety of IV pulse methylprednisolone therapy during breastfeeding in patients with multiple sclerosis**
BOZ C., Terzi M., Karahan S. Z., Sen S., Sarac Y., Mavis M. E.
MULTIPLE SCLEROSIS JOURNAL, vol.24, no.9, pp.1205-1211, 2018 (SCI-Expanded)
- XCV. **Reply to: Comment on Y.D. Fragoso et al.: "Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod" [Mult. Scler. Relat. Disord. (2017)]**
Fragoso Y. D., Spelman T., BOZ C., Alroughani R., Lugaresi A., Vucic S., Butzkueven H., Terzi M., Havrdova E., Horakova D., et al.
Multiple Sclerosis and Related Disorders, vol.22, pp.166, 2018 (SCI-Expanded)
- XCVI. **Prevalence of and risk factors for cognitive impairment in patients with relapsing-remitting multiple sclerosis: Multi-center, controlled trial**
ÖZAKBAŞ S., Turkoglu R., Tamam Y., Terzi M., Taskapilioglu O., YÜCESAN C., Baser H. L., Gencer M., AKIL E., Şen S., et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS, vol.22, pp.70-76, 2018 (SCI-Expanded)
- XCVII. **Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis**
Signori A., Izquierdo G., Lugaresi A., Hupperts R., Grand'Maison F., Sola P., Horakova D., Havrdova E., Prat A., Girard M., et al.
MULTIPLE SCLEROSIS JOURNAL, vol.24, no.5, pp.642-652, 2018 (SCI-Expanded)
- XCVIII. **Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study**
Kappos L., Bar-Or A., Cree B. A. C., Fox R. J., Giovannoni G., Gold R., Arnold D. L., Arnould S., Scherz T., Wolf C., et al.
The Lancet, vol.391, no.10127, pp.1263-1273, 2018 (SCI-Expanded)
- XCIX. **The use of non-steroidal anti-inflammatory drugs diseases**
Terzi M., Altun G., Şen S., Kocaman A., KAPLAN A. A., Yurt K. K., Kaplan S.
JOURNAL OF CHEMICAL NEUROANATOMY, vol.87, pp.12-24, 2018 (SCI-Expanded)
- C. **Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod**
Fragoso Y. D., Spelman T., BOZ C., Alroughani R., Lugaresi A., Vucic S., Butzkueven H., Terzi M., Havrdova E., Horakova D., et al.
Multiple Sclerosis and Related Disorders, vol.19, pp.105-108, 2018 (SCI-Expanded)

- CI. **Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study**
Howard J. F., Utsugisawa K., Benatar M., Murai H., Barohn R. J., Illa I., Jacob S., Vissing J., Burns T. M., Kissel J. T., et al.
The Lancet Neurology, vol.16, no.12, pp.976-986, 2017 (SCI-Expanded)
- CII. **Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS**
Lorscheider J., Jokubaitis V. G., Spelman T., Izquierdo G., Lugaresi A., Havrdova E., Horakova D., Trojano M., Duquette P., Girard M., et al.
Neurology, vol.89, no.10, pp.1050-1059, 2017 (SCI-Expanded)
- CIII. **Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practice**
Spelman T., Meyniel C., Ignacio Rojas J., Lugaresi A., Izquierdo G., Grand'Maison F., BOZ C., Alroughani R., Havrdova E., Horakova D., et al.
MULTIPLE SCLEROSIS JOURNAL, vol.23, no.10, pp.1346-1357, 2017 (SCI-Expanded)
- CIV. **Towards personalized therapy for multiple sclerosis: prediction of individual treatment response**
Kalincik T., Manouchehrinia A., Sobisek L., Jokubaitis V., Spelman T., Horakova D., Havrdova E., Trojano M., Izquierdo G., Lugaresi A., et al.
BRAIN, vol.140, pp.2426-2443, 2017 (SCI-Expanded)
- CV. **Prognostic indicators in pediatric clinically isolated syndrome**
Iaffaldano P., Simone M., Lucisano G., Ghezzi A., Coniglio G., Brescia Morra V., Salemi G., Patti F., Lugaresi A., Izquierdo G., et al.
Annals of Neurology, vol.81, no.5, pp.729-739, 2017 (SCI-Expanded)
- CVI. **Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study**
Kalincik T., Brown J. W. L., Robertson N., Willis M., Scolding N., Rice C. M., Wilkins A., Pearson O., Ziemssen T., Hutchinson M., et al.
The Lancet Neurology, vol.16, no.4, pp.271-281, 2017 (SCI-Expanded)
- CVII. **Prevalence of Multiple Sclerosis in the Middle Black Sea Region of Turkey and Demographic Characteristics of Patients**
Akdemir N., Terzi M., Arslan H. N., Onar M.
NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY, vol.54, no.1, pp.11-14, 2017 (SCI-Expanded)
- CVIII. **Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis**
Terzi M.
The new england journal of medicine, no.3, pp.221-234, 2017 (SCI-Expanded)
- CIX. **Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis**
Tao C., Simpson S., Van Der Mei I., Blizzard L., Havrdova E., Horakova D., Shaygannejad V., Lugaresi A., Izquierdo G., Trojano M., et al.
Journal of Neurology, Neurosurgery and Psychiatry, vol.87, no.12, pp.1343-1349, 2016 (SCI-Expanded)
- CX. **The role of electromagnetic fields in neurological disorders**
Terzi M., Ozberk B., Deniz O. G., Kaplan S.
JOURNAL OF CHEMICAL NEUROANATOMY, vol.75, pp.77-84, 2016 (SCI-Expanded)
- CXI. **The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis**
Warrender-Sparkes M., Spelman T., Izquierdo G., Trojano M., Lugaresi A., Grand'Maison F., Havrdova E., Horakova D., BOZ C., Oreja-Guevara C., et al.
MULTIPLE SCLEROSIS JOURNAL, vol.22, no.4, pp.520-532, 2016 (SCI-Expanded)
- CXII. **Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial**
Terzi M.
the lancet, pp.1075-1084, 2016 (SCI-Expanded)
- CXIII. **Defining reliable disability outcomes in multiple sclerosis**

Kalincik T., Cutter G., Spelman T., Jokubaitis V., Havrdova E., Horakova D., Trojano M., Izquierdo G., Girard M., Duquette P., et al.

BRAIN, vol.138, 2015 (SCI-Expanded)

CXIV. Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder Patients in Turkish Cohort Demographic, Clinical, and Laboratory Features

Altintas A., Karabudak R., Balci B. P., Terzi M., Soysal A., SAİP S., Kurne A. T., UYGUNOĞLU U., Nalbantoglu M., Celik G., et al.

NEUROLOGIST, vol.20, no.4, pp.61-66, 2015 (SCI-Expanded)

CXV. Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis

He A., Spelman T., Jokubaitis V., Havrdova E., Horakova D., Trojano M., Lugaresi A., Izquierdo G., Grammond P., Duquette P., et al.

JAMA NEUROLOGY, vol.72, no.4, pp.405-413, 2015 (SCI-Expanded)

CXVI. Switch to Natalizumab versus Fingolimod in Active Relapsing-Remitting Multiple Sclerosis

Kalincik T., Horakova D., Spelman T., Jokubaitis V., Trojano M., Lugaresi A., Izquierdo G., Rozsa C., Grammond P., Alroughani R., et al.

ANNALS OF NEUROLOGY, vol.77, no.3, pp.425-435, 2015 (SCI-Expanded)

CXVII. The relationship between familial Mediterranean fever gene (MEFV) mutations and clinical and radiologic parameters in multiple sclerosis patients

Terzi M., Taskin E., Akdemir N. U., Bagci H., Onar M.

INTERNATIONAL JOURNAL OF NEUROSCIENCE, vol.125, no.2, pp.116-122, 2015 (SCI-Expanded)

CXVIII. Restless Leg Syndrome and Sleep Quality in Lumbar Radiculopathy Patients

Kocabıçak E., Terzi M., Akpınar K., Paksoy K., Cebeci I., Iyigun O.

BEHAVIOURAL NEUROLOGY, vol.2014, 2014 (SCI-Expanded)

CXIX. Does Probe's Eye Subthalamic Nucleus Length on T2W MRI Correspond with Microelectrode Recording in Patients with Deep Brain Stimulation for Advanced Parkinson's Disease?

Kocabıçak E., AYGÜN D., Ozaydin I., Jahanshahi A., Tan S. K. H., Onar M., Böke Ö., KURT M., Güz H., Terzi M., et al.

TURKISH NEUROSURGERY, vol.23, no.5, pp.658-665, 2013 (SCI-Expanded)

CXX. Psychiatric symptoms in patients with multiple sclerosis

SARISOY G., Terzi M., Gumus K., Pazvantoglu O.

GENERAL HOSPITAL PSYCHIATRY, vol.35, no.2, pp.134-140, 2013 (SCI-Expanded)

CXXI. Clinical and radiological characteristics of tumefactive demyelinating lesions: follow-up study

Altintas A., Petek B., Isik N., Terzi M., Bolukbasi F., Tavsanlı M., SAİP S., BOZ C., Aydın T., Arici-Duz O., et al.

MULTIPLE SCLEROSIS JOURNAL, vol.18, no.10, pp.1448-1453, 2012 (SCI-Expanded)

CXXII. Lack of association of the CD14/C-159T polymorphism with susceptibility and progression parameters in Turkish multiple sclerosis patients

Kurne A., Sayat G., Aydın O. F., Turgutoglu N., Terzi M., Sackesen C., KARABULUT E., Karabudak R.

JOURNAL OF NEUROIMMUNOLOGY, vol.250, no.1-2, pp.83-86, 2012 (SCI-Expanded)

CXXIII. Prolonged cerebellar ataxia associated with lithium-valproic acid intoxication

SARISOY G., Kacar O. F., Pazvantoglu O., Terzi M.

ANADOLU PSIKIYATRI DERGİSİ-ANATOLIAN JOURNAL OF PSYCHIATRY, vol.13, no.2, pp.166, 2012 (SCI-Expanded)

CXXIV. Neuromyelitis Optica Spectrum Disorder in Sjogren's Syndrome

Terzi M., Yazici T., Akdemir N., Terzi T., Onar M.

NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY, vol.48, no.3, pp.221-223, 2011 (SCI-Expanded)

CXXV. Examination of the Relationship Between Average Plaque Volume and Clinical and Demographic Characteristics in Multiple Sclerosis Patients Using a Stereological Method

Terzi M., Yilmaz E., Şahin B., Kaplan S., Onar M.

INTERNATIONAL JOURNAL OF NEUROSCIENCE, vol.121, no.7, pp.366-372, 2011 (SCI-Expanded)

CXXVI. Does long term use of piracetam improve speech disturbances due to ischemic cerebrovascular diseases?

Gungor L., Terzi M., Onar M. K.

- BRAIN AND LANGUAGE, vol.117, no.1, pp.23-27, 2011 (SCI-Expanded)
- CXXVII. **Paraneoplastic Peripheral Neuropathy in a Case with an Anti-Yo Positive Ovarian Carcinoma**
Terzi M., Türker H., Yazici D., Akkurt A., Onar M.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.21, no.4, pp.249-252, 2011 (SCI-Expanded)
- CXXVIII. **The clinical, Demographical and Radiological Characteristics of Eight Patients Who Have Spinal Imaging Findings and The Diagnosis of Subacute Combined Degeneration**
Terzi M., Yazici D., Yazici T., Onar M.
JOURNAL OF NEUROLOGICAL SCIENCES-TURKISH, vol.28, no.4, pp.552-562, 2011 (SCI-Expanded)
- CXXIX. **Changes in bone mineral density and bone metabolism markers in premenopausal women with multiple sclerosis and the relationship to clinical variables**
Terzi T., Terzi M., Tander B., Canturk F., Onar M.
JOURNAL OF CLINICAL NEUROSCIENCE, vol.17, no.10, pp.1260-1264, 2010 (SCI-Expanded)
- CXXX. **Pure Sensory Stroke Due to Bilateral Basal Ganglion Hemorrhage: A Case Report**
Terzi M., Akkaya O., Onar M.
TURKISH NEUROSURGERY, vol.20, no.3, pp.406-408, 2010 (SCI-Expanded)
- CXXXI. **Interferon-beta Therapy in Multiple Sclerosis Patients: is Response Age Dependent?**
Kurne A., Terzi M., Aydın O. F., Onar M. K., Karabudak R.
JOURNAL OF NEUROLOGICAL SCIENCES-TURKISH, vol.26, no.2, pp.131-138, 2009 (SCI-Expanded)
- CXXXII. **The Eating Attitudes in Multiple Sclerosis Patients**
Terzi M., Kocamanoglu B., Güz H., Onar M.
JOURNAL OF NEUROLOGICAL SCIENCES-TURKISH, vol.26, no.3, pp.311-317, 2009 (SCI-Expanded)
- CXXXIII. **Visual Evoked Potentials in Differential Diagnosis of Multiple Sclerosis and Neurobehcet's Disease**
Türker H., Terzi M., Bayrak O., Cengiz N., Onar M., Us O.
TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, vol.216, no.2, pp.109-116, 2008 (SCI-Expanded)
- CXXXIV. **Hypothyroid myopathy with manifestations of Hoffman's syndrome and myasthenia gravis**
Türker H., Bayrak O., Gungor L., Yilmaz A., Terzi M., Turker C. M., Onar M. K., Kahraman H.
THYROID, vol.18, no.2, pp.259-262, 2008 (SCI-Expanded)
- CXXXV. **Rapid identification of disease-causing mutations using copy number analysis within linkage intervals**
Bayraklı F., Bilguvar K., Mason C. E., DiLuna M. L., Bayrı Y., Gungor L., Terzi M., Mane S. M., Lifton R. P., State M. W., et al.
HUMAN MUTATION, vol.28, no.12, pp.1236-1240, 2007 (SCI-Expanded)
- CXXXVI. **An unusual presentation of late onset multiple sclerosis with amyotrophic lateral sclerosis**
Turker H., Terzi M., Cengiz N., Onar M. K.
NEUROSCIENCES, vol.12, no.4, pp.346-347, 2007 (SCI-Expanded)
- CXXXVII. **Isolated lesion of the cervical spine in a case of neuro-Behcet**
Terzi M., Türker H., Cengiz N., Onar M. K.
NEUROSCIENCES, vol.12, no.3, pp.259-260, 2007 (SCI-Expanded)
- CXXXVIII. **Isolated lesion of the cervical spine in a case of neuro-Behçet**
Terzi M., Türker H., Cengiz N., Onar M. K.
Neurosciences, vol.12, no.3, pp.259-260, 2007 (SCI-Expanded)
- CXXXIX. **Cerebrospinal fluid total tau protein levels in patients with multiple sclerosis**
Terzi M., Birinci A., Cetinkaya E., Onar M. K.
ACTA NEUROLOGICA SCANDINAVICA, vol.115, no.5, pp.325-330, 2007 (SCI-Expanded)
- CXL. **Frontal functions in young patients with essential tremor: A case comparison study**
Sahin H., Terzi M., Ucak S., Yapici O., Basoglu T., Onar M.
JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES, vol.18, no.1, pp.64-72, 2006 (SCI-Expanded)
- CXLI. **Congenital afibrinogenemia complicated by spontaneous cerebral hemorrhage and unusually quick resorption**
Terzi M., Sahin H., Yilmaz A., Ozbenli T., Onar M.
JOURNAL OF NEUROLOGY, vol.252, no.3, pp.367-368, 2005 (SCI-Expanded)

Articles Published in Other Journals

- I. **Making the Discrimination in the Walking Parameters of Individuals with Multiple Sclerosis and Parkinson's Disease with Machine Learning**
GÜL S., SOYLU E., TERZİ M., TÜRKOĞLU M., Aslan KOCA K.
TURK NOROLOJI DERGISI, vol.29, 2023 (ESCI)
- II. **A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis: results from the MSBase registry**
Spelman T., ÖZAKBAŞ S., Alroughani R., Terzi M., Hodgkinson S., Laureys G., Kalincik T., Der Walt A. V., Yamout B., Lechner-Scott J., et al.
Neurodegenerative Disease Management, vol.13, no.4, pp.215-221, 2023 (ESCI)
- III. **Two-year Assessment of the Efficacy and Safety of Ocrelizumab in Switching Patients from Other Disease Modifying Therapies**
TERZİ M., BOZ C., DEMİR C. F., ÇİLİNGİR V., HELVACI E. M.
Journal of Multiple Sclerosis, 2023 (Peer-Reviewed Journal)
- IV. **Multipl Skleroz Tanılı Bireylerin Öznel İyi Oluş Düzeyleri Subjective Well-Being Levels of Individuals Diagnosed with Multiple Sclerosis**
ÖZKAN N., GÜLEÇ KESKİN S., TERZİ M.
Türkiye Klinikleri Hemşirelik Bilimleri Dergisi, vol.14, no.3, pp.861-867, 2022 (Peer-Reviewed Journal)
- V. **Why are the First-Line Therapies Used as Injections Discontinued in the Treatment of Multiple Sclerosis?**
ŞEN S., TERZİ M.
International Archives of Medical Research, vol.14, no.1, pp.7-13, 2022 (Peer-Reviewed Journal)
- VI. **Multipl Sklerozda Ölüm Nedenleri**
ŞEN S., TERZİ M.
Dicle Tıp Dergisi, vol.49, no.1, pp.243-248, 2022 (Peer-Reviewed Journal)
- VII. **Sinir Bilim ve Yapay Zekâ**
GÜL S., TERZİ M.
Academician Publishing, vol.2, 2022 (Peer-Reviewed Journal)
- VIII. **EVALUATION OF EATING ATTITUDES IN PATIENTS ATTENDING MULTIPLE SCLEROSIS PATIENT CAMP**
UZDİL Z., KAYA S., SÖKÜLMEZ KAYA P., TERZİ M.
Samsun Sağlık Bilimleri Dergisi, vol.6, no.1, pp.49-54, 2021 (Peer-Reviewed Journal)
- IX. **MULTİPL SKLEROZ HASTALARINDA EL FONKSİYONUNUN YAŞAM KALİTESİ İLE OLAN İLİŞKİSİ**
PİR Ö., TERZİ M.
Samsun Sağlık Bilimleri Dergisi, 2021 (Peer-Reviewed Journal)
- X. **Marriage and life satisfactions with sexual dysfunction in patients with multiple sclerosis**
AYDIN T., ÖNGER M. E., TERZİ M.
Medicine Science, vol.10, 2021 (Peer-Reviewed Journal)
- XI. **NSAIDs medication for headache as the presenting symptom with migraine and COVID-19**
Türkdönmez E., Terzi M.
Journal of Experimental and Clinical Medicine (Turkey), vol.38, no.4, pp.645-648, 2021 (Scopus)
- XII. **Gastroenterit Nedenli Uzun Süreli Çömelle Pozisyonuna Bağlı Gelişen Bilateral Düşük Ayak**
GÜL TÜRK S., TERZİ M.
Samsun Sağlık Bilimleri Dergisi, 2021 (Peer-Reviewed Journal)
- XIII. **Üniversite öğrencilerinde sigara kullanımı ve nikotin bağımlılık düzeylerinin belirlenmesi**
Terzi M.
The Turkish Journal On Addictions, vol.6, no.4, pp.168-181, 2020 (Peer-Reviewed Journal)
- XIV. **Üniversite Öğrencilerinde Akıllı Telefon Bağımlılığı**
Terzi M.
vol.9, no.1, pp.13-39, 2020 (Peer-Reviewed Journal)
- XV. **Değiştirilemez Gerçekte Anlam Bulmak: Varoluşçu Logoterapinin MS Tanılı Bireylerde Depresyon,**

Anksiyete, Affektif Kişilik Ve Yaşam Kalitesi Düzeylerine Etkisi

OĞUZ G., ÇAĞLI S., GÜLEÇ KESKİN S., İÇÖZ F. J., TERZİ M., AKER S., ŞEN S.

Samsun Sağlık Bilimleri Dergisi, vol.5, no.2, pp.182-190, 2020 (Peer-Reviewed Journal)

- XVI. **DEĞİŞTİRİLEMEZ GERÇEKTE ANLAM BULMAK: VAROLUŞCU LOGOTERAPİNİN MS TANILI BİREYLERDE DEPRESYON, ANKSİYETE , AFFEKTİF KİŞİLİK VE YAŞAM KALİTESİ DÜZEYLERİNE ETKİSİ**
OĞUZ G., Çağlı S., Güleç Keskin S., İÇÖZ F. J., TERZİ M., AKER S., ŞEN S.
Samsun Sağlık Bilimleri Dergisi, 2020 (Peer-Reviewed Journal)
- XVII. **MULTİPL SKLEROZ HASTALARINA VE AİLELERİNE VERİLEN BESLENME EĞİTİMİNİN BİLGİ DÜZEYİ VE BESLENME ALIŞKANLIKLARINA ETKİSİNİN DEĞERLENDİRİLMESİ**
UZDİL Z., TÜRKER P. F., TERZİ M.
Samsun Sağlık Bilimleri Dergisi, vol.4, no.2, pp.77-85, 2019 (Peer-Reviewed Journal)
- XVIII. **Clinical Use of Neuronal Growth Factors in Neurodevelopmental Disorders**
USTA M. B., TERZİ M., KARABEKİROĞLU K., ARAL A.
Arşiv Kaynak Tarama Dergisi, vol.28, no.2, pp.98-107, 2019 (Peer-Reviewed Journal)
- XIX. **Cigarette Smoking and Determination of Nicotine Dependence Levels in University Students**
Terzi Ö., Kumcağız H., Terzi M., Dündar C.
ADDICTA-THE TURKISH JOURNAL ON ADDICTIONS, vol.6, no.4, pp.168-181, 2019 (ESCI)
- XX. **Cryptococcal Meningoencephalitis Treated with Fingolimod in a Patient with Multiple Sclerosis**
KURUOĞLU T., DEVECİ A., TANYEL E., TERZİ M.
Türkiye Klinikleri Journal of Medical Research, vol.27, pp.200-203, 2019 (Peer-Reviewed Journal)
- XXI. **Two multiple sclerosis cases developed herpes zoster during use of fingolimod**
Terzi M., Duman T., Şen S., Güntel M., Şen N. Ö.
Journal of Experimental and Clinical Medicine (Turkey), vol.35, no.1, pp.27-30, 2018 (Scopus)
- XXII. **Effects of short and long term electromagnetic fields exposure on the human hippocampus**
Deniz O. G., KAPLAN S., SELÇUK M. B., TERZİ M., ALTUN G., YURT K. K., ASLAN K., DAVIS D.
Journal of Microscopy and Ultrastructure, vol.5, no.4, pp.191-197, 2017 (Peer-Reviewed Journal)
- XXIII. **Testing patient-reported outcome measurement equivalence in multinational clinical trials: An exemplar using the 12-item Multiple Sclerosis Walking Scale**
Dib H., Tamam Y., Terzi M., Hobart J.
Multiple Sclerosis Journal - Experimental, Translational and Clinical, vol.3, no.3, 2017 (Scopus)
- XXIV. **Pediatric Yaş Başlangıçlı Multipl Skleroz ile Erişkin Yaş Başlangıçlı Multipl Sklerozun Karşılaştırılması**
KAMAŞAK T., CANSU A., ACAR ARSLAN E., ŞAHİN S., DİLER DURGUT B., DİLBER B., KURT T., TERZİ M., BOZ C.
Türkiye Klinikleri Journal of Neurology, vol.12, no.3, pp.57-63, 2017 (Peer-Reviewed Journal)
- XXV. **Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS**
Spelman T., Kalincik T., Jokubaitis V., Zhang A., Pellegrini F., Wiendl H., Belachew S., Hyde R., Verheul F., Lugaresi A., et al.
Neurology: Clinical Practice, vol.6, no.2, pp.102-115, 2016 (ESCI)
- XXVI. **The Benefits of Visual Evoked Potential Examination in the Diagnosis and Prognosis Of Multiple Sclerosis**
TERZİ M., ŞEN S., CANBAZ S., ONAR M. K.
Akonder Journal of Advanced Neurological Science, vol.3, no.4, pp.167-171, 2015 (Peer-Reviewed Journal)
- XXVII. **The Effects of Structural Transformations in Economy on Labor Markets The Case of OECD Countries**
OYTUN M., AFŞAR M., Yurt K. K., ATILLA A., TERZİ M., KAVAZ E.
International Journal of Business and Social Science, vol.5, no.9, pp.230-237, 2014 (Peer-Reviewed Journal)
- XXVIII. **An atypical chronic inflammatory demyelinating polyradiculoneuropathy that radiologically mimicking neurofibromatosis: Case report**
Akpınara C. K., Dogru H., Balci K., Terzi M.
Journal of Experimental and Clinical Medicine (Turkey), vol.31, no.2, pp.111-113, 2014 (Scopus)
- XXIX. **Comparison of The Cognitive Performance Between Healthy Controls, Rheumatoid Arthritis and Fibromyalgia Patients Without Depression**

Bilgici A., Terzi M., Güz H., Kuru O.

JOURNAL OF CLINICAL AND ANALYTICAL MEDICINE, vol.5, no.3, pp.214-219, 2014 (ESCI)

- XXX. **Multipl Skleroz da Hastalık Modifiye Edici Tedaviler**
ŞEN S., TERZİ M.
Ajans, vol.2, no.1, pp.1-13, 2014 (Peer-Reviewed Journal)
- XXXI. **Anti-John Cunningham Virus antibody prevalence in multiple sclerosis patients in Turkey**
ERAKSOY M., AĞAN K., AK F., ANLAR Ö., BALCI B. P., BOZ C., ÇELİK Y., DEMİRKAYA Ş., EFENDİ H., GÜNAL D., et al.
JOURNAL OF EXPERIMENTAL AND CLINICAL MEDICINE, vol.31, no.1, pp.31-36, 2014 (Scopus)
- XXXII. **Targeting thalamic tremor cells in deep brain stimulation for multiple sclerosis-induced complex tremor**
Terzi M.
SURGICAL NEUROLOGY INTERNATIONAL, pp.1-3, 2013 (Scopus)
- XXXIII. **Bilateral Brakial Nöropati Kliniği ile Prezante olan Sjögren Sendromu**
TERZİ M., CENGİZ N., TÜRKER H., TÜRKEKEL Y., YAZICI T.
JOURNAL OF CLINICAL AND ANALYTICAL MEDICINE, vol.3, 2012 (ESCI)
- XXXIV. **Santral Sinir Sistemi Tutulumu ile Prezente Olan Sjögren Sendromu**
TERZİ M., TÜRKEKEL Y., YAZICI T., TERZİ T.
Journal of Clinical and Analytical Medicine, vol.3, no.1, pp.94-96, 2012 (Peer-Reviewed Journal)
- XXXV. **Lityum-valproik asit zehirlenmesi sonrasında ortaya çıkan uzun süreli serebellar ataksi**
SARISOY G., KAÇAR Ö., Pazvantoğlu O., TERZİ M.
Anadolu Psikiyatri Dergisi, vol.2, no.13, pp.166, 2012 (Peer-Reviewed Journal)
- XXXVI. **Sjogren's syndrome presenting with central nervous system involvement Santral Sinir Sistemi Tutulumu ile Prezente Olan Sjögren Sendromu**
Terzi M., Türkel Y., Yazici T., Terzi T.
Journal of Clinical and Analytical Medicine, vol.3, no.1, pp.94-96, 2012 (ESCI)
- XXXVII. **Sjogren Syndrome Presented with Dibrachial Neuropathy Clinic**
Terzi M., Cengiz N., Türker H., Turkel Y., Yazici T.
JOURNAL OF CLINICAL AND ANALYTICAL MEDICINE, vol.2, no.3, pp.91-93, 2011 (ESCI)
- XXXVIII. **Pure Motor Aphasia Developed After Cerebral Vasculitis due to Systemic Lupus Erythematosus**
Terzi M., Demir O., Onar M.
JOURNAL OF CLINICAL AND ANALYTICAL MEDICINE, vol.2, no.3, pp.116-118, 2011 (ESCI)
- XXXIX. **Bilateral Brakhial Nöropati Kliniği ile Prezente Olan Sjögren Sendromu**
TERZİ M., CENGİZ N., TÜRKER H., TÜRKEKEL Y., YAZICI T.
Journal of Clinical and Analytical Medicine, vol.2, no.3, pp.91-93, 2011 (Peer-Reviewed Journal)
- XL. **Reversible posterior cerebral artery ischemia related to migraine with aura**
Terzi M., Yücel D. K., Akdemir N. Ü.
Journal of Experimental and Clinical Medicine (Turkey), vol.28, no.1, pp.35-37, 2011 (Scopus)
- XLI. **Multipl sklerozda kaplan gözü işareti: Bir olgu sunumu**
AYGÜN D., TERZİ M., GÜNGÖR İ. L., ONAR M. K.
Parkinson hastalığı ve Hareket Bozuklukları Dergisi, vol.1, no.14, pp.17-20, 2011 (Peer-Reviewed Journal)
- XLII. **Central pontine myelinolysis: Report of four cases Santral pontin miyelinolizis: Dört olgu sunumu**
Akar H., Cengiz N., Bayrak A. O., Özbenli T., Onar M. K., Incesu L., Güngör L., Terzi M.
Turk Noroloji Dergisi, vol.16, no.3, pp.154-158, 2010 (Scopus)
- XLIII. **Motor Nöron Hastalığını Taklit Eden Yaygın İdiyopatik İskelet Hiperostozu Olgusu**
TERZİ M., TÜRKEKEL Y., YAZICI T., CENGİZ N., TUNALI G.
AİBÜ İzzet Baysal Tıp Fakültesi Dergisi, vol.3, no.5, pp.24-27, 2010 (Peer-Reviewed Journal)
- XLIV. **Sneddon Syndrome with Factor V Leiden, Methylene Tetrahydrofolate Reductase and FMF Gene Mutations**
Terzi M., Yazici D., Sabancilar E., Onar M.
TURKISH JOURNAL OF NEUROLOGY, vol.16, no.1, pp.47-50, 2010 (ESCI)
- XLV. **Santral Sinir Sistemi Tutulumu Olan ve Bilateral Oftalmopleji Kliniği ile Prezente Olan Mukormikoz**

Olgusu Olgu Sunumu

TÜRKEL Y., TERZİ M., YAZICI T., CENGİZ N.

Türk Nöroloji Dergisi, vol.15, no.2, pp.89-93, 2009 (Peer-Reviewed Journal)

- XLVI. **Role of statins in the practice of clinic neurology Statinlerin nöroloji pratiğindeki yeri**
Türkel Y., Terzi M.
Journal of Experimental and Clinical Medicine (Turkey), vol.26, no.2, pp.55-61, 2009 (Scopus)
- XLVII. **Sexual dysfunction in multiple sclerosis patients Multipl skleroz hastalarında cinsel fonksiyon bozukluğu**
Terzi M., Kocamanoğlu B., Güz H., Onar M., Şahin A. R.
Journal of Experimental and Clinical Medicine (Turkey), vol.26, no.2, pp.81-85, 2009 (Scopus)
- XLVIII. **Statinlerin Nöroloji Pratiğindeki Yeri**
TÜRKEL Y., TERZİ M.
Deneyssel ve Klinik Tıp Dergisi, vol.26, no.2, pp.55-61, 2009 (Scopus)
- XLIX. **Sexual dysfunction in multiple sclerosis patients.**
TERZİ M., kocamanoğlu b., GÜZ H., onar m., ŞAHİN A. R.
Journal of Experimental and Clinical Medicine, vol.26, no.2, pp.81-85, 2009 (Peer-Reviewed Journal)
- L. **”Üç Subakut Kombine Dejenerasyon Olgusunun Spinal MRG ve Klinik Bulguları”**
TERZİ M., TÜRKER H., Akkurt A., Yazıcı D., ONAR M. K.
TÜRKİYE KLİNİKLERİ NÖROLOJİ, vol.4, pp.41-46, 2009 (Peer-Reviewed Journal)
- LI. **Parkinsonizmle Ortaya Çıkan Kronik Karaciğer Sirozu İki Olgu Sunumu**
TÜRKEL Y., TERZİ M., YAZICI T., SANDIKÇI U., CENGİZ N.
Parkinson Hastalığı ve Hareket Bozuklukları Dergisi, vol.12, no.1, pp.25-29, 2009 (Peer-Reviewed Journal)
- LII. **Anatomic and functional importance of thalamus Talamus'un anatomik ve fonksiyonel önemi**
Türkel Y., Terzi M.
Ondokuz Mayıs Üniversitesi Tıp Dergisi, vol.24, no.4, pp.144-154, 2007 (Scopus)
- LIIL. **”Guillain-Barre Sendromunda klinik ve demografik özellikler”**
TERZİ M., TÜRKER H., ONAR M. K.
Fırat Tıp Dergisi, vol.12, pp.112-114, 2007 (Peer-Reviewed Journal)
- LIV. **Talamus un Anatomik ve Fonksiyonel Önemi**
TÜRKEL Y., TERZİ M.
Ondokuz Mayıs Üniversitesi Tıp Dergisi, vol.27, no.4, pp.144-154, 2007 (Peer-Reviewed Journal)
- LV. **Radiation myelopathy: Case report Radyasyon miyelopatisi: Olgu sunumu**
Terzi M., Cengiz N., Özbenli T., Onar M. K.
Ondokuz Mayıs Üniversitesi Tıp Dergisi, vol.22, no.1, pp.46-49, 2005 (Scopus)
- LVI. **The effectiveness of magnetization transfer technique in the evaluation of acute plaques in the central nervous system of multiple sclerosis patients and its correlation with the clinical findings**
Atalay K., Diren H. B., Gelmez S., İncesu L., Terzi M.
Diagnostic and Interventional Radiology, vol.11, no.3, pp.137-141, 2005 (Scopus)
- LVII. **Diabetic neuropathy Diyabetik nöropati**
Terzi M., Cengiz N., Onar M. K.
Ondokuz Mayıs Üniversitesi Tıp Dergisi, vol.21, no.1, pp.39-49, 2004 (Scopus)
- LVIII. **Demographic and clinical features in multiple sclerosis Multipl sklerozda klinik ve demografik özellikler**
Terzi M., Onar M. K.
Ondokuz Mayıs Üniversitesi Tıp Dergisi, vol.21, no.4, pp.149-155, 2004 (Scopus)

Books & Book Chapters

I. Her Yönüyle Kenevir

Terzi M., Helvacı E. M.

Ondokuz Mayıs Üniversitesi, Samsun, 2023

- II. **Multipl Skleroz'da Nörorehabilitasyon**
TERZİ M.
Hipokrat, 2023
- III. **Yaşlılık ve Deliryum**
KABATAŞ YILDIZ M., TERZİ M., TAN F.
in: Geriatrik Psikiyatri, KABATAŞ YILDIZ Mükerrerem, Editor, Nobel Akademik Yayıncılık, Ankara, pp.99-120, 2022
- IV. **Multipl Sklerozda Tanı Yöntemleri Beyin Omurilik Sıvısı**
TERZİ M., ŞEN S.
in: Multipl Skleroz, Yeşim Beckmann, Cihat Uzunköprü, Editor, Ema Tıp Kitap Evi, Samsun, pp.179-192, 2021
- V. **MULTİPL SKLEROZ VE BESLENME**
UZUNKÖPRÜ C., BALCI B. P., GÜNDÜZ T., PİRİ ÇINAR B., TÜTÜNCÜ M., BECKMANN Y., ÖZAKBAŞ S., ETHEMOĞLU Ö., SİVA A., TUNCER M. A., et al.
in: MULTİPL SKLEROZ, YEŞİM BECKMAN CİHAT UZUNKÖPRÜ, Editor, EMA TİP KİTAPEVİ, İstanbul, pp.537-549, 2021
- VI. **Multipl Skleroz**
BOZ C., TERZİ M., BÖLÜKBAŞI O.
Sakarya Matbaacılık, 2020
- VII. **Multipl Skleroz**
BOZ C., TERZİ M., BÖLÜKBAŞI O.
Sakarya, 2020
- VIII. **Multipl Skleroz Tedavi Geçişlerinde Uygulamalar**
AKÇALI A., AKSOY D., Altıntaş A., ALTUN Y., ALTUNRENDE B., ARDUÇ AKÇAY A., BİLGE N., BİR L. S., BOZ C., Bünül D., et al.
in: Türkiye Klinikleri Nöroloji Özel Konular-Multipl Skleroz, Taşkın Duman, Editor, Türkiye Klinikleri, pp.88-93, 2020
- IX. **Soru ve Yanıtlarla Multipl Skleroz**
TERZİ M., BOZ C., BÖLÜKBAŞI O.
No-bel Matbaacılık San.Tic.Ltd. Şti., 2018
- X. **Soru ve Yanıtlar ile Multipl Skleroz**
BOZ C., TERZİ M., BÖLÜKBAŞI O.
Ömür matbaacılık, 2016
- XI. **Soru ve Yanıtlarla Multipl Skleroz**
TERZİ M., BOZ C., BÖLÜKBAŞI O.
Ömür Matbaacılık, 2016
- XII. **Benim MS'im öyküler**
BOZ C., TERZİ M., Turan Ö.
Sakarya, 2014

Refereed Congress / Symposium Publications in Proceedings

- I. **MULTİPL SKLEROZ TEDAVİSİNDE DİMETİL FUMARATIN İKİ YILLIK TÜRKİYE GERÇEK YAŞAM VERİSİ**
TERZİ M., ŞEN S., BECKMANN Y., KARABUDAK R., HELVACI E. M., YETKİN M. F., UZUNKÖPRÜ C., TÜRKOĞLU R., KOÇ E. R., BALCI F. B., et al.
59.Ulusal Nöroloji Kongresi, Turkey, 13 December 2023
- II. **MULTİPL SKLEROZ HASTALARININ KLİNİK VE MR BULGULARI İLE ANTROPOMETRİK ÖLÇÜMLERİ ARASINDAKİ İLİŞKİ**
HELVACI E. M., TERZİ M.
59.Ulusal Nöroloji Kongresi, Turkey, 13 December 2023
- III. **A Multi-Country Comparative Effectiveness Study of Dimethyl Fumarate and Non-Specific**

Immunosuppressants in a Real-World Setting: Evidence from MSBase

Spelman T., Butzkueven H., Eichau S., Alroughani R., Ozakbas S., Khoury S. J., Patti F., Havrdova E. K., BOZ C., Terzi M., et al.

Pan-Asian Committee on Treatment and Research in Multiple Sclerosis (PACTRIMS), Perth, Australia, 23 - 25 November 2022

- IV. **MS Hastalarında Refleksoloji ve Kegel Egzersizinin Ütiner İnkontinans Üzerin Etkisi**
ÖZDELİKARA A., AĞAÇDİKEN ALKAN S., TERZİ M.
3. Uluslararası 5. Ulusal Tamamlayıcı Terapiler Kongresi, İzmir, Turkey, 21 April 2022
- V. **Comparative effectiveness of autologous haematopoietic stem cell transplantation vs. fingolimod, ocrelizumab and natalizumab in relapsing-remitting MS**
Kalincik T., Sharmin S., BOZ C., TERZİ M., TÜRKÖĞLU R., ÖZAKBAŞ S., Horáková D., Roos I.
ECTRIMS 2022 26 - 28 October 2022 Amsterdam, the Netherlands 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Amsterdam, Netherlands, 26 - 28 October 2022, vol.28, pp.11-14
- VI. **Yapay Zeka Temelli Yürüme Analizi ile Nörolojik Hastalıkların Tanı ve Prognostik Sürecinin Belirlenmesi**
TERZİ M., SOYLU E., GÜL S.
58. ULUSAL NÖROLOJİ KONGRESİ, Antalya, Turkey, 18 November 2022
- VII. **Description of Multiple Sclerosis cohorts from the Middle East between 2009 and 2019**
Moradi N., Sharmin S., Malpas C., Ozakbas S., Shaygannejad V., Terzi M., BOZ C., Yamout B., Turkoglu R., Karabudak R., et al.
MS Australia Progress in MS Research Scientific Conference, Hobart, Australia, 4 - 05 April 2022, pp.17-18
- VIII. **MULTİPL SKLEROZDA İMMÜNOMODÜLATÖR TEDAVİ ALAN VE ALMAYAN HASTALARDA İNAKTİVE VİRÜS VE MRNA AŞILARINI TAKİBEN HÜMORAL YANITLAR VE HÜCRESEL İMMÜN PROFİLLER**
TÜTÜNCÜ M., DEMİR S., ŞEN S., DİNÇ Ö., GÜNDÜZ T., UZUNKÖPRÜ C., GÜMÜŞ H., ARSLAN G., ELVERDİ T., AKÇİN R., et al.
58. ULUSAL NÖROLOJİ KONGRESİ, Antalya, Turkey, 19 - 24 November 2022
- IX. **MİYELİN OLİGODENDROSİT GLİKOPROTEİN ANTİKORU İLE İLİŞKİLİ HASTALIK TEDAVİSİNDE RİTUKSİMAB ETKİNLİĞİ: ÇOK MERKEZLİ, RETROSPEKTİF ULUSAL ÇALIŞMA**
ŞEN S., DEMİR S., DEMİREL ÖZBEK E., TÜTÜNCÜ M., UZUNKÖPRÜ C., GÜNDÜZ T., ÇETİNKAYA TEZEL D., KIZILAY F., BALCI B., DEMİR C. F., et al.
58. ULUSAL NÖROLOJİ KONGRESİ, Antalya, Turkey, 19 - 24 November 2022
- X. **MULTİPL SKLEROZ HASTALARINDA COVID-19 AŞILARININ ENFEKSİYON GELİŞMESİ ÜZERİNE ETKİSİ**
BÜNÜL S. D., ŞEN S., SİVA A., TERZİ M., UZUNKÖPRÜ C., TÜTÜNCÜ M., EFENDİ H.
58. ULUSAL NÖROLOJİ KONGRESİ, 20 November 2022
- XI. **PARANEOPLAZİ PANELİ POZİTİF 110 HASTANIN DEMOGRAFİK ÖZELLİKLERİ**
TERZİ M., ESER M. Z., HELVACI E. M.
58. Ulusal Nöroloji Kongresi, 19 November 2022
- XII. **MİYELİN OLİGODENDROSİT GLİKOPROTEİN ANTİKORU İLE İLİŞKİLİ HASTALIK TEDAVİSİNDE RİTUKSİMAB ETKİNLİĞİ: ÇOK MERKEZLİ, RETROSPEKTİF ULUSAL ÇALIŞMA**
BÜNÜL S. D., ŞEN S., EFENDİ H., TERZİ M., DEMİR S., UZUNKÖPRÜ C., SİVA A., BECKMANN Y., KÜRTÜNCÜ M., KARABUDAK R., et al.
58. ULUSAL NÖROLOJİ KONGRESİ, 20 November 2022
- XIII. **GEBELİĞİN NÖROMYELITİS OPTİKA SPEKTRUM HASTALIĞI (NMOSD) VE MYELİN OLİGODENDROSİT GLİKOPROTEİN İLİŞKİLİ HASTALIK (MOGAD) PROGNOZU ÜZERİNE ETKİ**
UZUNKÖPRÜ C., ŞEN S., ALTINTAŞ A., ÇAKAN M., BÜNÜL S. D., AKMAN DEMİR G., BALCI B., GÜRİSOY A. E., ARSLAN G., KOÇ R., et al.
58. ULUSAL NÖROLOJİ KONGRESİ, Antalya, Turkey, 19 - 24 November 2022
- XIV. **GEBELİĞİN NÖROMYELITİS OPTİKA SPEKTRUM HASTALIĞI (NMOSD) VE MYELİN OLİGODENDROSİT GLİKOPROTEİN İLİŞKİLİ HASTALIK (MOGAD) PROGNOZU ÜZERİNE ETKİLERİ**
UZUNKÖPRÜ C., ŞEN S., ALTINTAŞ A., ÇAKAN M., BÜNÜL S. D., AKMAN G., GÜRİSOY A. E., KOÇ E. R., GÜNDÜZ T., GÜMÜŞ H., et al.

58. ULUSAL NÖROLOJİ KONGRESİ, Antalya, Turkey, 19 November 2022

- XV. **MULTİPL SKLEROZDA İMMÜNOMODÜLATÖR TEDAVİ ALAN VE ALMAYAN HASTALARDA İNAKTİVE VİRÜS VE MRNA AŞILARINI TAKİBEN HÜMORAL YANITLAR VE HÜCRESEL İMMÜN PROFİLLER**
TÜTÜNCÜ M., DEMİR S., ŞEN S., DİNÇ H. Ö., GÜNDÜZ T., UZUNKÖPRÜ C., GÜMÜŞ H., ÖZAKBAŞ S., KÖSEOĞLU M., BÜNÜL S. D., et al.

58. ULUSAL NÖROLOJİ KONGRESİ, Antalya, Turkey, 19 November 2022

- XVI. **SS-89 MİYELİN OLİGODENDROSİT GLİKOPROTEİN ANTİKORU İLE İLİŞKİLİ HASTALIK TEDAVİSİNDE RİTUKSİMAB ETKİNLİĞİ: ÇOK MERKEZLİ, RETROSPEKTİF ULUSAL ÇALIŞMA**
ŞEN S., DEMİR S., DEMİREL E., TÜTÜNCÜ M., UZUNKÖPRÜ C., GÜNDÜZ T., Çetinkaya Tezer D., Kızılay F., Petek Balcı B., DEMİR C. F., et al.

58. Ulusal Nöroloji Kongresi, Antalya, Turkey, 18 November 2022

- XVII. **Cladribine treatment in turkish MS patients**
BÜNÜL S. D., GÜNDÜZ T., KÖSEOĞLU M., ACAR ÖZEN N. P., TÜTÜNCÜ M., UZUNKÖPRÜ C., DEMİR S., DEMİR S., GÜMÜŞ H., ŞEN S., et al.

ECTRIMS 2022, 26 October 2022

- XVIII. **The risk of secondary progressive multiple sclerosis is geographically determined but modifiable**
Kalincik T. K., BOZ C., TÜRKOĞLU R., TERZİ M., KARABUDAK R., ALTINTAŞ A., Sharmin S., Roos I., Havrdova E., Sharmin S.
ECTRIMS 2022 26 – 28 October 2022 Amsterdam, the Netherlands 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Amsterdam, Netherlands, 26 - 28 October 2022, vol.28, pp.967-970

- XIX. **MULTİPL SKLEROZ HASTALARINDA KİŞİLİK ÖZELLİKLERİNİN STİGMA, DEPRESYON VE YAŞAM KALİTESİ İLE İLİŞKİSİ**
YENİ K., TERZİ M.

6. ULUSLARARASI HEMŞİRELİK VE İNOVASYON KONGRESİ, İstanbul, Turkey, 22 - 23 October 2022, pp.741

- XX. **EPİLEPSİ HASTALARINDA UYKU BOZUKLUKLARININ YAŞAM KALİTESİNE ETKİSİ; TÜRKİYE'DEN ÇOK MERKEZLİ ÇALIŞMA**
AKDAĞ G., CANBAZ KABAY S., BİCAN DEMİR A., ERGİN BAKAR E., KOÇ G., ÖZEK ÜSTÜN S., KÜÇÜK A., ÜNSAL M., NEYAL A., ATEŞ M. F., et al.

58. ULUSAL NÖROLOJİ KONGRESİ, 19 October 2022

- XXI. **Artificial Intelligence Applications in Neuroscience**
GÜL S., TERZİ M.

2. International Balkan Congress on Neurology and Neuroscience IBCNN, Tekirdağ, Turkey, 07 October 2022

- XXII. **Emulating randomized clinical trials in relapsing-remitting multiple sclerosis with nonrandomized real-world evidence: an application using data from the MSBase registry**
TERZİ M., TÜRKOĞLU R., BOZ C., ÖZAKBAŞ S., Butzkueven H., Horakova D., Kalincik T. K., Sormani M. P.
ECTRIMS 2022 26 – 28 October 2022 Amsterdam, the Netherlands 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Amsterdam, Netherlands, 26 - 28 October 2022, vol.28, pp.379-380

- XXIII. **Early Predictors of Disability in Paediatric Multiple Sclerosis: Evidence from a Multi-National Registry (P17-4.001)**

Kalincik T. K., TERZİ M., TÜRKOĞLU R., BOZ C., ALTINTAŞ A., Malpas C. B. M., Horakova D., Sharmin S.
American Academy of Neurology, Seattle, United States Of America, 20 May 2022, vol.98, pp.17

- XXIV. **FİNGOLİMOD, NATALİZUMAB VE OKRELİZUMABIN RELAPSİNG-REMİTTİNG MULTİPL SKLEROZDA KARŞILAŞTIRMALI ETKİNLİĞİ**

BOZ C., ÖZAKBAŞ S., TERZİ M., KARABUDAK R., SEVİM M. S., TÜRKOĞLU R., SOYSAL A., BALCI F. B., EFENDİ H., TURAN Ö. F., et al.

12.KLİNİK NÖROİMMÜNOLOJİ SEMPOZYUMU, Turkey, 12 - 15 May 2022, pp.10

- XXV. **Early Predictors of Disability in Paediatric Multiple Sclerosis: Evidence from a Multi -National Registry**

Sharmin S., Malpas C., Roos I., Diouf I., Alroughani R., Ozakbas S., Izquierdo G., Eichau S., Horakova D., Havrdova E. K., et al.

Annual Meeting of the American-Academy-of-Neurology, Washington, United States Of America, 2 - 07 April 2022

- XXVI. **Multiple Skleroz Hastalarında Geniş Band Timpanometri Bulguları**
KÜÇÜKÖNER A., KÜÇÜKÖNER Ö., KÖMÜR F. N., KAVAZ UŞTU E., TERZİ M.
9. Ulusal Otoloji Nörootoloji Kongresi-11. Koklear İmplant ve Odyoloji Kongresi, Turkey, 10 March 2022
- XXVII. **Obez Olan ve Olmayan Multipl Skleroz Hastalarında Kontrolateral Supresyon Bulguları**
KÜÇÜKÖNER A., HELVACI E. M., KÜÇÜKÖNER Ö., TERZİ M.
11.Ulusal Obezite Kongresi, Turkey, 3 - 06 March 2022
- XXVIII. **Biopsychosocial Evaluation in A Case with Multipl Sclerosis Accompanied by Lower Urinary Tract Dysfunctions**
KARAMAN S., GÜL S., TERZİ M.
3rd World Congress on Primary Healthcare and Medicare Summit, 2022, Samsun, Turkey, 07 February 2022
- XXIX. **MULTİPLE SKLEROZ HASTALARINDA BOS OLİGOKLONAL BANT SAYISI İLE HASTALARIN DEMOGRAFİK VE KLİNİK ÖZELLİKLER ARASINDAKİ İLİŞKİ**
TAŞKIRAN E., TERZİ M., TURAN Ö. F., YETKİN M. F., ÇİLİNGİR V., BİR L. S., CANBAZ KABAY S., BİLGE N., KOTAN DÜNDAR D., DEMİR C. F., et al.
57. ULUSAL NÖROLOJİ KONGRESİ, Antalya, Turkey, 27 November - 01 December 2021
- XXX. **MULTİPLE SKLEROZ HASTALARINDA BOS OLİGOKLONAL BANT SAYISI İLE HASTALARIN DEMOGRAFİK VE KLİNİK ÖZELLİKLER ARASINDAKİ İLİŞKİ**
TAŞKIRAN E., TERZİ M., TURAN Ö. F., YETKİN M. F., CANBAZ KABAY S., ÇİLİNGİR V., BİLGE N., KOTAN DÜNDAR D., DEMİR C. F., POYRAZ T., et al.
57. Ulusal Nöroloji kongresi, Antalya, Turkey, 27 November 2021
- XXXI. **Multipl Skleroz Hastalarının Alternatif Ürün Kullanım Oranlarının Saptanması ve Hastalık Seyri üzerine Olan Etkisinin Değerlendirilmesi**
HELVACI E. M., ERTAŞ ÖZTÜRK Y., TERZİ M., SÖKÜLMEZ KAYA P.
57.Ulusal Nöroloji Kongresi, 27 November - 01 December 2021
- XXXII. **Multipl Skleroz Klinik Takip ve İzleminde Akıllı Telefon Uygulaması(MUTLUSUN)**
TERZİ M., GÜL TÜRK S., COŞKUN US N., HELVACI E. M., KOÇ S.
57.Ulusal Nöroloji Kongresi, Antalya, Turkey, 27 November - 01 December 2021
- XXXIII. **Disease reactivation after cessation of disease-modifying therapy in relapsing-remitting multiple sclerosis**
ROOS I., MALPAS C., LERAY E., CASEY R., HORAKOVA D., Havrdova E., DEBOUVERIE M., PATTI F., DE SEZE J., IZQUIERDO G., et al.
ECTRIMS, 13 December 2021
- XXXIV. **Association of Latitude and Exposure to Ultraviolet B Radiation with Severity of Multiple Sclerosis**
Marianna V., Ibrahima D., Charles M., HORAKOVA D., KUBALA HAVRDOVA E., FRANCESKO P., OZAKBAŞ S., IZQUIERDO G., EICHAU S., Shaygannejad V., et al.
ECTRIMS, 13 October 2021
- XXXV. **Multipl Skleroz ve Mikrobiyota**
TERZİ M., HELVACI E. M.
8. Ulusal Bağırsak Mikrobiyotası ve Probiyotik Kongresi, 11 - 14 September 2021
- XXXVI. **TÜRKİYE DİMETİL FUMARAT ETKİNLİK VE GÜVENLİK ÇALIŞMASI: 'MS'İN GENÇ RUHU ÇALIŞMA GRUBU' GERÇEK YAŞAM VERİLERİ**
SEVİM M. S., ÇİLİNGİR V., DEMİR S., YÜCEYAR A. N., DEMİRKIRAN D. M., GÖKÇE Ş. F., GÜLER S., GÜMÜŞ H., BİR L. S., TERZİ M., et al.
57 ulusal nöroloji kongresi, Konya, Turkey, 27 November 2021
- XXXVII. **SARS-COV-2 ENFEKSİYONU İLİŞKİLİ YENİ TANILI MULTİPL SKLEROZ VE TÜMEFAKTİF DEMİYELİNİZAN LEZYON GELİŞEN LETM: VAKA SERİSİ**
ERDOĞAN T., KOÇER E. B., ŞEN S., BALCI F. B., TERZİ M.
57. Ulusal Nöroloji Kongresi, Antalya, Turkey, 27 November 2021
- XXXVIII. **Real-world experience with cladribine in the MSBase Registry**
BUTZKUEVEN h., SPELMAN T., Hodgkinson S., MADUENO S., IZQUIERDO G., BUZZARD K., SKABINA O., Van der Walt A., KALİNCİK T., GRANDMAISON F., et al.

ECTRIMS, 13 - 15 October 2021

XXXIX. Assessment of sexual dysfunction and related factors in female patients with multiple sclerosis

YENİ K., Tulek Z., TERZİ M.

ECTRIMS, 13 October 2021

XL. Real-world experience with ocrelizumab in relapsing multiple sclerosis: insights from the MSOCR-R cohort, an MSBase registry sub-study

BUTZKUEVEN H., SPELMAN T., OZAKBAŞ S., BOZ C., BUZZARD K., SKIBINA O., KALİNCİK T., Van der Walt A., ALROUGHANİ R., LECHNER-SCOTT J., et al.

ECTRIMS, 13 - 15 October 2021

XLI. Long-term outcomes in patients presenting with optic neuritis: analyses of the MSBase registry

KENNEY R., LIU M., ALROUGHANİ R., AMPAPA R., BERGAMASCHI R., BOZ C., BUTZKUEVEN H., GOMEZ J., CARTECHINI E., MADUENO S., et al.

ECTRIMS, 13 - 15 October 2021

XLII. Examination of tear fluid in patients with pre-diagnosis of MS

TERZİ M., HELVACI E. M., CAN N. N.

ECTRIMS, 13 - 16 October 2021

XLIII. Assessment of fatigue and related factors patients with multiple sclerosis

YENİ K., Tulek Z., TERZİ M.

ECTRIMS, 13 October 2021

XLIV. Comparison of the effectiveness of ocrelizumab vs interferons, fingolimod and natalizumab on relapses in relapsing-remitting multiple sclerosis

ROOS I., SHARMİN S., OZAKBAŞ S., HORAKOVA D., Havrdova E., BOZ C., ALROUGHANİ R., PATTI F., TERZİ M., LECHNER-SCOTT J., et al.

ECTRIMS, 13 - 15 October 2021

XLV. External validation of the MSBase model of individual treatment response

MORADİ N., SHARMİN S., MALPAS C., OZAKBAŞ S., SHAYGANNEJAD V., TERZİ M., BOZ C., YAMOUT B., KHOURY S., TÜRKOĞLU R., et al.

ECTRIMS, 13 - 15 October 2021

XLVI. A year with the fear of COVID-19 in multiple sclerosis patients: Examination of depression, sleep quality and quality of life before and after the pandemic

YENİ K., Tulek Z., TERZİ M.

ECTRIMS, 13 October 2021

XLVII. Relationship between stigma and symptom burden in patients with multiple sclerosis

YENİ K., ÖZDELİKARA A., TERZİ M.

ECTRIMS, 13 October 2021

XLVIII. Effect of self-acupressure on fatigue among patients with multiple sclerosis

YENİ K., TULEK Z., TERZİ M.

37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 13 - 15 October 2021, vol.27, pp.737

XLIX. Early predictors of disability in paediatric multiple sclerosis: evidence from a multi-national cohort

SHARMİN S., MALPAS c., ROOS I., DIOUF I., ALROUGHANİ R., OZAKBAŞ S., IZQUIERDO G., EICHAU S., HORAKOVA D., Havrdova E., et al.

National Health and Medical Research Council of Australia, 1 - 03 October 2021

L. Artificial Intelligence Based Gait Analysis in Multiple Sclerosis Patients

GÜL TÜRK S., TERZİ M.

1st International Balkan Congress on Neurology and Neuroscience, Turkey, 3 - 04 September 2021

LI. Tıpta dijitalleşme ve yapay zeka

GÜL TÜRK S., TERZİ M.

Azerbeycan Tıpta Güncel Sorunlar Kongresi, Azerbaijan, 08 October 2021

LII. Sinir Bilim ve Yapay Zeka

GÜL TÜRK S., TERZİ M.

6. İlaç ve Tedavi Kongresi-Akıllı İlaç Kullanımı, Turkey, 22 - 26 September 2021

- LIII. **Sanal Nörorehabilitasyon Uygulamasının Multipl Skleroz Hastalarının Yaşam Kalitesine ve Hastalık Seyrine Etkisi**
GÜL TÜRK S., TERZİ M.
Eskişehir Nöroloji Günleri Nöro-Romatoloji Sempozyumu Multipl Skleroz ve Ayrıcı Tanıda Romatolojik Hastalıklar, Turkey, 3 - 05 September 2021
- LIV. **Multiple Skleroz Hastalarında Kontralateral Supresyon**
KÜÇÜKÖNER A., KÜÇÜKÖNER Ö., ÖZGÜR A., TERZİ M.
8. Ulusal Otoloji Nörotoloji Kongresi, online, Turkey, 26 June 2021
- LV. **Delay from treatment start to full effect of immunotherapies for multiple sclerosis**
ROOS I., LERAY E., FRASCOLI F., CASEY R., WILLIAM J., HORAKOVA D., Havrdova E., Trojano M., PATTI F., IZQUIERDO G., et al.
NEUROLOGY, Philippines, 13 April 2021
- LVI. **Disability Accrual in Primary Progressive & Secondary Progressive Multiple Sclerosis**
Harding-Forrester S., ROOS I., SHARMİN S., DIOUF I., MALPAS C., NGUYEN A., MORADİ N., HORAKOVA D., KUBALA HAVRDOVA E., PATTI F., et al.
NEUROLOGY, 13 April 2021
- LVII. **Variability of the Response to Immunotherapy Among Sub-groups of Patients With Multiple Sclerosis**
DIOUF I., MALPAS C., HORAKOVA D., Havrdova E., PATTI F., SHAYGANNEJAD V., OZAKBAŞ S., AYUSO G., MADUENO S., ZAKARIA M., et al.
NEUROLOGY, 13 April 2021
- LVIII. **AİLE KATILIMLI BESLENME EĞİTİMİNİN MULTİPL SKLEROZ HASTALARININ BİLGİ DÜZEYİ VE BESLENMEYE YÖNELİK DAVRANIŞLARINA ETKİSİ**
UZDİL Z., TÜRKER P. F., TERZİ M.
4th International Health Sciences and Life Congress, Burdur, Turkey, 8 - 10 April 2021
- LIX. **MULTİPL SKLEROZ HASTALARINDA YORGUNLUK VE İLİŞKİLİ FAKTÖRLERİN DEĞERLENDİRİLMESİ**
YENİ K., TÜLEK Z., TERZİ M.
56. ULUSAL NÖROLOJİ KONGRESİ, Turkey, 28 November - 02 December 2020, pp.69
- LX. **MULTİPL SKLEROZ TANILI KADIN HASTALARDA CİNSEL İŞLEV BOZUKLUĞU VE İLİŞKİLİ FAKTÖRLERİN DEĞERLENDİRİLMESİ**
YENİ K., TÜLEK Z., TERZİ M.
56. ULUSAL NÖROLOJİ KONGRESİ, Turkey, 28 - 02 December 2020, pp.146
- LXI. **Multiple Skleroz (MS) Tanısı Almış Bireylerin, MS'e İlişkin Algılarının Belirlenmesi: Bir Metafor Analizi Çalışması**
GÜLEÇ KESKİN S., GÜLİRMAL K., TERZİ M.
1. Lisansüstü Hemşirelik Araştırmaları Sempozyumu, Samsun, Turkey, 26 - 29 November 2020
- LXII. **Multipl Skleroz (MS) Tanılı Bireylerin Öznel İyi Oluş Durumlarının İncelenmesi**
ÖZKAN N., GÜLEÇ KESKİN S., TERZİ M.
1. Lisansüstü Hemşirelik Araştırmaları Sempozyumu, Samsun, Turkey, 26 November 2020
- LXIII. **Davetli Konuşmacı**
TERZİ M.
56.Ulusal Nöroloji Kongresi, Turkey, 25 November 2020
- LXIV. **Bilimsel Sekreteryası**
TERZİ M.
11.Klinik Nöroimmunoloji Sempozyumu, Turkey, 19 November 2020
- LXV. **MOG IgG Related Disorders: Different Clinical Presentations**
DEMİR S., GÜMÜŞ H., ŞEN S., UZUNKÖPRÜ C., TOĞROL R. E., BECKMANN Y., TERZİ M.
6th Congress of the European Academy of Neurology, 23 May 2020
- LXVI. **Determinants of Therapeutic Lag in Multiple Sclerosis (2059)**
Roos I., Leray E., Frascoli F., Horakova D., Trojano M., Patti F., ÖZAKBAŞ S., BOZ C., TERZİ M., TÜRKÖĞLU R., et al.
American Academy of Neurology, United States Of America, 14 - 27 April 2020, vol.94, pp.2059

- LXVII. **Immunotherapies Improve Long-Term Disability Outcomes in Relapsing-Remitting Multiple Sclerosis**
Kalincik T., Ibrahima D., Malpas C., Horakova D., Havrdova E., Trojano M., Ayuso G., Eichau S., Onafre M., Lugaresi A., et al.
Annual Meeting of the American-Academy-of-Neurology, Toronto, Canada, 25 April - 01 May 2020
- LXVIII. **Identification of Therapeutic Lag in Multiple Sclerosis**
ROOS I., Leray E., FRASCOLI F., Casey R., Horakova D., Havrdova E., Trojano M., GI A., Madueno S., Patti F., et al.
Annual Meeting of the American-Academy-of-Neurology, Toronto, Canada, 25 February - 01 March 2020
- LXIX. **Predicting Long-Term Sustained Disability Progression in Multiple Sclerosis**
Sharmin S., Bovis F., Malpas C., Horakova D., Havrdova E., Ayuso G., Eichau S., Trojano M., Prat A., Girard M., et al.
Annual Meeting of the American-Academy-of-Neurology, Toronto, Canada, 25 April - 01 May 2020
- LXX. **Predicting Long-Term Sustained Disability Progression in Multiple Sclerosis (2002)**
Sharmin S., Bovis F., Malpas C. B., Horakova D., Trojana M., BOZ C., ÖZAKBAŞ S., TERZİ M., TÜRKOĞLU R., Sormani M. P., et al.
American Academy of Neurology, United States Of America, 14 - 26 April 2020, vol.94, pp.2002
- LXXI. **Identification of Therapeutic Lag in Multiple Sclerosis (1787)**
Roos I., Leray E., Frascoli F., Horakova D., Trojana M., ÖZAKBAŞ S., BOZ C., TERZİ M., TÜRKOĞLU R., Butzkueven H., et al.
American Academy of Neurology, United States Of America, 14 - 19 April 2020, vol.94, pp.1787
- LXXII. **Impact of Eculizumab on Health Outcomes in Patients with Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder: Findings from the PREVENT Study**
Berthele A., Pittock S. J., Fujihara K., Kim H. J., Levy M., Palace J., Nakashima I., Terzi M., Totolyan N., Viswanathan S., et al.
Annual Meeting of the American-Academy-of-Neurology, Toronto, Canada, 25 April - 01 May 2020, vol.94
- LXXIII. **Impact of Eculizumab on Hospitalization Rates and Relapse Treatment in Patients with Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder: the Phase 3 PREVENT Study**
Kim H. J., Pittock S. J., Berthele A., Fujihara K., Levy M., Palace J., Nakashima I., Terzi M., Totolyan N., Viswanathan S., et al.
Annual Meeting of the American-Academy-of-Neurology, Toronto, Canada, 25 April - 01 May 2020, vol.94
- LXXIV. **Long-term Safety and Efficacy of Eculizumab in Neuromyelitis Optica Spectrum Disorder**
Wingerchuk D. M., Pittock S. J., Berthele A., Fujihara K., Kim H. J., Levy M., Palace J., Nakashima I., Terzi M., Totolyan N., et al.
Annual Meeting of the American-Academy-of-Neurology, Toronto, Canada, 25 April - 01 May 2020, vol.94
- LXXV. **Benefit of Eculizumab for a Broad Range of Patients with Aquaporin-4 Antibody-positive Neuromyelitis Optica Spectrum Disorder: Findings from the Phase 3 PREVENT Study**
Fujihara K., Berthele A., Kim H. J., Levy M., Nakashima I., Oreja-Guevara C., Palace J., Pittock S. J., Terzi M., Totolyan N., et al.
Annual Meeting of the American-Academy-of-Neurology, Toronto, Canada, 25 April - 01 May 2020, vol.94
- LXXVI. **Impact of Eculizumab on Disability Worsening and Quality of Life in Patients with Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder: Results from the Phase 3 PREVENT Study**
Palace J., Pittock S. J., Berthele A., Fujihara K., Kim H. J., Levy M., Nakashima I., Terzi M., Totolyan N., Viswanathan S., et al.
Annual Meeting of the American-Academy-of-Neurology, Toronto, Canada, 25 April - 01 May 2020, vol.94
- LXXVII. **Efficacy and Safety of Eculizumab in Patients with Neuromyelitis Optica Spectrum Disorder Previously Treated with Rituximab: Findings from the Phase 3 PREVENT Study**
Levy M., Berthele A., Kim H. J., Fujihara K., Nakashima I., Oreja-Guevara C., Palace J., Pittock S., Terzi M., Totolyan N., et al.
Annual Meeting of the American-Academy-of-Neurology, Toronto, Canada, 25 April - 01 May 2020, vol.94
- LXXVIII. **of Therapeutic Lag in Relapsing Multiple Sclerosis**
ROOS I., FRASCOLI F., Horakova D., Havrdova E., Trojano M., Izquierdo G., Eichau S., Patti F., Prat A., Girard M., et al.
Conference of MS-Research-Australia, 31 October - 01 November 2019

- LXXIX. **Impact Of Eculizumab On Quality Of Life In AQP4NMOSD: Findings From The PREVENT Study**
BERTHELE A., PİTTOCK S. J., FUJİHARA K., KİM H. J., LEVY M., PALACE J., NAKASHİMA I., TERZİ M., TOTOLYAN N.,
Viswanathan S., et al.
Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS) Forum, 27 - 29 February 2020
- LXXX. **Long-term Safety And Effectiveness Of Eculizumab In Neuromyelitis Optica Spectrum Disorder**
WİNGERCHUK D. M., PİTTOCK S. J., BERTHELE A., FUJİHARA K., KİM H. J., LEVY M., PALACE J., NAKASHİMA I., TERZİ
M., TOTOLYAN N., et al.
Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS) Forum, 27 - 29 February 2020,
pp.107
- LXXXI. **Caregiver Burden in MS**
TERZİ M., Imanova R., Koc S.
Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS) Forum, 27 - 29 February 2020
- LXXXII. **Impact Of Eculizumab On Hospitalization Rates And Relapse Treatment In Patients With
AQP4NMOSD: The Phase 3 PREVENT Study**
KİM H. J., PİTTOCK S. J., BERTHELE A., FUJİHARA K., LEVY M., PALACE J., NAKASHİMA I., TERZİ M., TOTOLYAN N.,
Viswanathan S., et al.
Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS) Forum, 27 - 29 February 2020
- LXXXIII. **Does Obesity Affect Clinical Course in Patients with Multiple Sclerosis?**
UZDİL Z., KAYA S., SÖKÜLMEZ KAYA P., TERZİ M.
2. Uluslararası Sağlıklı Beslenme Kongresi, Ankara, Turkey, 10 - 12 October 2019
- LXXXIV. **MULTİPL SKLEROZ HASTALARINDA OBEZİTE KLİNİK SEYRİ ETKİLER Mİ?**
UZDİL Z., KAYA S., SÖKÜLMEZ KAYA P., TERZİ M.
2. Uluslararası Sağlıklı Beslenme Kongresi, Ankara, Turkey, 10 - 12 October 2019
- LXXXV. **SS-78 GEÇ VE ERKEN BAŞLANGIÇLI MULTİPLE SKLEROZHASTALARINDA, KLİNİK VE HASTALIK
PROGRESYONUFARKLILIKLARI**
ZENGİN KARAHAHAN S., bilgiç a. b., KARAMAN A. G., BOZ C., TERZİ M.
55. Ulusal Nöroloji Kongresi, Turkey, 15 - 21 November 2019
- LXXXVI. **BİR ULUSAL ÇALIŞMANIN YÖNTEMİ (ENVIROPIMS): YENİ TANI ALMIŞ ERİŞKİN, ERGEN VE ÇOCUK
MULTİPLE SKLEROZ(MS) OLGULARINDA OBEZİTE, SAĞLIKLI BESLENME VE FİZİKSEL AKTİVİTE
DURUMUNUN ARAŞTIRILMASI**
YÜCEYAR A. N., AKMAN DEMİR G., ALTUNRENDE B., BECKMANN Y., BOZ C., CANBAZ KABAY S., ÇİLİNGİR V.,
DEMİRKİRAN D. M., DEMİR C. F., EFENDİ H., et al.
55. ULUSAL NÖROLOJİ KONGRESİ, Antalya, Turkey, 15 - 21 November 2019
- LXXXVII. **MULTİPL SKLEROZ HASTALARINDA FİNGOLİMOD TEDAVİSİNİN ETKİLİLİĞİ : TÜRKİYE GERÇEK
YAŞAM VERİLERİ (REFINE)**
TUNCER M. A., UYGUNOĞLU U., TERZİ M., KÜRTÜNCÜ M., YÜCEYAR A. N., EKMEKÇİ Ö., TÜRKOĞLU R., SOYSAL A.,
KÖSEOĞLU M., GÖZÜBATIK ÇELİK G., et al.
55. ULUSAL NÖROLOJİ KONGRESİ, Antalya, Turkey, 15 - 21 November 2019
- LXXXVIII. **Multipl Skleroz Hastalarında Fingolimod Tedavisinin Etkililiği : Türkiye Gerçek Yaşam Verileri**
TUNCER M. A., UYGUNOĞLU U., TERZİ M., KÜRTÜNCÜ M., YÜCEYAR A. N., EKMEKÇİ Ö., TÜRKOĞLU R., SOYSAL A.,
KÖSEOĞLU M., GÖZÜBATIK ÇELİK R. G., et al.
55. Ulusal Nöroloji Kongresi, Antalya, Turkey, 15 - 21 November 2019
- LXXXIX. **Gebelik ve İmmün Kökenli Nörolojik Hastalıklar:Planlama-İzlem ve Tedavi**
TERZİ M.
55. Ulusal Nöroloji Kongresi, Antalya, Turkey, 16 - 20 November 2019
- XC. **Olgu örnekleri ile MS, NMO, ADEM ve demyelinizan hastalıklar spektrumunda BOS incelemesi**
TERZİ M.
55. Ulusal Nöroloji Kongresi, Antalya, Turkey, 16 - 20 November 2019
- XCİ. **MULTİPL SKLEROZ HASTALARINDA FİNGOLİMODTEDAVİSİNİN ETKİLİLİĞİ : TÜRKİYE GERÇEK
YAŞAMVERİLERİ (REFINE)**
TUNCER M. A., UYGUNOĞLU U., TERZİ M., KÜRTÜNCÜ M., YÜCEYAR A. N., Ekmekci Ö., Türkoğlu R., Soysal A.,

KÖSEOĞLU M., GÖZÜBATIK ÇELİK G., et al.

55. Ulusal Nöroloji Kongresi, Antalya, Turkey, 15 - 21 November 2019, pp.276

XCII. SS-46 OCRELİZUMAB TEDAVİSİ GERÇEK YAŞAM VERİLERİ:3 MULTİPL SKLEROZ MERKEZİNİN TECRÜBELERİ

VURAL E., TERZİ M., SÜNTER G., GÜNAL D., AĞAN YILDIRIM K., BOZ C.

55. Ulusal Nöroloji Kongresi, Antalya, Turkey, 16 - 20 November 2019, pp.30

XCIII. EP - 12 PARKİNSON HASTALIĞINDA SUBKUTANAPOMORFİN DENEYİMİ

OCAK Ş., SEMİZ P., ŞEN S., TERZİ M.

55. Ulusal Nöroloji Kongresi, Antalya, Turkey, 16 - 20 November 2019, pp.122

XCIV. SS-77 BİR ULUSAL ÇALIŞMANIN YÖNTEMİ (ENVIROPIMS):YENİ TANI ALMIŞ ERİŞKİN, ERGEN VE ÇOCUK MULTİPLESKLEROZ(MS) OLGULARINDA OBEZİTE, SAĞLIKLIBESLENME VE FİZİKSEL AKTİVİTE DURUMUNUNARAŞTIRILMASI

YÜCEYAR A. N., AKMAN G., ALTUNRENDE B., BECKMANN Y., BOZ C., CANBAZ KABAY S., ÇİLİNGİR V., DEMİRKIRAN D. M., DEMİR C. F., EFENDİ H., et al.

55. Ulusal Nöroloji Kongresi, Antalya, Turkey, 16 - 20 November 2019, pp.45

XCIV. Multipl Skleroz Hastalarında Fingolimod Tedavisinin etkililiği: Türkiye Gerçek Yaşam Verileri

TUNCER M. A., UYGUNOĞLU U., TERZİ M., KÜRTÜNCÜ M., Yüceyar N., EKMEKÇİ Ö., TÜRKOĞLU R., Soysal A., köseoğlu m., GÖZÜBATIK ÇELİK R. G., et al.

55. Ulusal Nöroloji Kongresi, Antalya, Turkey, 15 - 21 November 2019

XCVI. Efficacy Of Rituximab in Neuromyelitis Optica Spectrum Disorder: A Retrospective-Multicenter Study

UZUNKÖPRÜ C., TÜTÜNCÜ M., GÜNDÜZ T., ŞEN S., GÜMÜŞ H., DEMİR S., PİRİ ÇINAR B., TÜRE H. S., KÜRTÜNCÜ M., TERZİ M., et al.

İstanbul MS Days VI, İstanbul, Turkey, 31 October - 02 November 2019

XCVII. Panel Tartışması

TERZİ M.

MS Days VI, İstanbul, Turkey, 31 October - 02 November 2019

XCVIII. Effect of kinesiophobia on functional level and quality of life inmultiple sclerosis

TERZİ M., PINAR E.

XXIV WORLD CONGRESS OF NEUROLOGY - WCN 2019, Dubai, United Arab Emirates, 27 - 31 October 2019

XCIX. The relationship between clinical and demographic characteristics and suicidal ideation in patients with multiple sclerosis

TERZİ M., ALLAHGULUZADE N.

XXIV WORLD CONGRESS OF NEUROLOGY - WCN 2019, Dubai, United Arab Emirates, 27 - 31 October 2019

C. Does obesity affect clinical course in patients with multiple sclerosis

UZDİL Z., KAYA S., SÖKÜLMEZ KAYA P., TERZİ M.

2. ULUSLARARASI SAĞLIKLI BESLENME KONGRESİ, Ankara, Turkey, 10 - 12 October 2019, pp.391-402

CI. OTURUM BAŞKANI

TERZİ M.

4. Multipl Sklerozda Fizyoterapi ve Nörerehabilitasyon Sempozyumu, Kütahya, Turkey, 4 - 05 October 2019

CII. SEMPOZYUM DÜZENLEME KURULU

TERZİ M.

Multipl Skleroz Hasta Bakım Sempozyumu, Mardin, Turkey, 20 - 22 September 2019

CIII. EDSS, MSFC, 25 Adım Yürüme Testi Nasıl Yapılır? Hasta Takibinde ve İlaç Raporlarındaki Yeri Nedir?

TERZİ M.

Multipl Skleroz Hasta Bakım Sempozyumu, Mardin, Turkey, 20 - 22 September 2019

CIV. OTURUM BAŞKANI-25 Adım Yürüme Testi, 9 Delikli Test, PASAT Testi Eğitimi ve Sertifikasyon

TERZİ M.

Multipl Skleroz Hasta Bakım Sempozyumu, Mardin, Turkey, 20 - 22 September 2019

CV. Aggressive form of multiple sclerosis can be predicted early after disease onset

Malpas C., Manouchehrinia A., Sharmin S., ROOS I., Horakova D., Havrdova E., Trojano M., Izquierdo G., Eichau S., Bergamaschi R., et al.

35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, Sweden, 11 - 13 September 2019

CVI. Modifiers of the effectiveness of MS immunotherapies

Kalincik T., Malpas C., Sharmin S., Horakova D., Havrdova E., Trojano M., Izquierdo G., Eichau S., Onofrj M., Lugaresi A., et al.

35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, Sweden, 11 - 13 September 2019

CVII. MS cohorts and treatment utilization in academic centres in the Middle East

MORADI N., Sharmin S., Malpas C., ÖZAKBAŞ S., Shaygannejad V., Alroughani R., TERZİ M., BOZ C., Yamout B., Türkoğlu R., et al.

35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, Sweden, 11 - 13 September 2019

CVIII. Therapeutic lag in relapsing multiple sclerosis

ROOS I., FRASCOLI F., Horakova D., Havrdova E., Trojano M., Izquierdo G., Eichau S., Patti F., Onofrj M., Lugaresi A., et al.

35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, Sweden, 11 - 13 September 2019

CIX. Comparison of the effectiveness of rituximab versus alemtuzumab and natalizumab in active relapsing-remitting MS

Kalincik T., Malpas C., Sharmin S., ROOS I., Patti F., Butzkueven H., Alroughani R., Izquierdo G., Eichau S., Onofrj M., et al.

35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, Sweden, 11 - 13 September 2019

CX. Introducing Machine Learning for full MS patient trajectories improves predictions for disability score progression

BROUWER E., PEETERS L., BECKER T., ALTINTAŞ A., Soysal A., Van Wijmeersch B., BOZ C., OrejaGuevara C., GOBBİ C., Solaro C., et al.

35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, Sweden, 11 - 13 September 2019

CXI. Real-world experience with Ocrelizumab in the MSBase Registry

Butzkueven H., Spelman T., Patti F., ÖZAKBAŞ S., Eichau S., Alroughani R., TERZİ M., BOZ C., GrandMaison F., Grammond P., et al.

35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, Sweden, 11 - 13 September 2019

CXII. Determinants of therapeutic lag in relapsing multiple sclerosis

ROOS I., FRASCOLI F., Horakova D., Havrdova E., Trojano M., Izquierdo G., Eichau S., Patti F., Prat A., Girard M., et al.

35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, Sweden, 11 - 13 September 2019

CXIII. Multiple Sclerosis Severity Score (MSSS) helps predict relapses and recovery from disability in patients treated for multiple sclerosis in the MSBase model

Kister I., BACON T., Malpas C., Sharmin S., Horakova D., Havrdova E., Patti F., Izquierdo G., Eichau S., ÖZAKBAŞ S., et al.

35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, Sweden, 11 - 13 September 2019

CXIV. Comparative effectiveness of natalizumab and fingolimod in different subgroups of patients with relapsing-remitting multiple sclerosis

Sharmin S., Lefort M., Andersen J., Horakova D., Havrdova E., Alroughani R., Izquierdo G., Eichau S., ÖZAKBAŞ S., Butzkueven H., et al.

35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, Sweden, 11 - 13 September 2019

CXV. Long-term safety and effectiveness of eculizumab in neuromyelitis optica spectrum disorder

Wingerchuk D. M., Pittock S. J., Berthele A., Fujihara K., Kim H., Levy M., Palace M., Nakashima I., TERZİ M., Totolyan N., et al.

35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, Sweden, 11 - 13 September 2019

CXVI. EVALUATION OF RELATIONSHIP BETWEEN VISCERAL ADIPOSITY INDEX (VAI) AND LIPIDS IN MULTIPLE SCLEROSIS (MS) PATIENTS

UZDİL Z., KAYA S., SÖKÜLMEZ KAYA P., TERZİ M.

4 1ST ESPEN CONGRESS, Krakow, Poland, 31 August - 03 September 2019, vol.38, pp.234

CXVII. Impact of eculizumab on disability measures in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: phase 3 PREVENT study

Palace J., Pittock S. J., Berthele A., Fujihara K., Kim H. J., Levy M., Nakashima I., Terzi M., Totolyan N., Viswanathan S., et al.

35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, Sweden, 11 - 13 September 2019, vol.25, pp.737-738

CXVIII. Subgroup analyses from the Phase 3 PREVENT study in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder

Pittock S., Berthele A., Fujihara K., Kim H. J., Levy M., Palace J., Terzi M., Totolyan N., Viswanathan S., Wang K. -, et al.

35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, Sweden, 11 - 13 September 2019, vol.25, pp.289-290

CXIX. Real world efficacy and safety of teriflunomide in multiple sclerosis: an observational study with four years follow-up

BOZ C., Terzi M., ÖZAKBAŞ S., YÜCEYAR A. N., Efendi H., Balci B. P., Turkoglu R., Karabudak R., Soysal A., YETKİN M. F., et al.

35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, Sweden, 11 - 13 September 2019, vol.25, pp.870

CXX. A multicenter international study to evaluate different aspects of relationship between MS and pregnancy

Altintas A., Zakaria M., Alroughani R., Moghadasi A. N., Terzi M., Sen S., Koseoglu M., Efendi H., Soysal A., Gozubatik-Celik G., et al.

35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, Sweden, 11 - 13 September 2019, vol.25, pp.176-177

CXXI. Impact of eculizumab on reported quality of life in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: findings from the PREVENT study

Berthele A., Pittock S. J., Fujihara K., Kim H. J., Levy M., Palace J., Nakashima I., Terzi M., Totolyan N., Viswanathan S., et al.

35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, Sweden, 11 - 13 September 2019, vol.25, pp.294-295

CXXII. Impact of eculizumab on hospitalization rates and relapse treatment in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: findings from the phase 3 PREVENT study

Kim H. J., Pittock S. J., Berthele A., Fujihara K., Levy M., Palace J., Nakashima I., Terzi M., Totolyan N., Viswanathan S., et al.

35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, Sweden, 11 - 13 September 2019, vol.25, pp.288-289

CXXIII. Personalizing treatment effect based on patient's baseline profile: a statistical modelling approach applied to randomized clinical trial and observational study data

Bovis F., Kalincik T., Lublin F., Cutter G., Malpas C., Horakova D., Havrdova E. K., Trojano M., Prat A., Girard M., et al.

35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, Sweden, 11 - 13 September 2019, vol.25, pp.788-790

CXXIV. Real-life outcomes of Ocrelizumab treatment from 3 multiple sclerosis centers in Turkey

Vural E., Terzi M., Sunter G., Gunal D., Agan K., BOZ C.

35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th

Annual Conference of Rehabilitation in MS, Stockholm, Sweden, 11 - 13 September 2019, vol.25, pp.751

- CXXV. **EVALUATION OF RELATIONSHIP BETWEEN VISCERAL ADIPOSITY INDEX (VAI) AND BLOOD LIPIDS IN MULTIPLE SCLEROSIS (MS) PATIENTS**
UZDİL Z., KAYA S., SÖKÜLMEZ KAYA P., TERZİ M.
41st ESPEN Congress, Krakow, Poland, 31 August - 03 September 2019, vol.38, pp.234
- CXXVI. **Multipl Skleroz Epidemiyolojisi, Genetik ve Çevresel Risk Faktörleri**
TERZİ M.
1. Multipl Skleroz ve Otoimmün Hastalıklarda Çocukluktan Erişkinliğe Geçiş Sempozyumu, Kütahya, Turkey, 14 - 16 June 2019
- CXXVII. **OTURUM BAŞKANI - Erken MS Rehabilitasyonu: Gözden Kaçan Bir Fırsat Penceresi mi ?**
TERZİ M.
MS'xxDE SAĞLIKLI YAŞAM SEMPOZYUMU, İzmir, Turkey, 25 - 26 May 2019
- CXXVIII. **Clinical determinants and therapeutic modifiers of relapse and disability outcomes in neuromyelitis optica spectrum disorder**
Kunchok A., Malpas C., Nytrova P., Havrdova E., Alroughani R., TERZİ M., Yamout B., HOR J., KARABUDAK R., BOZ C., et al.
71st Annual Meeting of the American-Academy-of-Neurology (AAN), Philadelphia, United States Of America, 4 - 10 May 2019
- CXXIX. **Nöroimmünolojik hastalıklarda laboratuvar dan kliniğe**
TERZİ M.
III. Klinik Nöroimmünoloji Akademisi, Trabzon, Turkey, 20 - 21 April 2019
- CXXX. **MODERATÖR**
TERZİ M.
III. Klinik Nöroimmünoloji Akademisi, Trabzon, Turkey, 20 - 21 April 2019
- CXXXI. **Tedaviyi Sonlandırmak Mümkün mü?**
TERZİ M.
8. TEMEL İMMUNOLOJİ VE NÖROİMMUNOLOJİ OKULU 2019, Muğla, Turkey, 4 - 07 April 2019
- CXXXII. **OTURUM BAŞKANI :Nöroimmünolojik Testleri Tanımak ve Anlamak – Laboratuvar dan Kliniğe**
TERZİ M.
8. TEMEL İMMUNOLOJİ VE NÖROİMMUNOLOJİ OKULU 2019, Muğla, Turkey, 4 - 07 April 2019
- CXXXIII. **ANTİ MYELİNE OLİGODENDROCYTE GLİCOPROTEİN (ANTİ-MOG) POZİTİF TESPİT EDİLEN 3 OLGU: 3 FARKLI KLİNİK PREZENTASYON**
DEMİR S., ŞEN S., TERZİ M., TOĞROL R. E.
9.NÖROİMMUNOLOJİ OKULU, MUĞLA DALAMAN, Turkey, 4 - 07 April 2019
- CXXXIV. **MOG'la İlişkili Demiyelinizan Hastalıklar**
TERZİ M.
14. Uludağ Nöroloji Günleri, Bursa, Turkey, 10 - 13 March 2019
- CXXXV. **The relationship between CSF oligoclonal band positivity and IgG index and visual evoked potential measurements in patients with multiple sclerosis**
TOSUN S., DUMAN KIYMIK İ., TERZİ M.
17. ulusal sinir bilim kongresi, Turkey, 4 - 07 April 2019, vol.13, pp.26
- CXXXVI. **P148 - Familial Involvement in Multiple Sclerosis**
TERZİ M., ŞEN S., EVİN Ö.
Americas Committee for Treatment and Research in Multiple Sclerosis 2019, DALLAS, United States Of America, 28 February - 02 March 2019
- CXXXVII. **DÜZENLEME VE BİLİMSEL KURUL**
TERZİ M.
International Turkic World Congress of Multiple Sclerosis, İstanbul, Turkey, 14 - 17 February 2019
- CXXXVIII. **OTURUM BAŞKANI - MULTİPL SKLEROZ'DA LABROTUVAR**
TERZİ M.
International Turkic World Congress of Multiple Sclerosis, İstanbul, Turkey, 14 - 17 February 2019

- CXXXIX. **Multipl Skleroz'da BOS**
TERZİ M.
International Turkic World Congress of Multiple Sclerosis, İstanbul, Turkey, 14 - 17 February 2019
- CXL. **NÖROLOJİDE MESLEK HASTALIKLARI VE ÇEVRE SAĞLIĞI ÇALIŞTAYI- Çevresel Faktörler ve Multipl Skleroz**
TERZİ M.
54. ULUSAL NÖROLOJİ KONGRESİ, Antalya, Turkey, 30 November - 06 December 2018
- CXLI. **MS, NMO, ADEM ve Demiyelinizan Hastalıklar Spektrumunda BOS İncelemesi**
TERZİ M.
54. ULUSAL NÖROLOJİ KONGRESİ, Antalya, Turkey, 30 November - 06 December 2018
- CXLII. **Nöromiyelitis Optika Spektrumunda Anti Miyelin Oligodendrosit Glikoprotein (Mog) Pozitifliği**
TERZİ M., GÜR VURAL D., GÜNGÖR B., AVCI B., İDİMAN E., KÖSEOĞLU M., SOYSAL A., YAYLA V. A., KIZILAY F., BİLGE N., et al.
54. Ulusal Nöroloji Kongresi, Antalya, Turkey, 30 November - 06 December 2018
- CXLIII. **KARDEŞ SIRASININ MULTİPL SKLEROZ TANISIYLA İLİŞKİSİ**
KOÇ S., EVİN Ö., TERZİ M.
54. ULUSAL NÖROLOJİ KONGRESİ, Antalya, Turkey, 30 November - 06 December 2018, pp.315
- CXLIV. **MULTİPL SKLEROZ'DA FİNGOLİMOD TEDAVİSİNİN BEŞİNCİ YIL ETKİNLİK VE GÜVENİLİRLİK VERİLERİ**
EVİN Ö., TERZİ M.
54. ULUSAL NÖROLOJİ KONGRESİ, Antalya, Turkey, 30 November - 06 December 2018, pp.64
- CXLV. **MULTİPL SKLEROZ AİLE ÖYKÜSÜ OLAN HASTALARIN KLİNİK VE DEMOGRAFİK ÖZELLİKLERİ**
EVİN Ö., KOÇ S., TERZİ M.
54. ULUSAL NÖROLOJİ KONGRESİ, Antalya, Turkey, 30 November - 06 December 2018, pp.315
- CXLVI. **NÖROMİYELİTİS OPTİKA SPEKTRUMUNDA ANTİ MYELİN OLİGODENDROSİT GLİKOPROTEİN(MOG) POZİTİFLİĞİ**
TERZİ M., GÜR VURAL D., GÜNGÖR B., AVCI B., İDİMAN E., KÖSEOĞLU M., Soysal A., YAYLA V., KIZILAY F., BİLGE N., et al.
54. ULUSAL NÖROLOJİ KONGRESİ, Antalya, Turkey, 30 November - 06 December 2018, pp.236
- CXLVII. **MS'TE SEMPTOMATİK TEDAVİLER**
TERZİ M.
3. MULTİPL SKLEROZDA KOGNİSYON SEMPOZYUMU, İzmir, Turkey, 10 - 11 November 2018
- CXLVIII. **UNDERSTANDING MS AND ITS MANAGEMENT IN TURKEY IN 2018**
TERZİ M.
MS DAYS V, 2 - 04 November 2018
- CXLIX. **MULTİPL SKLEROZDA FİNGOLİMOD TEDAVİSİ SONRASI GELİŞEN GEBELİĞİN HASTALIK SEYRİNE OLAN ETKİSİ**
TERZİ M., EVİN Ö., BOZ C., ONAR M. K.
MS DAYS V, KYRENIA, 2 - 04 November 2018, pp.15
- CL. **MULTİPL SKLEROZDA OLİGOKLONAL BAND POZİTİFLİĞİNİN KLİNİK VE PROGNOSTİK ÖNEMİ**
TERZİ M., EVİN Ö., KOÇ S., TERZİ Y.
MS DAYS V, 2 - 04 November 2018, pp.6
- CLI. **Nöroimmünoloji Laboratuvarı**
TERZİ M.
13. ÇUKUROVA NÖROLOJİ GÜNLERİ, Gaziantep, Turkey, 19 - 21 October 2018
- CLII. **Olğularla İnflamatuar SSS ve PSS Hastalıklarında Tanı ve Tedavi Gecesi**
TERZİ M.
13. ÇUKUROVA NÖROLOJİ GÜNLERİ, Gaziantep, Turkey, 19 - 21 October 2018
- CLIII. **Methylprednisolone concentration in milk and serum during and shortly after IV pulse therapy in patients with MS**
BOZ C., Özer B., TERZİ M., ZENGİN KARAHAN S., ŞEN S., MAVİŞ M., SARAÇ Y.

34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Berlin, Germany, 10 - 12 October 2018, pp.251

- CLIV. **Familial multiple sclerosis: comparing demographic and clinical characteristics with sporadic form**
Eichau S., Spelman T., Izquierdo G., Laffaldano P., OrejaGuevara C., Butzkueven H., Larochelle C., BOZ C., TERZİ M., Alroughani R., et al.

34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Berlin, Germany, 10 - 12 October 2018, pp.31

- CLV. **RLS is an important and frequent cause of depression and anxiety in patients with MS: striking results of the 'xxRELOMS-T'xx**

SEVİM M. S., DEMİRKIRAN D. M., TERZİ M., YÜCEYAR A. N., TAŞDELEN B., İDİMAN E., KÜRTÜNCÜ M., BOZ C., TUNCEL D., KARABUDAK R., et al.

34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Berlin, Germany, 10 - 12 October 2018, pp.100

- CLVI. **Determinants of MS re-activation after discontinuing therapies**

Husin H., Wallace J., Malpas C., Sharmin S., Horakova D., Izquierdo G., Eichau S., Prat A., Girard M., Duquette P., et al.

34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Berlin, Germany, 10 - 12 October 2018, pp.122

- CLVII. **Comparative effectiveness of switching to natalizumab or fingolimod after relapse on first-line relapsing-remitting multiple sclerosis therapy: propensity score matching analysis from the MSBase registry**

Spelman T., Havrdova E., Horakova D., Izquierdo G., Kalincik T., Lugaresi A., Onofrij M., Duquette P., Girard M., Prat A., et al.

34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Berlin, Germany, 10 - 12 October 2018, pp.31

- CLVIII. **Clinical and therapeutic predictors of relapse and disability outcomes in neuromyelitis optica spectrum disorder**

Kunchok A., Malpas C., Horakova D., Havrdova E., Alroughani R., TERZİ M., Yamout B., KARABUDAK R., BOZ C., ÖZAKBAŞ S., et al.

34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Berlin, Germany, 10 - 12 October 2018, pp.164

- CLIX. **Early clinical predictors of severe MS**

Malpas C., Sharmin S., Horakova D., Havrdova E., Havrdova E. K., Trojano M., Izquierdo G., Bergamaschi R., Sola P., Ferraro D., et al.

34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Berlin, Germany, 10 - 12 October 2018, pp.164

- CLX. **Disability outcomes in patients with early cerebellar symptoms in multiple sclerosis**

Le M. V. H., Malpas C., Sharmin S., Horakova D., Havrdova E., Trojano M., Izquierdo G., Eichau S., ÖZAKBAŞ S., Lugaresi A., et al.

34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Berlin, Germany, 10 - 12 October 2018, pp.93

- CLXI. **Determinants of disability accumulation in secondary-progressive multiple sclerosis**

Lizak N., Malpas C., Sharmin S., Havrdova E., Horakova D., Izquierdo G., Eichau S., Lugaresi A., Girard M., Duquette P., et al.

34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Berlin, Germany, 10 - 12 October 2018, pp.30

- CLXII. **Demiyelinizan Hastalıklarda Ayırıcı Tanı**

TERZİ M.

MS MASTER 2018, Nevşehir, Turkey, 28 - 30 September 2018

- CLXIII. **SEMPOZYUM BİLİMSEL KURULU**

TERZİ M.

MS MASTER 2018, Nevşehir, Turkey, 28 - 30 September 2018

- CLXIV. **Yeni Ufuklar – Bunun “medium”u var mı? Engelliğin Ölçümünde Giyilebilir Teknolojiler Oturum Başkanları: Dr. Murat Terzi**
TERZİ M.
2. Multipl Sklerozda Fiziksel Engelliliğin Ölçümü Sempozyumu, İzmir, Turkey, 19 - 20 May 2018
- CLXV. **KOORDİNATÖR**
TERZİ M.
3. Multipl Sklerozda Fizyoterapi ve Nörorehabilitasyon Sempozyumu, Samsun, Turkey, 11 - 13 May 2018
- CLXVI. **V.Oturum: Nörorehabilitasyonda Müzik Terapi- Oturum Başkanı**
TERZİ M.
3. Multipl Sklerozda Fizyoterapi ve Nörorehabilitasyon Sempozyumu, Samsun, Turkey, 11 - 13 May 2018
- CLXVII. **X. Oturum: MS’de Nörorehabilitasyon Çalışma Gruplarının Oluşturulması- Oturum Başkanı**
TERZİ M.
3. Multipl Sklerozda Fizyoterapi ve Nörorehabilitasyon Sempozyumu, Samsun, Turkey, 11 - 13 May 2018
- CLXVIII. **Let’s raise the awareness of MS specialists concerning the frequency and impact of RLS in MS and consequently the life quality of patients with MS: Striking results of the ‘RELOMS-T’ Study.**
SEVİM M. S., DEMİRKIRAN D. M., TERZİ M., YÜCEYAR A. N., TAŞDELEN B., idiman e., KÜRTÜNCÜ M., TUNCEL D., KARABUDAK R., SİVA A., et al.
American Academy of Neurology, 21 March - 27 April 2018
- CLXIX. **KONUŞMACI.**
TERZİ M.
10. KLİNİK NÖROİMMUNOLOJİ SEMPOZYUMU, Turkey, 1 - 05 April 2018
- CLXX. **Multipl Sklerozda Veri Girişinde Karşılaşılan Sorunlar**
TERZİ M.
Multiple Skleroz Hemşire Sempozyumu, Gaziantep, Turkey, 24 - 25 March 2018
- CLXXI. **Oturum Başkanı: Multipl Skleroz’da Klinik Hemşireliği Desteğinin Geliştirilmesi ve Ortak Projeler – Yurtdışı Proje Örnekleri**
TERZİ M.
Multiple Skleroz Hemşire Sempozyumu, Gaziantep, Turkey, 24 - 25 March 2018
- CLXXII. **Örnek Veri Tabanlarına Hasta Girişi Pratiği**
TERZİ M.
Multiple Skleroz Hemşire Sempozyumu, Gaziantep, Turkey, 24 - 25 March 2018
- CLXXIII. **Oturum Başkanı**
TERZİ M.
Multiple Skleroz Hemşire Sempozyumu, Gaziantep, Turkey, 24 - 25 March 2018
- CLXXIV. **DÜZENLEME KURULU**
TERZİ M.
Multiple Skleroz Hemşire Sempozyumu, Gaziantep, Turkey, 24 - 25 March 2018
- CLXXV. **Mortality in Multiple Sclerosis**
Terzi M., Sen S., Kizilates G., Onar M.
10th Congress of the Pan-Asian-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (PACTRIMS), Ho Chi Minh City, Vietnam, 23 - 25 November 2017, vol.24, pp.383
- CLXXVI. **Vitamin D Receptor Gene Polymorphism in Patients with Multiple Sclerosis**
TERZİ M., Şen S., GÜNEŞ S., CANBAZ S., ONAR M. K.
Forum of the Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS), 24 - 26 February 2018, vol.24, pp.117-118
- CLXXVII. **Tumor Necrosis Factor Alpha and Beta Receptor Gene Polymorphism in Multiple Sclerosis Patients**
Terzi M., Güneş S., Sen S., Kizilates G.
Forum of the Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS), California, United States Of America, 1 - 03 February 2018, vol.24, pp.62
- CLXXVIII. **Vitamin D Receptor Gene Polymorphism in Patients with Multiple Sclerosis**
Terzi M., Sen S., Güneş S., CANBAZ S., Onar M.

Forum of the Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS), California, United States Of America, 1 - 03 February 2018, vol.24, pp.61-62

- CLXXIX. **MULTİPL SKLEROZ'DA FİNGOLİMOD TEDAVİSİNİN LABORATUAR PARAMETRELERİ ÜZERİNE ETKİSİ**
TERZİ M., BEKİR Ö., ŞEN S., ONAR M. K.
53. ULUSAL NÖROLOJİ KONGRESİ, Turkey, 24 - 30 November 2017
- CLXXX. **EPİLEPTİK NÖBET İLE PREZENTE OLAN NÖROSARKOİDOZ OLGUSU**
DOĞAN B., KORKUT GEDİK D., TERZİ M.
53. ULUSAL NÖROLOJİ KONGRESİ, Turkey, 24 - 30 November 2017
- CLXXXI. **MULTİPL SKLEROZDA TERİFLUNAMİD TEDAVİSİ GERÇEK YAŞAM VERİSİ**
TERZİ M., ŞEN S., ONAR M. K.
53. ULUSAL NÖROLOJİ KONGRESİ, Turkey, 24 - 30 November 2017
- CLXXXII. **MULTİPL SKLEROZDA FAMPRİDİNE TEDAVİSİ SONRASI TRİGEMİNAL NEVRALJİ**
TERZİ M., BOZ C., ŞENER M., BEKİR Ö., ŞEN S.
53. ULUSAL NÖROLOJİ KONGRESİ, Turkey, 24 - 30 November 2017
- CLXXXIII. **Variables that affect life satisfaction of multiple sclerosis patients acomparative study**
TERZİ M., ŞEN S., KUMCAĞIZ H., TERZİ Y.
PACTRİMS 2017, Vietnam, 22 - 25 November 2017, pp.33
- CLXXXIV. **LEPTOMENİNGEAL KARSİNÖMATOZİS İLE PREZENTE OLAN MİDE ADENOKARSİNOM OLGUSU**
DOĞAN B., BOLAT N., TERZİ M.
53. ULUSAL NÖROLOJİ KONGRESİ, Turkey, 24 - 30 November 2017
- CLXXXV. **MULTİPL SKLEROZ HASTALARINDA DOĞUM SIRASININ KLİNİKLE OLAN İLİŞKİSİ**
TERZİ M., KIZILATEŞ G., BEKİR Ö., ŞENER M., ŞEN S.
53. ULUSAL NÖROLOJİ KONGRESİ, Turkey, 24 - 30 November 2017
- CLXXXVI. **FİNGOLİMOD KULLANIMI SIRASINDA GELİŞEN DERİN VEN TROMBOZU**
TERZİ M., BEKİR Ö., ŞEN S.
53. ULUSAL NÖROLOJİ KONGRESİ, Turkey, 24 - 30 November 2017
- CLXXXVII. **Variables that Affect Life Satisfaction of Multiple Sclerosis Patients a Comparative Study**
TERZİ M., şen s., KUMCAĞIZ H., TERZİ Y.
PACTRIMS 2017, Vietnam, 23 - 25 November 2017, pp.33
- CLXXXVIII. **MULTİPL SKLEROZ'DA MORTALİTE**
TERZİ M., BOZ C., KIZILATEŞ G., ŞEN S., BEKİR Ö.
53. ULUSAL NÖROLOJİ KONGRESİ, Turkey, 24 - 30 November 2017
- CLXXXIX. **AKTİF RELAPSİNG REMİTTİNG MULTİPL SKLEROZ HASTALARINDA BİRİNCİ BASAMAKTA FİNGOLİMOD KULLANIMI**
TERZİ M., BEKİR Ö., ŞEN S., ONAR M. K.
53. ULUSAL NÖROLOJİ KONGRESİ, Turkey, 24 - 30 November 2017
- CXC. **MULTİPL SKLEROZ HASTALARINDA İNTERFERON BETA 1A SUBKUTAN HAFTADA 3 TEDAVİSİ GERÇEK YAŞAM VERİSİ**
TERZİ M., ŞEN S., BEKİR Ö., ONAR M. K.
53. ULUSAL NÖROLOJİ KONGRESİ, Turkey, 24 - 30 November 2017
- CXCI. **Orta ve Doğu Karadeniz Bölgesinde Pediyatrik ve Yetişkin Multipl Skleroz Hastalarının Demografik ve Klinik Özellikleri**
Şipal C., Akçaoğlu Y., BOZ C., TERZİ M.
53. ULUSAL NÖROLOJİ KONGRESİ, Turkey, 24 - 30 November 2017, pp.87
- CXCII. **MS TEDAVİSİNDE TERİFLUNOMİDE VE FİNGOLUMOD'UN KARŞILAŞTIRMALI ETKİNLİK VERİLERİ**
BOZ C., ÖZAKBAŞ S., TERZİ M., TÜRKOĞLU R., SOYSAL A., TUNCER M. A., ALTINTAŞ A., EFENDİ H., AKMAN G.
53. ULUSAL NÖROLOJİ KONGRESİ, Turkey, 24 - 30 November 2017, pp.54-55
- CXCIII. **MULTİPL SKLEROZ'DA NATALİZUMAB TEDAVİSİ GERÇEK YAŞAM VERİSİ**
TERZİ M., BOZ C., ÇİLİNGİR V., ŞEN S., ŞENER M., GÜLER S.
53. ULUSAL NÖROLOJİ KONGRESİ, Antalya, Turkey, 24 - 30 November 2017, pp.229-230
- CXCIV. **Klinik İzole Sendromda Cladribine Deneyimi**

TERZİ M., ONAR M. K.

53. ULUSAL NÖROLOJİ KONGRESİ, Turkey, 24 - 30 November 2017

- CXCV. **Multipl Skleroz Artık HBS Sekonder Nedenleri Arasında Yerini Almalı! : Bu Alanda Şimdiye Kadar Yapılmış En Geniş Çaplı Çalışmanın(Multipl Sklerozun Huzursuz Bacakları- Türkiye (RELOMS-T)) Çarpıcı Sonuçları**
SEVİM M. S., DEMİRKIRAN D. M., TERZİ M., YÜCEYAR A. N., TAŞDELEN B., İDİMAN E., KÜRTÜNCÜ M., BOZ C., TUNCEL D., KARABUDAK R., et al.
53. ULUSAL NÖROLOJİ KONGRESİ, Turkey, 24 - 30 November 2017, pp.54
- CXCVI. **MULTİPL SKLERODA DİMETİL FUMARAT TEDAVİSİ GERÇEK YAŞAM VERİSİ**
TERZİ M., BOZ C., ŞEN S., GÜLER S., ÇİLİNGİR V., ŞENER M.
53. ULUSAL NÖROLOJİ KONGRESİ, Antalya, Turkey, 24 - 30 November 2017, pp.229
- CXCVII. **Ms Tedavisinde Kullanılan İlaçların Kesilme Oranları ve Nedenleri**
Çağlar Okumuş A., BOZ C., TERZİ M., ÖZAKBAŞ S., Türkoğlu R., Soysal A., TUNCER M. A., ALTINTAŞ A.
53. ULUSAL NÖROLOJİ KONGRESİ, Turkey, 24 - 30 November 2017
- CXCVIII. **MULTİPL SKLEROZ HASTALARINDA GLATİRAMER ASETAT TEDAVİSİNİN GÜNLÜK VE HAFTADA 3 KULLANIMI İLAÇ MEMNUNİYETİ**
TERZİ M., BOZ C., BİLGE N., ÇİLİNGİR V., BEKİR Ö., BIÇAKCI D., ÇAĞLAR A., ŞEN S.
53. ULUSAL NÖROLOJİ KONGRESİ, Antalya, Turkey, 24 - 30 November 2017, pp.230-231
- CXCIX. **MS Tedavisinde Teriflunomide ve Fingolimod'un Karşılaştırmalı Etkinlik Verileri**
BOZ C., ÖZAKBAŞ S., TERZİ M., Türkoğlu R., Soysal A., TUNCER M. A., ALTINTAŞ A., EFENDİ H., AKMAN G.
53. ULUSAL NÖROLOJİ KONGRESİ, Turkey, 24 - 30 November 2017, pp.54
- CC. **MULTİPL SKLEROZ ARTIK HBS SEKONDER NEDENLERİ ARASINDA YERİNİ ALMALI!: BU ALANDA ŞİMDİYE KADAR YAPILMIŞ EN GENİŞ ÇAPLI ÇALIŞMANIN [MULTİPL SKLEROZUN HUZURSUZ BACAKLARI-TÜRKİYE (RELOMS-T)] ÇARPICI SONUÇLARI**
SEVİM M. S., DEMİRKIRAN D. M., TERZİ M., YÜCEYAR A. N., TAŞDELEN B., İDİMAN E., KÜRTÜNCÜ M., BOZ C., TUNCEL D., KARABUDAK R., et al.
53. ULUSAL NÖROLOJİ KONGRE, Turkey, 24 November 2017 - 30 January 2018, pp.54
- CCI. **De Novo Trigeminal Neuralgia Induced by Dalfampridine (4-aminopyridine): 3 cases**
ÖZMENOĞLU M., TERZİ M., BOZ C., ŞEKER D., HOROZOĞLU H.
Pan-Asian Committee for treatment and research in multiple sclerosis, 23 - 25 November 2017
- CCII. **VARIABLES THAT AFFECT LIFE SATISFACTION OF MULTIPLE SCLEROSIS PATIENTS A COMPARATIVE STUDY**
TERZİ M., ŞEN S., KUMCAĞIZ H., TERZİ Y.
Pan-Asian Committee on Treatment and Research in Multiple Sclerosis (PACTRIMS), 22 - 25 November 2017
- CCIII. **Risk of secondary progressive multiple sclerosis: a longitudinal study**
Fambiatos A., Jokubaitis V., Spelman T., Harakova D., Havrdova E., TROJANO M., Prat A., Girard M., duguette A., Lugaresi A., et al.
MULTIPLE SCLEROSIS JOURNAL, Paris, France, 25 - 28 October 2017, vol.23, pp.109-112
- CCIV. **A comparative-effectiveness analysis applying a 3 way propensity matching to real-world data from MSBase Registry in preparation for a cost effectiveness model: patients switching within firstline agents or to natalizumab or fingolimod in active RRMS**
Spelman T., Havrdova E., horakova D., TROJANO M., Lugaresi A., Izquierdo G., Grammond P., duguette A., Alroughani R., Pucci M. E., et al.
7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS)Location: Paris, FRANCEDate: OCT 25-28, 2017, Paris, France, 25 - 28 October 2017, vol.23, pp.395-397
- CCV. **Timing of high-efficacy disease modifying therapies for relapsing-remitting multiple sclerosis**
Merkel B., Jokubaitis V., Spelman T., Harakova D., Havrdova E., Guillermo T., Izquierdo A., Izquierdo A., Lugaresi A., Girard M., et al.
7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS)Location: Paris, FRANCEDate: OCT 25-28, 2017, Paris,

France, 25 - 28 October 2017, vol.23, pp.71-73

- CCVI. **Predictors of relapses and disability progression after stopping disease-modifying therapies for multiple sclerosis**
Kister A., Spelman T., Patti A., duquette A., TROJANO M., Izquierdo G., Lugaresi A., Grammond P., Sola R., ferraro A., et al.
MULTIPLE SCLEROSIS JOURNAL, Paris, France, 25 - 28 October 2017
- CCVII. **Effectiveness of fingolimod, dimethyl fumarate and teriflunomide in relapsing-remitting multiple sclerosis: a comparative longitudinal study**
Kalincik T., Spelman T., Jokubaitis V., horakova D., Havrdova E., Izquierdo G., Prat A., Girard M., duquette A., Lugaresi A., et al.
MULTIPLE SCLEROSIS JOURNAL, Paris, France, 25 - 28 October 2017, vol.23, pp.325-327
- CCVIII. **Disease modifying therapy improves disability outcomes in relapsing-remitting multiple sclerosis over 22 years**
Kalincik T., Spelman T., Jokubaitis V., horakova D., Havrdova E., TROJANO M., Sola A., ferraro A., Lugaresi A., Izquierdo G., et al.
MULTIPLE SCLEROSIS JOURNAL, Paris, France, 25 - 28 October 2017, vol.23, pp.361-363
- CCIX. **Halting disability progression in multiple sclerosis with immunomodulatory injectable treatments: is it achievable?**
Fragoso Y. D., Spelman T., Duquette P., Girard M., Trojano M., Izquierdo G., Grammond P., Lugaresi A., Van Pesch V., GrandMaison F., et al.
ECTRIMS 2017, 25 - 28 October 2017, pp.254
- CCX. **Contribution of inflammation to disability accrual in primary progressive multiple sclerosis**
Hughes A., Jokubaitis V., Spelman T., Lugaresi A., Hupperts R., Izquierdo G., Prat A., Girard M., duquette A., Grand Maisen f., et al.
MULTIPLE SCLEROSIS JOURNAL, Paris, France, 25 - 28 October 2017, vol.23, pp.399-401
- CCXI. **METHYLPREDNISOLONE CONCENTRATIONS IN BREAST MILK AND SERUM IN PATIENT WITH MULTIPLE SCLEROSIS TREATED IV PULSE METHYLPREDNISOLONE**
BOZ C., TERZİ M., KARAHAN S., ŞEN S., SARAÇ Y., MAVİŞ E.
ECTRIMS 2017, 25 - 28 October 2017
- CCXII. **The effect of disease-modifying treatments on conversion to secondary progressive multiple sclerosis**
Brown W., Coles A., Horakova D., Havrdova E., Trojano M., Izquierdo G., Prat A., Girard M., Hupperts R., Van Pesch V., et al.
ECTRIMS 2017, 25 - 28 October 2017, pp.47
- CCXIII. **Pregnancy incidence and therapy exposure in relapsing forms of MS: a 12-year retrospective multicentre analysis**
Jokubaitis V., Havrdova E., horakova D., Izquierdo G., Kalincik T., Van der Walt A., Nguyen A., TERZİ M., Alroughani R., duquette A., et al.
MULTIPLE SCLEROSIS JOURNAL, Paris, France, 25 - 28 October 2017, vol.23, pp.130-132
- CCXIV. **The risk of relapse following on-treatment clinically silent lesions in patients with relapsing-remitting multiple sclerosis**
Brown J. W., Lugaresi A., horakova D., Havrdova E., Jokubaitis V., LechnerScot J., TROJANO M., AA M., Shaw A., Shuey A., et al.
MULTIPLE SCLEROSIS JOURNAL, Paris, France, 25 - 28 October 2017, vol.23, pp.992-994
- CCXV. **Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis**
Kalincik T., Jokubaitis V., Spelman T., Horakova D., Havrdova E., Trojano M., LechnerScott J., Lugaresi A., Prat A., Girard M., et al.
ECTRIMS 2017, 25 - 28 October 2017
- CCXVI. **FREQUENCY OF COGNITIVE IMPAIRMENT IN RELAPSING-REMITTING MULTIPLE SCLEROSIS PATIENTS IN TURKEY AND AFFECTING FACTORS**
ÖZAKBAŞ S., TÜRKOĞLU R., TAMAM Y., TERZİ M., TAŞKAPILIOĞLU Ö., YÜCESAN C., LİMONCU H., GENCER M., AKİL

E., ŞEN S., et al.

ECTRIMS 2017, 25 - 28 October 2017

CCXVII. Deep brain stimulation for Multiple Sclerosis related tremor: clinical reports

ŞEN S., TERZİ M., YILDIZ M. O., TEMEL Y., KOCABIÇAK E.

3RD CLINICAL NEUROSCIENCE COURSE, Samsun, Turkey, 19 - 22 October 2017

CCXVIII. Relation of fingolimod treatment to disability in multiple sclerosis

Sen S., Terzi M., Evin O., Onar M.

23rd World Congress of Neurology (WCN), Kyoto, Japan, 16 - 21 September 2017, vol.381, pp.1058

CCXIX. Real world efficacy and safety of teriflunomide in patients with relapsing-remitting multiple sclerosis

BOZ C., ÖZAKBAŞ S., Terzi M., Turkoglu R., Akman G., Efendi H., Akcali A., Tuncer A., YÜCEYAR A. N., Turan O. F., et al.
7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS), Paris, France, 25 - 28 October 2017, vol.23, pp.327-328

CCXX. Familial involvement in multiple sclerosis

Terzi M., Sen S., Evin O., Onar M.

7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS), Paris, France, 25 - 28 October 2017, vol.23, pp.775

CCXXI. Susac syndrome: clinical features, laboratory testing and treatment responses of 20 cases

Karahan S. Z., Boz C., Usta N. C., SAİP S., Kale N., Demirkaya S., Tuncer A., Demir S., Terzi M., Celik Y., et al.

7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS), Paris, France, 25 - 28 October 2017, vol.23, pp.90-91

CCXXII. Frequency of cognitive impairment in relapsing-remitting multiple sclerosis patients in Turkey and affecting factors

ÖZAKBAŞ S., Turkoglu R., Tamam Y., Terzi M., Taskapilioglu O., YÜCESAN C., Limoncu H., Gencer M., Akil E., Sen S., et al.

7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS), Paris, France, 25 - 28 October 2017, vol.23, pp.458-459

CCXXIII. Methylprednisolone concentrations in breast milk and serum in patients with multiple sclerosis treated with IV pulse methylprednisolone

BOZ C., Terzi M., Karahan S. Z., Ozbudun B., Sen S., Sarac Y., Mavis M.

7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS), Paris, France, 25 - 28 October 2017, vol.23, pp.462

CCXXIV. DRUG SATISFACTION İN MULTİPLE SCLEROSİS USİNG FİNGOLİMOD TREATMENT

TERZİ M., EVİN Ö., TERZİ Y., ŞEN S., CEYLANDAĞ A. E.

WORLD CONGRESS OF NEUROLOGY 2017, 16 - 21 September 2017

CCXXV. Safety of IV pulse methylprednisolone therapy during breastfeeding in patients with multiple sclerosis

BOZ C., TERZİ M., ZENGİN KARAHAN S., SEN S., SARAC Y., MAVİS M.

3rd EAN Congress, Amsterdam 2017, 24 - 27 June 2017

CCXXVI. Pediatrik başlangıçlı multiple skleroz ile erişkin başlangıçlı multiple sklerozun klinik özelliklerinin karşılaştırılması

KAMAŞAK T., CANSU A., ACAR ARSLAN E., ŞAHİN S., DURGUT B. D., DİLBER B., TERZİ M., BOZ C.

19. Ulusal Çocuk Nörolojisi Kongresi, Antalya, Turkey, 19 - 23 April 2017

CCXXVII. FİNGOLİMOD TEDAVİSİ KULLANAN MULTİPL SKLEROZHASTALARINDA İLAÇ MEMNUNİYETİ

EVİN Ö., CEYLANDAĞ A. E., TERZİ M.

8. Nöroimmunoloji Okulu, Turkey, 30 March - 02 April 2017

CCXXVIII. Multipl Skleroz Hastalarında Yorgunluğun Yaşam Kalitesine Olan Etkisi

CEYLANDAĞ A. E., TERZİ M., EVİN Ö.

8. Nöroimmunoloji Okulu, Turkey, 30 March - 02 April 2017

- CCXXXIX. **Multiple Sclerosis Injection in The Form of Use Disease Modifying Drugs, Why is The End?**
Terzi M., Şen S.
9th Congress of the Pan-Asian-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (PACTRIMS),
Bangkok, Thailand, 27 - 29 October 2016, vol.23, pp.332-333
- CCXXX. **Nöromiyelitis Optica ve Gebelik**
ALTINTAŞ A., UYGUNOĞLU U., TERZİ M., BOZ C., SAİP S., KÖSEOĞLU M., KALE N., ÖZTÜRK M., DEMİR C. F., SOYSAL A., et al.
52.Ulusal Nöroloji Kongresi, Antalya, Turkey, 25 November - 01 December 2016
- CCXXXI. **S 32 Dramaterapi nin Multipl Skleroz Hastalarının Yaşam Kalitesine Olan Etkisi**
TERZİ M., UYGUR M., MUSLUGİL K., EVİN Ö., ŞEN S.
52. ULUSAL NÖROLOJİ KONGRESİ, Turkey, 25 November - 01 December 2016
- CCXXXII. **S 80 Multipl Sklerozda Fingolimod Tedavisinin Özürllülük ile İlişkisi**
ŞEN S., TERZİ M., EVİN Ö., ONAR M. K.
52. Ulusal Nöroloji Kongresi, Turkey, 25 November - 01 December 2016, pp.51
- CCXXXIII. **BP 63 Nöromiyelitis Optika ve Gebelik**
ALTINTAŞ A., UYGUNOĞLU U., TERZİ M., BOZ C., SAİP S., KÖSEOĞLU M., KALE N., ÖZTÜRK M., DEMİR C. F., SOYSAL A., et al.
52. Ulusal Nöroloji Kongresi, Turkey, 25 November - 01 December 2016
- CCXXXIV. **TEP 140 Nöromiyelitis Optika ve Gebelik**
ALTINTAŞ A., UYGUNOĞLU U., TERZİ M., BOZ C., SAİP S., KÖSEOĞLU M., KALE N., ÖZTÜRK M., DEMİR C. F., SOYSAL A., et al.
52. Ulusal Nöroloji Kongresi, Turkey, 25 November - 01 December 2016
- CCXXXV. **BP 59 Susac Sendromlu 19 Olgu**
ZENGİN KARAHAN S., BOZ C., CAN USTA N., SAİP S., KALE N., TUNCER M. A., DEMİRKAYA Ş., DEMİR S., TERZİ M., ÇELİK Y., et al.
52. Ulusal Nöroloji Kongresi, Turkey, 25 November - 01 December 2016
- CCXXXVI. **MS İN 1 BASAMAK TEDAVİSİNDE ORAL SEÇENEK TERİFLUNOMİD VE TÜRKİYE GERÇEK YAŞAM VERİLERİ**
TERZİ M., BOZ C., GRİGORLADİS N.
52. ULUSAL NÖROLOJİ KONGRESİ, Turkey, 25 November - 01 December 2016
- CCXXXVII. **MULTİPL SKLEROZDA PROGNOZDA BOS UN ÖNEMİ**
TERZİ M.
52. ULUSAL NÖROLOJİ KONGRESİ, Turkey, 25 November - 01 December 2016
- CCXXXVIII. **S 88 Multipl Skleroz Hastalarında Fingolimod Tedavisinin Türkiye Gerçek Yaşam Verisi**
TERZİ M., ERAKSOY M., KÜRTÜNCÜ M., KARABUDAK R., TUNCER M. A., ALTUNRENDE B., AKÇALI A., BOZ C., SEVİM M. S., YÜCEYAR A. N., et al.
52. Ulusal Nöroloji Kongresi, Turkey, 25 November - 01 December 2016
- CCXXXIX. **İKİNCİ BASAMAK TEDAVİ KARARINDA DİKKAT EDİLECEK NOKTALAR NELERDİR**
TERZİ M.
52. ULUSAL NÖROLOJİ KONGRESİ, Turkey, 25 November - 01 December 2016
- CCXL. **MS TE 1 BASAMAK ENJEKSİYON TEDAVİLERİNE HALA İHTİYAÇ VAR MI**
KARABUDAK R., TERZİ M., EFENDİ H., DUMAN A. T., TURAN Ö. F.
52. ULUSAL NÖROLOJİ KONGRESİ, Turkey, 25 November - 01 December 2016
- CCXLI. **TÜRKİYE DE FİNGOLİMOD İLE İLGİLİ GERÇEK YAŞAM DENEYİMLERİNDE ETKİNLİK**
TERZİ M.
52. ULUSAL NÖROLOJİ KONGRESİ, Turkey, 25 November - 01 December 2016
- CCXLII. **EP 249 Osteo artiküler Tutulum ve Polinöropati ile Prezente Olan Amiloidoz Vakası**
POLAT M., DOĞAN B., TERZİ M., ONAR M. K.
52. Ulusal Nöroloji Kongresi, Turkey, 25 November - 01 December 2016
- CCXLIII. **Nöromiyelitis Optika ve Gebelik**

ALTINTAŞ A., UYGUNOĞLU U., TERZİ M., BOZ C., SAİP S., KÖSEOĞLU M., KALE İÇEN N., ÖZTÜRK M., DEMİR C., SOYSAL A., et al.

52. Ulusal Nöroloji Kongresi, Antalya, Turkey, 25 November - 01 December 2016

CCXLIV. TEP 147 MS Tedavisinde Teriflunomide in Etkinlik ve Tolerabite Gerçek Yaşam Verileri

BOZ C., TERZİ M., TÜRKOĞLU R., AKMAN G., EFENDİ H., AKÇALI A., SOYSAL A., KÖSEOĞLU M., PETEK BALCI B., SEVİM S., et al.

52. Ulusal Nöroloji Kongresi, Turkey, 25 November - 01 December 2016

CCXLV. multiple skleroz hastalığında fingolimod tedavisinin Türkiye gerçek yaşam verisi

TERZİ M., ERAKSOY M., KÜRTÜNCÜ M., KARABUDAK R., TUNCER M. A., AKÇALI A.

52. ULUSAL NÖROLOJİ KONGRESİ, Turkey, 25 November - 01 December 2016

CCXLVI. SUSAC SENDROMLU 19 OLGU

ZENGİN KARAHAN S., BOZ C., CAN USTA N., SAİP S., KALE N., TUNCER M. A., DEMİRKAYA Ş., DEMİR S., TERZİ M., ÇELİK Y., et al.

52. ULUSAL NÖROLOJİ KONGRESİ, Turkey, 25 November - 01 December 2016, pp.107

CCXLVII. MULTIPL SKLEROZ HASTALARINDA FİNGOLİMOD TEDAVİSİNİN TÜRKİYE GERÇEK YAŞAM VERİSİ

TERZİ M., ERAKSOY M., KÜRTÜNCÜ M., KARABUDAK R., TUNCER M. A., ALTUNRENDE B., AKÇALI A., BOZ C., SEVİM M. S., YÜCEYAR A. N., et al.

52. ULUSAL NÖROLOJİ KONGRESİ, Turkey, 25 November - 01 December 2016, pp.56

CCXLVIII. MS TEDAVİSİNDE TERİFLUNOMİDE'İN ETKİNLİK VE TOLERABİTE GERÇEK YAŞAM VERİLERİ

BOZ C., TERZİ M., TÜRKOĞLU R., AKMAN G., EFENDİ H., AKÇALI A., SOYSAL A., KÖSEOĞLU M., BALCI F. B., SEVİM M. S., et al.

52. Ulusal Nöroloji Kongresi, Antalya, Turkey, 25 November 2016

CCXLIX. Değiştirilemez gerçekte anlam bulmak

OĞUZ G., Çağlı S., Sezgin S., İÇÖZ F. J., TERZİ M.

52. Ulusal Psikiyatri Kongresi, Antalya, Turkey, 16 - 20 November 2016, vol.27, pp.173

CCL. Multiple Sclerosis Injection in The Form of Use Disease Modifying Drugs Why is The End

TERZİ M., ŞEN S.

9th Pan Asian Committee for Treatment and Research in Multiple Sclerosis (PACTRIMS), 27 - 29 October 2016

CCLI. OLGU EŞLİĞİNDE MS HASTASINA YAKLAŞIM

TERZİ M.

11. ÇUKUROVA NÖROLOJİ GÜNLERİ, Turkey, 30 September - 02 October 2016

CCLII. Individual response to disease modifying therapies a global observational cohort study

Kalincik T., Sobisek L., Jokubaitis V., Spelman T., Horakova D., Havrdova E., Trojano M., Izquierdo G., Lugaresi A., Girard M., et al.

32nd The European Committee for Treatment and Research in Multiple Sclerosis(ECTRIMS), 14 - 17 September 2016

CCLIII. Outcomes of pregnancy in neuromyelitis optica patients:turkish multicenter study data

ALTINTAŞ A., UYGUNOĞLU U., TERZİ M., BOZ C., SAİP S., KÖSEOĞLU M., KALE İÇEN N., ÖZTÜRK M., DEMİR C., SOYSAL A., et al.

ECTRIMS 2016 - 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis., Londrina, Brazil, 14 - 17 September 2016

CCLIV. Anti inflammatory disease modifying treatment does not attenuate disability progression in secondary progressive multiple sclerosis

Lorscheider J., Jokubaitis V., Spelman T., Izquierdo G., Lugaresi A., Havrdova E., Horakova D., Troiano M., Duquette P., Girard M., et al.

32nd The European Committee for Treatment and Research in Multiple Sclerosis(ECTRIMS), 14 - 17 September 2016

CCLV. Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod

Fragoso Y. D., Alroughani R., Barnett M., Brooks J. B. B., Butzkueven H., BOZ C., Granello F., Haartsen J., Havrdova E., Lugaresi A., et al.

32nd The European Committee for Treatment and Research in Multiple Sclerosis(ECTRIMS), 14 - 17 September 2016

CCLVI. Comparative analysis of MS outcomes in natalizumab treated patients using a novel three way multinomial propensity score match

Spelman T, Pellegrini F, Zhang A, Trojano M, Wiendl H, Kappos L, Hyde R, Koendgen H, Verheul F, Grand Maison F, et al.

32nd The European Committee for Treatment and Research in Multiple Sclerosis(ECTRIMS), 14 - 17 September 2016

CCLVII. Real-life data from efficacy of fingolimod treatment in multiple sclerosis patients in Turkey

TERZİ M., KÜRTÜNCÜ M., ERAKSOY M., KARABUDAK R., TUNCER M. A., ALTUNRENDE B., AKÇALI A., BOZ C., SEVİM M. S., NUR Y., et al.

ECTRIMS 2016 - 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Londrina, Brazil, 14 - 17 September 2016

CCLVIII. Efficacy and the safety profile of fingolimod treatment in multiple sclerosis patients: Real-life data from Turkey

TERZİ M., KÜRTÜNCÜ M., ERAKSOY M., KARABUDAK R., TUNCER M. A., ALTUNRENDE B., AKÇALI A., BOZ C., SEVİM M. S., YÜCEYAR A. N., et al.

32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis. ECTRIMS-2016, Londrina, Brazil, 14 - 17 September 2016

CCLIX. Comparative analysis of MS outcomes in dimethyl fumarate treated patients relative to propensity matched fingolimod interferon glatiramer acetate or teriflunomide

Spelman T, Kalincik T, Trojano M, GrandMaison F, Izquierdo G, Havrdova E, Horakova D, Lugaresi A, Duquette P, Grammond P, et al.

ECTRIMS, 16 September 2016

CCLX. Long term disability trajectories in primary progressivs MS patients a latent class growth analysis

Signori A, Izquierdo, G, Lugaresi A, Hupperts R, GrandMaison F, Sola P, Horakova D, Havrdova E, Prat A, Girard M., et al.

ECTRIMS, 15 September 2016

CCLXI. Comparison of 5 year treatment outcomes between alemtuzumab versus natalizumab fingolimod and interferon 1a

Kalincik T, Brown j, Robertson R, Willis m, Scolding N, Pearson O, Ziemsen T, Hutchinson m, Jacoubatis v, Spelman T, et al.

ECTRIMS 2016, 13 - 16 September 2016

CCLXII. Anti inflammatory disease modifying treatment does not attenuate disability progression in secondary progressive multiple sclerosis
Author s J Lorscheider V Jokubaitis T Spelman G Izquierdo A Lugaresi E Havrdova D Horakova M Trojano P Duquette M Girard A Prat F Grand Maison R Hupperts P Grammond E Pucci C Boz P Sola D Spitaleri J Lechner Scott M Terzi V Van Pesch G Iuliano R Bergamaschi R Fernández Bolaños C Ramo Tello F Granella M E Rio C Oreja Guevara H Butzkueven T Kalincik MSBase Study Group

Lorscheider l, jocubatis v, spelman t, Izquierdo g, lugaresi a, hardova e, harakova d, Duquette p, BOZ C., TERZİ M., et al.

ECTRIMS 2016, 14 - 16 September 2016

CCLXIII. NÖRODEJENERASYON

TERZİ M.

IX. KLİNİK NÖROİMMUNOLOJİ SEMPOZYUMU, Turkey, 2 - 04 June 2016

CCLXIV. MS TE YORGUNLUĞUN DEĞERLENDİRİLMESİ

TERZİ M.

IX. KLİNİK NÖROİMMUNOLOJİ SEMPOZYUMU, Turkey, 2 - 04 June 2016

CCLXV. Prospectively Tracking DiseaseCourse and Treatment Changes in Neuromyelitis Optica Using

NMOBase a Global Online Registry Ilya Kister Tamar Bacon Vahid Shaygannejad JyhYung Hor Raed Alroughani Shannon Haas Murat Terzi Cavit Boz Javier Olascoaga Pamela McCombe Yara Fragoso

AlessandraLugaresi Patrizia Sola Steve Vucic EugenioPucci Talal Al Harbi Seyed Aidin Sajedi Juan Ignacio Rojas Liliana Patrucco EdgardoCristiano Jose Alberto Suarez MagdaliniTsolaki Bruce Taylor Gerardo Iuliano Paschalis Devranis Mark Marriott HelmutButzkueven
Kister I., bocan t., Shaygannejad v., Yung Hor j., Alroughani r., Shannon h., TERZİ M., BOZ C., Olascoaga o., Butzkueven h.
aan2016, 12 - 18 April 2016

- CCLXVI. **GBS**
TERZİ M.
VI. TEMEL İMMÜNOLOJİ VE NÖROİMMÜNOLOJİ ÖĞRENCİ OKULU, Turkey, 8 - 09 April 2016
- CCLXVII. **OTURUM BASKANI**
TERZİ M.
VI. TEMEL İMMÜNOLOJİ VE NÖROİMMÜNOLOJİ ÖĞRENCİ OKULU, Turkey, 8 - 09 April 2016
- CCLXVIII. **MULTI PLE SKLEROZ I LI S KI LI TREMOR VAKALARINDA DERI N BEYI N STI MU LASYONU**
YILDIZ M. O., TERZİ M., TUĞCU B., TAŞKIN Ö., YILMAZ B., ALPTEKİN O., YASİN T., KOCABIÇAK E.
TND 30. BİLİMSSEL KONGRESİ, Turkey, 8 - 12 April 2016
- CCLXIX. **Multiple Skleroz İlişkili Tremor Vakalarında Derin Beyin Stimülasyonu.**
YILDIZ M. O., TERZİ M., TUĞCU B., TAŞKIN Ö., YILMAZ S. B., ALPTEKİN O., temel y., KOCABIÇAK E.
XXX. Ulusal Nöroşirurji Kongresi, Antalya, Turkey, 8 - 11 April 2016, vol.26
- CCLXX. **Demyelinating diseases of the central nervous system**
TERZİ M.
2nd Neuroscience Stereology and Scientific Writing, 15 - 19 March 2016
- CCLXXI. **EP 35 Deep brain stimulation for multiple sclerosis related tremor Clinical reports**
YILDIZ M. O., TERZİ M., KOCABIÇAK E.
1. INTERNATİANOL CONFERENCEON DEEP BRAİN STİMULATİON, 5 - 16 March 2016
- CCLXXII. **MS TEDAVİSİNDE GEÇİŞLERİ NE ZAMAN YAPALIM**
TERZİ M.
11. ULUDAĞ NÖROLOJİ GÜNLERİ, Turkey, 10 - 13 March 2016
- CCLXXIII. **Ailevi multipl skleroz**
TERZİ M.
51. ulusal nöroloji kongresi konuşma, Turkey, 28 November - 03 December 2015
- CCLXXIV. **elektrokonvülfik tedavi uygulanan gebede anestezi yönetimi olgu sunumu**
ÇOPUROĞLU E., SAĞIROĞLU G., ÖZTEKİN İ., HEKİMOĞLU ŞAHİN S., ÇOKER T., KARAMANLIOĞLU B., TERZİ M., ÖZKARA Ç., ERDAĞ E.
Türk Anesteziyoloji Derneği 49. Ulusal Kongresi, Antalya, Turkey, 2 - 06 December 2015
- CCLXXV. **MULTİPL SKLEROZUN HUZURSUZ BACAKLARITÜRKİYE ÇOK MERKEZLİ ULUSAL ÇALIŞMANINMETODOLOJİSİ**
SEVİM M. S., SİVA A., İDİMAN E., BOZ C., TERZİ M., KÜRTÜNCÜ M., EFENDİ H., NEYAL A. M., DUMAN A. T., TAŞKAPILIOĞLU Ö., et al.
Ulusal Nöroloji Kongresi, Antalya, Turkey, 27 November - 03 December 2015
- CCLXXVI. **Nörolojik Hastalıklarda plazmaferes ve IVIG**
TERZİ M.
51. ulusal nöroloji kongresi konuşma, Turkey, 28 November - 03 December 2015
- CCLXXVII. **fingolimod tedavisinin güvenilirliği**
TERZİ M., ONAR M. K.
51. ULUSAL nöroloji kongresi, Turkey, 28 November - 02 December 2015
- :CLXXVIII. **SLEEVE GASTREKTOMİ SONRASI GELİŞEN WERNİCKE ENSEFALOPATİSİ**
GENÇ E., DOĞAN B., DOĞRU H., ALTINTAŞ B., TERZİ M.
51. ULUSAL NÖROLOJİ KONGRESİ, Turkey, 27 November - 03 December 2015
- CCLXXIX. **RELAPSİNG REMETTİNG MULTİPL SKLEROZ HASTALARINDA FİNGOLİMOD TEDAVİSİNİN GÜVENİLİRLİĞİ**
TERZİ M., ŞEN S., AYKAÇ G., ONAR M. K.

51. ULUSAL NÖROLOJİ KONGRESİ, Turkey, 27 November - 03 December 2015
- CCLXXX. **MULTİPL SKLEROZUN HUZURSUZ BACAĞLARI-TÜRKİYE: ÇOK MERKEZLİ ULUSAL ÇALIŞMANIN METODOLOJİSİ**
SEVİM M. S., SİVA A., İDİMAN E., BOZ C., TERZİ M., KÜRTÜNCÜ M., DEMİRKIRAN D. M., EFENDİ H., NEYAL A. M., DUMAN A. T., et al.
51. ULUSAL NÖROLOJİ KONGRESİ, Turkey, 27 November - 03 December 2015
- CCLXXXI. **MULTİPL SKLEROZ HASTALARINDA KLİNİK TECRÜBEYE GÖRE TANI, TEKİP VE TEDAVİ STRATEJİSİNDEKİ FARKLILIKLAR: MULTİPL SKLEROZ UZMANLARI VE GENEL NÖROLOGLAR İLE YAPILAN ANKET ÇALIŞMASI**
KURNE A., KÜRTÜNCÜ M., UYGUNOĞLU U., ÇALIŞKAN Z., SEVGİ S., EFENDİ H., SAĞDUYU KOCAMAN A., ÖZCAN A., TERZİ M., TURAN Ö. F., et al.
51. ULUSAL NÖROLOJİ KONGRESİ, Turkey, 27 November - 03 December 2015
- CCLXXXII. **RELAPSİNG REMİTTİNG MULTİPL SKLEROZ HASTALARINDA FİNGOLİMOD TEDAVİSİNİN KLİNİK ÜZERİNE OLAN ETKİSİ**
TERZİ M., ŞEN S., AYKAÇ G., ONAR M. K.
51. ULUSAL NÖROLOJİ KONGRESİ, Turkey, 27 November - 03 December 2015
- :CLXXXIII. **RRMS HASTALARINDA 12 AYLIK FİNGOLİMOD TEDAVİSİ SONUÇLARI: FİNE ÇALIŞMASI**
AKMAN DEMİR G., Türkoğlu R., SAİP S., YÜCEYAR A. N., EFENDİ H., TURAN Ö. F., AĞAN YILDIRIM K., TERZİ M., BOZ C., TUNCER M. A., et al.
51. ULUSAL NÖROLOJİ KONGRESİ, Turkey, 27 November - 03 December 2015
- :CLXXXIV. **MULTİPL SKLEROZDA ENJEKSİYON ŞEKLİNDE KULLANILAN HASTALIK MODİFİYE EDİCİ İLAÇLAR NEDEN SONLANDIRILIR?**
ŞEN S., TERZİ M., ONAR M. K.
51. ULUSAL NÖROLOJİ KONGRESİ, Turkey, 27 November - 03 December 2015
- CCLXXXV. **NMO KLİNİĞİ İLE PREZENTE OLAN SJÖGREN SENDROMU**
DOĞAN B., POLAT M., YILDIZ M. O., TERZİ M.
51. ULUSAL NÖROLOJİ KONGRESİ, Turkey, 27 November - 03 December 2015
- :CLXXXVI. **MULTİPL SKLEROZ HASTALARINDA SPİNAL KORD DEĞERLENDİRİLMESİ İÇİN T2 VE SHORT T1 İNVERSION RECOVERY(STIR) MR BULGULARININ KARŞILAŞTIRILMASI**
TERZİ M., ŞEN S., ASLAN K., GÜNBEY H. P.
51. ULUSAL NÖROLOJİ KONGRESİ, Turkey, 27 November - 03 December 2015
- CLXXXVII. **Efficacy and Treatment Persistence of First line Natalizumab vs Interferon beta or Glatiramer Acetate in relapsing MS**
BUTZKUEVEN H., SPELMAN T., KALİNCİK T., JOKUBAİTİS V., ZHANQ A., PELLEGRİNİ F., WİENDL H., BELACHEW S., HYDE R., VERHEUL F., et al.
- 8th Congress of the Pan-Asian-Committee-for-Research-and-Treatment-of-Multiple-Sclerosis (PACTRIMS), 19 - 21 November 2015
- :LXXXVIII. **Nöromiyelitis optika klinik ve tedavisi**
TERZİ M.
10. çukurova nöroloji günleri, Turkey, 13 - 15 November 2015
- :CLXXXIX. **Short T1 inversion recovery and T2 weighted sequences comparing and correlation with clinical findings of multiple sclerosis spinal cord lesions**
TERZİ M., ŞEN S., ASLAN K., GÜNBEY H. P.
- 31st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), 7 - 10 October 2015
- CCXC. **10 year progression predictors after first treatment initiation in a relapsing remitting MS cohort**
Jokubaitis V., Spelman T., Kalincik T., Travaglini D., Paolicelli D., Duquette P., Girard M., Prat A., Havrdova E., Horakova D., et al.
- 31st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), 21 - 23 October 2015
- CCXCI. **Comparison of efficacy and persistence of first line fingolimod vs interferon beta glatiramer in the**

presence of prior disease activity

Spelman T, Izquierdo G, Alroughani R, Fernandez Bolanos R, Havrdova E, Horakova D, OrejaGuevara C, LechnerScott J, Slee M, Barnett M, et al.

31st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS, 21 - 23 October 2015

CCXCII. Comparative efficacy of first line natalizumab versus IFNb or glatiramer acetate in relapsing MS

Spelman T, Kalincik T, Jokubaitis V, Zhang A, Pelligrini F, Wiendl H, Belachew S, Hyde R, Verheul F, Lugaresi A, et al.

31st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS, 21 - 22 October 2015

CCXCIII. Effects of Short and Long Term of ElectromagneticField Exposure on the Human Hippocampus

KAPLAN S., SELÇUK M. B., TERZİ M., ALTUNKAYNAK B. Z., DENİZ A., ASLAN K., ALTUN G., pınar a., Önger m. e., İNCESU L., et al.

BIOMED 2015, 21 - 24 October 2015

CCXCIV. A case of molluscum contagiosum developed during use of fingolimod

TERZİ M., ONAR M. K.

XXII World Congress of Neurology, 19 - 21 November 2015

CCXCV. Defining secondary progressive multiple sclerosis

Lorscheider J, Buzzard K, Jokubaitis V, Spelman T, Havrdova E, Horakova D, Trojano M, Izquierdo G, Girard M, Duquette P., et al.

31st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Barcelona, Spain, 7 - 10 October 2015, vol.21, pp.798-800

CCXCVI. Immunomodulatory therapy slows accumulation of disability in moderately advanced multiple sclerosis

Lizak N., Lugaresi A., Alroughani R., Lechner-Scott J., Slee M., Havrdova E., Horakova D., Trojano M., Izquierdo G., Duquette P., et al.

31st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Barcelona, Spain, 7 - 10 October 2015, vol.21, pp.308-310

CCXCVII. Kent Konseylerinin Sosyal Medya Kullanımı Üzerine Karşılaştırmalı Bir Değerlendirme Küçükçekmece ve Yenimahalle Belediyeleri

ŞAHİN A., SÖYLEMEZ A., TAŞPINAR Y., TERZİ M.

II. Kent Konseyleri Sempozyumu, Bursa, Turkey, 10 - 11 May 2015

CCXCVIII. TİP II ODONTOİD KIRIĞINA KLİNİK VE CERRAHİ YAKLAŞIM

AYDIN K., ALTUN A., YARAR E., TERZİ M., ŞEN S.

Türk Nöroşirürji Derneği, 29. Bilimsel Kongresi, Turkey, 17 - 21 April 2015

CCXCIX. 1st Congress of the European Academy of Neurology

ALTINTAŞ A., KARABUDAK R., BALCI P., TERZİ M., SOYSAL A., SAİP S., TUNCER M. A., UYGUNOĞLU U., NALBANTOĞLU M., IŞIK N., et al.

MULTIPLE SCLEROSIS JOURNAL, 1 - 04 May 2015

CCC. Silika Destekli NiCoPt Nanokümelerinin Hazırlanması Tanımlanması ve Hidrazin Hidratın Dehidrojenlenme Tepkimesindeki Katalitik Performansının İncelenmesi

Sayççek S., Yeğiner G., Sağlam Ş., KARATAŞ Y., GÜLCAN M., ZAHMAKIRAN M., TERZİ M., ÖZKARA Ç., ÖZKARA BİLGİLİ Ç.

V. Ulusal Anorganik Kimya Kongresi, Turkey, 22 - 25 April 2015

CCCI. Differences in Treatment Strategies in Multiple Sclerosis According to Experience A Survey of Multiple Sclerosis Experts and General Neurologists

KÜRTÜNCÜ M., TUNCER M. A., Çalışkan Z., SEVİM M. S., EFENDİ H., KOCAMAN A., ÖZCAN A., TERZİ M., TURAN Ö. F., SAİP S.

67th Annual Meeting of American Academy of Neurology, Washington, Kiribati, 21 - 27 April 2015

CCCII. Differences in the Diagnosis and Follow up of Multiple Sclerosis Patients According to the Experience of Neurologists Results of a National Survey

- TUNCER M. A., KÜRTÜNCÜ M., Çalışkan Z., SEVİM M. S., KOCAMAN A., ÖZCAN A., TERZİ M., TURAN Ö. F., SAİP S.
67th Annual Meeting of American Academy of Neurology, Washington, Kiribati, 21 - 28 April 2015
- CCCIII. **MALİGN İSKEMİK İNME SONRASINDA DEKOMPRESİF CERRAHİ**
ALTUN A., TERZİ M., ŞEN S., AYDIN K., ÇOKLUK C., KURUOĞLU E.
Türk Nöroşirürji Derneği, 29. Bilimsel Kongresi, Turkey, 17 - 21 April 2015
- CCCIV. **Otizm Spektrum Bozukluğu Olan Çocuğa Sahip Ailelerle Gerçekleştirilen Ailelerle El Ele Aile Eğitim Programına İlişkin Aile Görüşleri**
CAVKAYTAR A., ÇELİK S., BOZKUŞ GENÇ G., SANİ BOZKURT S., TOMRİS G., TERZİ M., BOZ C.
24. Ulusal Özel Eğitim Kongresi, Trakya Üniversitesi, Edirne, Edirne, Turkey, 9 - 11 October 2014
- CCCV. **Patients with Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder: Turkish Multicenter Data**
ALTINTAŞ A., KARABUDAK R., BALCI F. B., TERZİ M., SOYSAL A., SAİP S., TUNCER M. A., UYGUNOĞLU U., NALBANTOĞLU M., Gozubatik-Celik R. G., et al.
MULTIPLE SCLEROSIS JOURNAL, 6 - 08 November 2014, vol.21, pp.824-825
- CCCVI. **DEMİYELİNİZAN HASTALIĞINI TAKLİT EDEN SPİNAL MENENJİOM OLGUSU**
SHUGAİV BİRDAY E., BAYRAKTAR B., TERZİ M.
50. ULUSAL NÖROLOJİ KONGRESİ, Turkey, 21 - 27 November 2014
- CCCVII. **RRMS HASTALARINDA FİNGOLİMOD TEDAVİSİ BAŞLANGICININ KARDİYAK GÜVENLİLİĞİ**
AKMAN G., TÜRKOĞLU R., SAİP S., YÜCEYAR A. N., EFENDİ H., TURAN Ö. F., AĞAN YILDIRIM K., TERZİ M., BOZ C., TUNCER M. A., et al.
50. ULUSAL NÖROLOJİ KONGRESİ, Turkey, 21 - 27 November 2014
- CCCVIII. **Comparative efficacy of switch to natalizumab or fingolimod in active relapsing-remitting multiple sclerosis**
KALİNCİK T., Horakova D., SPELMAN T., Jokubaitis V. G., Trojano M., Lugaresi A., Izquierdo G., Rozsa C., Grammond P., Alroughani R., et al.
ECTRIMS 2014, 10 - 13 September 2014
- CCCIX. **RESTLESS LEG SYNDROME AND MULTIPLE SCLEROSIS**
TERZİ M., YAZICI D., ONAR M. K.
ECTRIMS 2014, 10 - 13 September 2014
- CCCX. **Independent predictors of time to relapse after CIS in high-risk patients**
SPELMAN T., Meyniel C., Trojano M., Lugaresi A., Izquierdo G., GrandMaison F., BOZ C., Alroughani R., Havrdova E., Iuliano G., et al.
ECTRIMS 2014, 10 - 13 September 2014
- CCCXI. **Evaluation of common criteria of progression of disability in a large observational cohort**
Kalincik T., Jokubaitis V. G., Spelman T., Horakova D., Havrdova E., Trojano M., Guillermo I., Girard M., Duquette P., Lugaresi A., et al.
ECTRIMS 2014, 10 - 13 September 2014
- CCCXII. **NMOBase is a Web-based, global observational registry for an 'orphan' disorder: neuromyelitis optica**
Kister I., Bacon T. E., Alroughani R., BOZ C., Cristiano E., Iuliano G., Marriott M., Olascoaga J., Pucci E., Rojas J. I., et al.
ECTRIMS 2014, 10 - 13 September 2014
- CCCXIII. **Neuromyelitis optica and neuromyelitis optica spectrum disorder patients in Turkish cohort: demographic, clinical, laboratory and radiological features**
Altintas A., Karabudak R., Balci B. P., Terzi M., Soysal A., SAİP S., Kurne A. T., UYGUNOĞLU U., Nalbantoglu M., Celik G., et al.
Joint ACTRIMS-ECTRIMS Meeting, Massachusetts, United States Of America, 10 - 13 September 2014, vol.20, pp.348-349
- CCCXIV. **Effects of long term of electromagnetic field exposure on the human hippocampus.**
DENİZ Ö. G., KAPLAN S., SELÇUK M. B., TERZİ M., ALTUN G., TÜFEKÇİ K. K., ASLAN K., DAVIS D.
Stereology and Neuroscience Symposium, 23 June 2014
- CCCXV. **Panelist**

GÜNBEY E., GÜZEL A., TERZİ M., AĞAR E.

OMÜ Tıp Fakültesi Dekanlığı 'Kaliteli uyuyor muyum?' paneli, Turkey, 04 June 2014

CCCXVI. **Stereological and comparative evaluation of the carpal tunnel in patients with carpal tunnel syndrome using magnetic resonance images**

AK GÜVEN G., EMİRZEOĞLU M., ŞAHİN B., BALCI K., TERZİ M., SELÇUK M. B.

3. International Scientific Writing&Stereology Workshop, Ondokuz Mayıs University, 08-12 Nisan 2014 Samsun, Turkey, 8 - 12 April 2014, vol.31

CCCXVII. **Nöromiyelitis Optika ve Nöromiyelitis Optika Spektrumu**

TERZİ M.

8. Klinik Nöroimmünoloji Sempozyumu, Turkey, 3 - 06 April 2014

CCCXVIII. **KLİNİSYEN GÖZÜYLE NMO'NUN EVRİMİ**

TERZİ M.

8. Klinik Nöroimmünoloji Sempozyumu, Turkey, 3 - 06 April 2014

CCCXIX. **Türkiye de 18 60 Yaş Arası Multipl Skleroz Olgularının Tahmini İnsidans Değeri ve Demografik Özellikleri**

ÖZAKBAŞ S., İDİMAN E., SİVA A., SAİP S., ALTINTAŞ A., KARABUDAK R., TUNCER M. A., YÜCEYAR A. N., EKMEKÇİ Ö., TURAN Ö. F., et al.

49. Ulusal Nöroloji Kongresi, Antalya, Turkey, 15 - 21 November 2013

CCCXX. **Multipl Skleroz Hastalığı Tanı Süreci Klinik ve Radyolojik Bulgular ile Yardımcı İncelemelerin Yeri.**

ÖZAKBAŞ S., İDİMAN E., SİVA A., SAİP S., ALTINTAŞ A., KARABUDAK R., TUNCER KURNE A., YÜCEYAR A. N., EKMEKÇİ Ö., TURAN Ö. F., et al.

49. Ulusal Nöroloji Kongresi, Antalya, Turkey, 15 - 21 November 2013

CCCXXI. **MULTİPLE SKLEROZ OLGULARINDA VİTAMİN D DÜZEYİ VE VİTAMİN D RESEPTÖR GENİ POLİMORFİZMİNİN ETKİLERİ**

TERZİ M., GÜNEŞ S., ŞEN S., BAĞCI H., CANBAZ S., SEVGİLİ E., BEDİR A., ONAR M. K.

49. ULUSAL NÖROLOJİ KONGRESİ, Turkey, 15 - 21 November 2013

CCCXXII. **2000 YILINDAN SONRA KLİNİK BAŞLANGIÇ GÖSTEREN MULTİPL SKLEROZ DA KLİNİK VE DEMOGRAFİK ÖZELLİKLER FARKLI MI?**

ŞEN S., TERZİ M., CANBAZ S., GÜNGÖR İ. L., ONAR M. K.

49. ULUSAL NÖROLOJİ KONGRESİ, Turkey, 15 - 21 November 2013

CCCXXIII. **Does probe's eye subthalamic nucleus length on T2W MRI correspond with microelectrode recording in patients with deep brain stimulation for advanced Parkinson's disease ?**

KOCABIÇAK E., AYGÜN D., ÇAMLIDAĞ İ., JAHANSHAHİ A., ONAR M. K., BÖKE Ö., KURT M., GÜZ H., TERZİ M., ALPTEKİN O., et al.

The XV WFNS World Congress of Neurological Surgery Meeting, SEUL, 8 - 13 November 2013

CCCXXIV. **CLİNİCAL AND DEMOGRAPHİC CHARACTERİSTİCS OF PATİENTS WİTH EARLY AND LATE-ONSET MULTİPLE SCLEROSİS**

ŞEN S., TERZİ M., CAN N., BOZ C.

ECTRIMS 2013, 2 - 05 October 2013

CCCXXV. **THE BENEFİTS OF VİSUAL EVOKED POTENTİAL EXAMİNATİON İN THE DİAGNOSİS AND PROGNOSİS OF MULTİPL SCLEROSİS**

ONAR M. K., TERZİ M., ŞEN S., CANBAZ S.

WORLD CONGRESS OF NEUROLOGY 2013, 21 - 26 September 2013

CCCXXVI. **Derin beyin stimülasyonu uygulanan Parkinson hastalarında aksiyal T2W MR'da probe eye ile ölçülen subtalamik nukleus uzunluğu, mikroelektrod kayıtları uyumlu mu?**

KOCABIÇAK E., AYGÜN D., ÇAMLIDAĞ İ., JAHANSHAHİ A., ONAR M. K., BÖKE Ö., KURT M., GÜZ H., TERZİ M., ALPTEKİN O., et al.

Türk Nöroşirürji Derneği 27. Bilimsel Kongresi, Antalya, Turkey, 12 - 16 April 2013

CCCXXVII. **Multiple skleroz hastasında trigeminal-glossofaringeal nevralji birlikteliği**

KOCABIÇAK E., TERZİ M., ÇAMLIDAĞ İ., TÜRKÖZ D.

Türk Nöroşirürji Derneği 27. Bilimsel Kongresi, Antalya, Turkey, 12 - 16 April 2013

- :CCXXVIII. **Clinical And Radiological Characteristics Of Tumefactive Demyelinating Lesions: Follow-up Study**
Altintas A., Petek B., Isik N., Terzi M., Bolukbasi F., Tavsanli M., SAİP S., BOZ C., Aydın T., Arici-Duz O., et al.
5th Congress of the Pan-Asian-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (PACTRIMS), Beijing, China, 13 - 15 September 2012, vol.19, pp.656
- CCCXXIX. **NMO-spectrum disorders in Turkish population: Clinical, demographic characteristics and the presence of NMO-Ig G**
Altintas A., Soysal A., Terzi M., Isik N., Duman T., Gozubatik-Celik G., Nalbantoglu M., Kursun A., Deniz G.
11th International Congress of Neuroimmunology (ISNI), Massachusetts, United States Of America, 4 - 08 November 2012, vol.253, pp.27
- CCCXXX. **MULTİPL SKLEROZ HASTALARININ KLİNİK BAŞLANGIÇ SEMPTOMLARININ HASTALARIN KLİNİK VE DEMOGRAFİK ÖZELLİKLERİYLE OLAN İLİŞKİSİ**
ŞEN S., TERZİ M., CANBAZ S., ÇAĞLAR F., ONAR M. K.
48. ULUSAL NÖROLOJİ KONGRESİ, Turkey, 16 - 22 November 2012
- CCCXXXI. **TÜRKÇE MULTİPLE SKLEROZ YÜRÜYÜŞ ÖLÇEĞİ(MSWs-12V2T) : ORİJİNALİ İLE AYNI ÖLÇÜM MÜDÜR?**
TAMAM Y., TERZİ M., DİB H., HOBART J.
48. ULUSAL NÖROLOJİ KONGRESİ, Turkey, 16 - 22 November 2012
- CCCXXXII. **Targetin thalamic tremor cells in deep brain stimulation for multiple sclerosis induced complex tremor'**
KOCABIÇAK E., TERZİ M., TEMEL Y.
20. Congress of the European Society for Stereotactic and Functional Neurosurgery, 26 - 28 September 2012
- :CCXXXIII. **Radikülopatili Hastalarda Huzursuz Bacak Sendromu ve Yaşam Kalitesinin Değerlendirilmesi**
KOCABIÇAK E., TERZİ M., akpınar k., paksoy k., MARANGOZ A. H., KURUOĞLU E., AYDIN K., İYİĞÜN Ö. L., ÇOKLUK C.
Türk Nöroşirürji Derneği,26. Bilimsel Kongresi, Turkey, 20 - 24 April 2012
- :CCXXXIV. **Türkiye’de Multipl Skleroz Hastalarında Serum JCV Antikor Prevelansının Belirlendiği Gözlemsel Çalışma**
ERAKSOY M., AĞAN YILDIRIM K., AK F., ANLAR Ö., AYDIN GÜNGÖR H., BALCI B. P., BOZ C., ÇELİK Y., DEMİRKAYA Ş., DİB H., et al.
47. Ulusal Nöroloji Kongresi, Antalya, Turkey, 25 November - 01 December 2011
- CCCXXXV. **Evaluation of event related potentials in vitamin B12 deficient patients with functional cognitive deterioration**
AKGÜN H., KARADAŞ Ö., ÖZ O., TERZİ M., ULAŞ Ü. H., BEK S., DEMİRKAYA Ş., ODABAŞI Z.
JOURNAL OF NEUROLOGY (ENS 2011), 01 January 2011, vol.258, pp.179
- :CCXXXVI. **Evaluation of Anger Anger Expression Style and Mood Profiles inTension Type Headache**
AKGÜN H., KARADAŞ Ö., ÖZ O., TERZİ M., ULAŞ Ü. H., BEK S., DEMİRKAYA Ş., ODABAŞI Z.
NEUROLOGY (AAN 2011), 01 January 2011, vol.76, pp.202
- CCXXXVII. **Methyl prednisolone responsive myeloradiculopathy associated with EBV infection**
AKGÜN H., KARADAŞ Ö., ÖZ O., TERZİ M., ULAŞ Ü. H., BEK S., DEMİRKAYA Ş., ODABAŞI Z.
JOURNAL OF NEUROLOGY (ENS 2011), 01 January 2011, vol.258, pp.242-243
- :CXXXVIII. **Isaacs syndrome clinical and electrophysiological response to Botulinum toxin type A**
AKGÜN H., KARADAŞ Ö., ÖZ O., TERZİ M., ULAŞ Ü. H., BEK S., DEMİRKAYA Ş., ODABAŞI Z.
JOURNAL OF NEUROLOGY (ENS 2011), 01 January 2011, vol.258, pp.247
- :CCXXXIX. **Do polymorphisms at the CD14 promotor gene and soluble CD14 levels effect biological response to IFN therapy in Multiple Sclerosis**
KURNE A., SAYAT G., SAÇKESEN C., BİRBEN E., AYDIN Ö. F., TERZİ M., KARABUDAK R.
10th International Congress of Neuroimmunology., SITGES, Spain, 26 - 30 October 2010
- CCCXL. **Do polymorphism at the CD14 promotor gene and soluble CD14 levels effect biological response to IFNbeta therapy in multiple sclerosis?**
KURNE A., SAYAT G., AYDIN Ö. F., SAÇKESEN C., BİRBEN E., TERZİ M., KARABUDAK R.
10th International Congress of Neuroimmunology, 26 - 30 October 2010
- CCCXLI. **Tumefactive multiple sclerosis lesions: demographic, clinical, radiological characteristics**
ALTINTAŞ A., PETEK B., IŞIK N., TERZİ M., BÖLÜKBAŞI O., TAVŞANLI M., SAİP S., BOZ C., AYDIN T., ARICI O., et al.

26rd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, 10 - 12 October 2010

- CCCXLII. **Eye-of-tiger sign in multiple sclerosis: a case report**
AYGÜN D., TERZİ M., GÜNGÖR İ. L., ONAR M. K.
14th Congress of the European Federation of Neurological Societies, 26 - 28 September 2010
- CCCXLIII. **Decompression surgery in trigeminal neuralgia caused by basilar artery dolicoectasia**
AKGÜN H., KARADAŞ Ö., ÖZ O., TERZİ M., ULAŞ Ü. H., BEK S., DEMİRKAYA Ş., ODABAŞI Z.
EUROPEAN JOURNAL OF NEUROLOGY (EFNS 2010), 01 January 2010, vol.17, pp.264
- CCCXLIV. **Comparison of duloxetine and pregabalin treatments in neuropathic pain**
AKGÜN H., KARADAŞ Ö., ÖZ O., TERZİ M., ULAŞ Ü. H., BEK S., DEMİRKAYA Ş., ODABAŞI Z.
EUROPEAN JOURNAL OF NEUROLOGY (EFNS 2010), 01 January 2010, vol.17, pp.262
- CCCXLV. **Heteronim Hemianopsi Kliniği ile Başlangıç Gösteren Hipofiz Adenomu**
KORKMAZ M., KARADAŞ Ö., ÖZTÜRK B., AKGÜN H., TERZİ M., ODABAŞI Z.
45.ulusal nöroloji kongresi, Antalya, Turkey, 10 - 15 November 2009, vol.15
- CCCXLVI. **Tedaviye Dirençli Epileptik Nöbetleri Olan Multiple Skleroz Olgusu**
AKDEMİR N., İNCE H., AKPINAR K., TERZİ M., TÜRKER H.
45. Ulusal Nöroloji Kongresi, Turkey, 10 - 15 November 2009
- CCCXLVII. **Efficacy, safety and tolerability of natalizumab in Turkish multiple sclerosis patients with high disease activity: a prospective, multicentre study**
ERAKSOY M., AKMAN DEMİR G., AGAN K., SAİP S., TÜTÜNCÜ M., TURAN Ö. F., TAŞKAPILIOĞLU Ö., BOZ C., TERZİ M., ONAR M. K., et al.
19th World Congress of Neurology, 24 - 30 October 2009
- :CCXLVIII. **CSF oligoclonal band as a marker for prognosis in Multiple Sclerosis**
DEMİRKAYA Ş., TERZİ M., GENÇ G., KAŞIKCI G., ODABAŞI Z.
19th World Congress of Neurology, 24 - 30 October 2009
- CCCXLIX. **Is there a correlation between evoked potentials and clinical findings in Multiple Sclerosis?**
DEMİRKAYA Ş., TERZİ M., GENÇ G., BEK S., ODABAŞI Z.
19th World Congress of Neurology, 24 - 30 October 2009, pp.216-217
- CCCL. **Tedaviye Dirençli Epileptik Nöbetleri Olan Multipl Skleroz Olgusu**
AKDEMİR N., İNCE N., AKPINAR K., TERZİ M., TÜRKER H.
Tedaviye Dirençli Epileptik Nöbetleri Olan Multipl Skleroz Olgusu, Turkey, 10 - 15 October 2009
- CCCLI. **Multiple sclerosis and vitamin B12 metabolism**
DEMİRKAYA Ş., TERZİ M., GENÇ G., KAŞIKCI T., ODABAŞI Z.
25th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, 9 - 12 September 2009
- CCCLII. **Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis**
DEMİRKAYA Ş., TERZİ M., GENÇ G., HAMAMCIOĞLU K., ODABAŞI Z.
25th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, 9 - 12 September 2009, pp.200
- CCCLIII. **Evoked potentials in multiple sclerosis**
DEMİRKAYA Ş., TERZİ M., GENÇ G., BEK S., ODABAŞI Z.
25th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, 9 - 12 September 2009
- CCCLIV. **Any realltion between multiple sclerosis and bone metabolism?**
TERZİ M., TERZİ T., TANDER N. B., CANTÜRK F., ONAR M. K.
25th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, 9 - 12 September 2009, pp.166
- CCCLV. **Factors associated with osteoporosis in patients with multiple sclerosis**
TERZİ T., TANDER N. B., TERZİ M., ALİYAZICIOĞLU Y., ONAR M. K., CANTÜRK F.
5th World Congress of the International Society of Physical and Rehabilitation Medicine, 13 - 17 June 2009
- CCCLVI. **Parkinsonizmle Prezente Olan Karaciğer Sirozu İki Olgu Sunumu**

- TÜRKEL Y., TERZİ M., YAZICI T., SANDIKÇI U., CENGİZ N.
44.Ulusal Nöroloji Kongresi, Antalya, Turkey, 11 - 15 November 2008
- CCCLVII. **Santral Sinir Sistemi Tutulumu Olan ve Bilateral Oftalmopleji Kliniği ile Prezente Olan Mukormikoz Olgusu Olgu Sunumu**
TÜRKEL Y., TERZİ M., YAZICI T., CENGİZ N.
44.Ulusal Nöroloji Kongresi, Antalya, Turkey, 11 - 15 November 2008
- CCCLVIII. **Mononöritis Multipleks Kliniği İle Prezente Olan Sjögren Sendromu Olgu Sunumu**
TERZİ M., CENGİZ N., TÜRKER H., TÜRKEL Y., YAZICI T., SANDIKÇI U., ONAR M. K.
44. Ulusal Nöroloji Kongresi, Antalya, Turkey, 11 - 15 November 2008
- CCCLIX. **Motor Nöron Hastalığını Taklit Eden Yaygın İdiopatik İskelet Hiperostozu DISH Olgusu Olgu Sunumu**
TÜRKEL Y., TERZİ M., YAZICI T., CENGİZ N., TUNALI G.
44.Ulusal Nöroloji Kongresi, Antalya, Turkey, 11 - 15 November 2008
- CCCLX. **Mononöritis Multipleks Kliniği ile Prezante Olan Sjögren Sendromu: Olgu Sunumu**
TERZİ M., TÜRKEL Y., CENGİZ N., TÜRKER H., YAZICI T., SANDIKÇI U., ONAR M. K.
Mononöritis Multipleks Kliniği ile Prezante Olan Sjögren Sendromu: Olgu Sunumu, Turkey, 11 - 16 October 2008
- CCCLXI. **Santral Sinir Sistemi Tutulumu İle Prezente Olan Sjögren Sendromu Olgu Sunumu**
TÜRKEL Y., TERZİ M., TERZİ T.
43.Ulusal Nöroloji Kongresi, Antalya, Turkey, 10 - 15 November 2007
- CCCLXII. **The relationship between multiple sclerosis and other autoimmune diseases**
ACAR P., TURGUT S., BADAĞ E., DEMİRCİ T., UYANIK S., EVRAN S., İSKENDER Z., TERZİ M., KURNE A., ONAR M. K., et al.
23rd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, 11 - 14 October 2007
- CCCLXIII. **Tumefactive demyelinating disease is immunologically different from multiple sclerosis**
BOZ C., GAZİOĞLU S., TERZİ M.
23rd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, 11 - 14 October 2007
- CCCLXIV. **Subakut Kombine Dejenerasyon Tanısı Alan 9 Olgunun Klinik ve Demografik Özellikleri**
TERZİ M., TÜRKER H., GÜNGÖR İ. L., YAZICI D., ONAR M. K.
Subakut Kombine Dejenerasyon Tanısı Alan 9 Olgunun Klinik ve Demografik Özellikleri, Turkey, 10 - 15 October 2007
- CCCLXV. **Periferal Nöropati ile Prezante Olan Anti Yo (+) Over Karsinomu: Olgu Sunumu**
TERZİ M., TÜRKER H., AKKURT A., YAZICI D., ONAR M. K.
Periferal Nöropati ile Prezante Olan Anti Yo (+) Over Karsinomu: Olgu Sunumu, Turkey, 10 - 15 October 2007
- CCCLXVI. **Nörobeğçette Klinik, Radyolojik ve Demografik Özellikler**
TERZİ M., GÜNGÖR İ. L., CENGİZ N., YÖN S., TÜRKER H., ONAR M. K.
Nörobeğçette Klinik, Radyolojik ve Demografik Özellikler, Turkey, 10 - 15 October 2007
- CCCLXVII. **Evaluation Of Multiple Sclerosis Lesions With Diffusion Weighted Imaging**
İNCESU L., ATALAY K., DİREN B. H., AKSÖZ T., ÖZMEN Z., AKTAŞ F., TERZİ M.
Esnr 06 European Society Of Neuroradiology 31.Th Congress Advanced Courses, 13 - 16 September 2006
- CCCLXVIII. **Evaluation of multiple sclerosis lesions with diffusion weighted imaging**
İNCESU L., ATALAY K., DİREN B., AKSÖZ T., ÖZMEN Z., KÖKÇÜ F., TERZİ M.
31th European Society of Neuroradiology Congress, 13 - 16 September 2006
- CCCLXIX. **A comparative study of evoked potentials and EMG in Turkish patients with Multiple sclerosis and Neurobehçet's syndrome**
TÜRKER H., BAYRAK A. O., TERZİ M., CENGİZ N., ONAR M. K.
A comparative study of evoked potentials and EMG in Turkish patients with Multiple sclerosis and Neurobehçet's syndrome, Turkey, 2 - 07 July 2006
- CCCLXX. **A comparative study of evoked potentials and EMG in Turkish patients with multiple sclerosis and neurobehçet's syndrome**
TÜRKER H., TERZİ M., BAYRAK A. O., CENGİZ N., ONAR M. K.

- XIth international congress on neuromuscular diseases, 2 - 07 July 2006
- CCCLXXI. **A comparative study of evoked potentials and EMG in Turkish patients with Multiple Sclerosis and Neurobehcet's Syndrome**
Tuerker H., Terzi M., Bayrak O., Cengiz N., Onar M.
11th International Congress on Neuromuscular Diseases, İstanbul, Turkey, 2 - 07 July 2006, vol.16
- CCCLXXII. **Kluver-Bucy Sendromu**
İNCESU L., YAZMURADOV T., ASLAN K., TERZİ M., ŞAHİN H. A.
TMRD TÜRK MANYETİK REZONANS DERNEĞİ IX. Ulusal Manyetik Rezonans Derneği, Turkey, 25 - 27 May 2006
- CCCLXXIII. **Multipl skleroz plakları ile yaşlanmaya bağlı beyaz cevherde görülen hiperintens odakların ayrımında difüzyon ağırlıklı görüntülemenin yeri**
ATALAY K., DİREN H. B., AKSÖZ T., İNCESU L., ÖZMEN Z., ASLAN H. S., TERZİ M.
26 . Ulusal Radyoloji Kongresi, Turkey, 26 - 30 October 2005
- CCCLXXIV. **CSF total tau Protein Level and it Relation with Diffusion MRI in Multiple Sclerosis Patients**
TERZİ M., ONAR M. K., BİRİNCİ A., ATALAY K., İNCESU L.
21rd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, 28 September - 01 October 2005
- CCCLXXV. **Cognitive impairment in fibromyalgia patients without depression**
Bilgici A., Terzi M., Akdeniz O., Sahin H., Guz H.
Annual European Congress of Rheumatology, Vienna, Austria, 8 - 11 June 2005, vol.64, pp.346
- CCCLXXVI. **Esansiyel Tremorda Nöropsikolojik Profil ile Bölgesel Kan Akımı İlişkisi**
TERZİ M., ŞAHİN H. A., UÇAK SEMİRGİN S., YAPICI O., BAŞOĞLU T., ONAR M. K.
38. Ulusal Nöroloji Kongresi, Turkey, 19 - 23 October 2002

Supported Projects

Terzi M., Project Supported by Higher Education Institutions, Mobil Elektroensefalogram Cihazı, 2022 - Continues

Şen S., Terzi M., Other International Funding Programs, TEKRARLAYAN- DÜZELEN MULTİPL SKLEROZ TEDAVİSİ İÇİN 10 İLA 17 YAŞINDAKİ PEDİATRİK GÖNÜLLÜLERDE BG00012 VE BIIB017'xxNİN ETKİLİLİK VE GÜVENLİLİĞİNİN DEĞERLENDİRİLDİĞİ RANDOMİZE, ÇİFT KÖR, ÇİFT SAĞIR,PLASEBO KONTROLLÜ, 3 KOLLU, PARALEL GRUPLU ÇALIŞMA, 2019 - Continues

Terzi M., Other International Funding Programs, MN39889, 2018 - Continues

Terzi M., Other International Funding Programs, TERIS- Multi-center, randomized, double-blinded study of Teriflunomide in radiologically isolated syndrome (RIS), 2018 - Continues

Terzi M., Other International Funding Programs, RAPTOR- RAP-CS-01, 2018 - Continues

Terzi M., MD1003, 2018 - Continues

Terzi M., Other International Funding Programs, MA30143 ENSEMBLE, 2017 - Continues

Terzi M., Other International Funding Programs, COMB157G2301, 2017 - Continues

Terzi M., Other International Funding Programs, TERİFACT, 2016 - Continues

Terzi M., Other International Funding Programs, CASTİNG MA30005, 2016 - Continues

Terzi M., Other International Funding Programs, CD IA MEDİ 551 1155, 2015 - Continues

Şen S., Terzi M., Other International Funding Programs, CFTY720D2311, 2015 - Continues

Aydın F., Terzi M., Other International Funding Programs, BAF312A2304 Murat Terzi Musa Kazım Onar Sedat Şen Özlem Eşki Yücel Necdet Bolat Yankı Şahin Onur Yıldız Fatma Aydın Sekonder progresif multipl sklerozu olan hastalarda Siponimod un BAF312 etkililik ve güvenliliğinin değerlendirildiği çok merkezli randomize çift kör paralel gruplu plasebo kontrollü değişken tedavi süreli bir çalışma, 2013 - Continues

Terzi M., Other International Funding Programs, CBAF312A2304, 2013 - Continues

Terzi M., Other International Funding Programs, WA21093, 2012 - Continues

Terzi M., Other International Funding Programs, Protocol ID number: WA21093, 2012 - Continues

Terzi M., Multipl skleroz hastalığının orta Karadeniz bölgesindeki prevalansı Ondokuz Mayıs Üniversitesi bilisel araştırma projesi proje no PYO TIP 1904 10 031 Proje Sorumlu Araştırmacısı 2010, Continues

Terzi M., Multipl skleroz olgularında vitamin D reseptörü ve yatkınlık genlerinin polimorfik etkilerinin incelenmesi ve huzursuz bacak sendromu sıklığı Ondokuz Mayıs Üniversitesi bilisel araştırma projesi proje no PYO TIP 1901 11 028 Proje Sorumlu Araştırmacısı 2011, Continues

Kılıç S., Terzi M., Project Supported by Higher Education Institutions, Multipl Skleroz Tanılı Kadınlarda Pelvik Taban Kas Eğitimi ve Stabilizasyon Eğitiminin Alt Üriner Sistem Semptomları Üzerine Etkisi, 2023 - 2025

Terzi M., Project Supported by Higher Education Institutions, Ergenlerde Sorunlu İnternet Kullanımı ile Dikkat, Zamanlama ,Hiperaktivite ve Dürtüsellik Düzeyinin İlişkisinin Moxo Yetişkinlere Yönelik Çeldirici Sürekli Performans Testi ile Değerlendirilmesi, 2021 - 2023

Şen S., Terzi M., Other International Funding Programs, 800MS301, 2019 - 2022

Terzi M., Other International Funding Programs, CFTY720D2311_0133_DSL, 2015 - 2022

Terzi M., Project Supported by Higher Education Institutions, Multipl Skleroz Patogenezinin Farklı Basamaklarında HLA-DQB1 Ve HLA-DRB1 Gen Transkriptlerini Hedefleyen Mikro-RNA'ların Araştırılması, 2020 - 2021

Avcı B., Bilge S. S., Terzi M., Bozkurt A., Önger M. E., Project Supported by Higher Education Institutions, Farklı deneysel Multiple Skleroz (Allerjik ensefalopati) modellerinde JAK/STAT yolak inhibitörlerinin etkilerinin araştırılması, 2019 - 2021

Terzi M., Other International Funding Programs, MA300005 Roche, 2016 - 2021

Terzi M., Other International Funding Programs, ECU -NMO-302 Alexion 23/09/2014, 2014 - 2021

Terzi M., Nisbet C., Nisbet H. Ö., Project Supported by Higher Education Institutions, Deneysel Multipl Skleroz Benzeri Modelde (MOG uyarılı EAE) Arı Zehrinin Proflaktik ve İnterferon-Beta ile Konbine Kullanımındaki Etkinliğinin Araştırılması, 2018 - 2019

Terzi M., Other International Funding Programs, REFINE STUDY CFTY720DTR06, 2017 - 2019

Terzi M., Other International Funding Programs, ECU NMO 301, 2014 - 2018

Terzi M., Other International Funding Programs, EMR700568 012, 2014 - 2018

Terzi M., Other International Funding Programs, SA 309JG, 2016 - 2017

Terzi M., Other International Funding Programs, 109MS202, 2015 - 2016

Terzi M., Other International Funding Programs, ECU MG 301, 2015 - 2016

Terzi M., Other International Funding Programs, MT 1303 E05, 2014 - 2016

Terzi M., Other International Funding Programs, CFTT720D2306E1, 2014 - 2015

Güngör İ. L., Terzi M., GÜNGÖR İ., Other International Funding Programs, FTY 720 FAZ III KLİNİK ÇALIŞMA, 2011 - 2015

Terzi M., Other International Funding Programs, CFTT720D2399, 2011 - 2015

Terzi M., EFC10531 TOWER, 2009 - 2015

Terzi M., Other International Funding Programs, EFC 10531 TOWER FAZ III KLİNİK ÇALIŞMA, 2009 - 2012

Memberships / Tasks in Scientific Organizations

Türk Nöroloji Derneği, Vice President, 2022 - Continues, Turkey

Congress and Symposium Activities

4th International Turkic World Congres of Multiple Sclerosis, Attendee, Samarkand, Uzbekistan, 2022

12.Klinik Nöroimmunoloji Sempozyumu, Invited Speaker, Antalya, Turkey, 2022

Uluslararası Katılımlı V.Hemşireliği Güçlendirme Sempozyumu, Attendee, Samsun, Turkey, 2022

Doktora Öğretimi Değerlendirme Çalıştay, Attendee, Samsun, Turkey, 2022

57.Ulusal Nöroloji Kongresi, Session Moderator, Antalya, Turkey, 2021

III.MS Hemşire Okulu, Session Moderator, Şanlıurfa, Turkey, 2021

9.Nöroradyoloji Okulu, Invited Speaker, Lefkosia, Cyprus (Gkry), 2021

9.Nöroradyoloji Okulu, Attendee, Lefkosia, Cyprus (Gkry), 2021

Conference Dedicated to World Multiple Sclerosis Day, Attendee, Baku, Azerbaijan, 2021

III.Klinik Nöroimmunoloji Akademisi, Invited Speaker, Trabzon, Turkey, 2021

15.Uludağ Nöroloji Günleri, Attendee, Bursa, Turkey, 2020
15.Uludağ Nöroloji Günleri, Invited Speaker, Bursa, Turkey, 2020
2.Uluslararası Multipl Skleroz Kongresi, Invited Speaker, Antalya, Turkey, 2020
İstanbul MS Days, Attendee, İstanbul, Turkey, 2019
4.Multipl Sklerozda Fizyoterapi ve Nörorehabilitasyon Sempozyumu, Invited Speaker, Kütahya, Turkey, 2019
Multipl Skleroz Hasta Bakım Sempozyumu, Invited Speaker, Mardin, Turkey, 2019
III.Multipl Sklerozda Fiziksel Engelliliğin Ölçümü Sempozyumu, Invited Speaker, İzmir, Turkey, 2019
14.Uludağ Nöroloji Günleri, Invited Speaker, Bursa, Turkey, 2019
54.Ulusal Nöroloji Kongresi, Invited Speaker, Antalya, Turkey, 2018
3.Multipl Sklerozda Kognisyon Sempozyumu, Attendee, İzmir, Turkey, 2018
54.Ulusal Nöroloji Kongresi, Invited Speaker, Antalya, Turkey, 2018
İstanbul MS DAYS V, Attendee, Lefkosia, Cyprus (Gkry), 2018
13.Çukurova Nöroloji Günleri, Invited Speaker, Gaziantep, Turkey, 2018
13.Çukurova Nöroloji Günleri, Invited Speaker, Gaziantep, Turkey, 2018
MS MASTER Demiyelinizan Hastalıklarda Ayırıcı Tanı, Session Moderator, Nevşehir, Turkey, 2018
ECOMS 2018, Invited Speaker, Shtip, Macedonia, 2018
7.Nöroradyoloji Okulu, Invited Speaker, Ankara, Turkey, 2018
2.Multipl Sklerozda Fiziksel Engelliliğin Ölçümü Sempozyumu, Invited Speaker, İzmir, Turkey, 2018
3.Multipl Sklerozda Fizyoterapi ve Nörorehabilitasyon Sempozyumu, Attendee, İzmir, Turkey, 2018
Klinik Nöroimmunoloji Akademisi, Attendee, Trabzon, Turkey, 2018
Klinik Nöroimmunoloji Akademisi, Invited Speaker, Trabzon, Turkey, 2018
10.Klinik Nöroimmunoloji Sempozyumu, Attendee, Lefkosia, Cyprus (Gkry), 2018
Multipl Skleroz Hemşire Sempozyumu, Invited Speaker, Gaziantep, Turkey, 2018
13.Uludağ Nöroloji Günleri, Attendee, Bursa, Turkey, 2018
53.Ulusal Nöroloji Kongresi, Invited Speaker, Antalya, Turkey, 2017
12.Çukurova Nöroloji Günleri, Attendee, Kahramanmaraş, Turkey, 2017
8.Nöroimmunoloji Okulu, Invited Speaker, Lefkoşa, Cyprus (Kkct), 2017
52.Ulusal Nöroloji Kongresi, Invited Speaker, Antalya, Turkey, 2016
VI.Temel İmmünoloji ve Nöroimmunoloji Öğrenci Okulu, Invited Speaker, Samsun, Turkey, 2016
1.Multipl Sklerozda Fizyoterapi ve Rehabilitasyon Sempozyumu, Attendee, İzmir, Turkey, 2016
51.Ulusal Nöroloji Kongresi, Invited Speaker, Antalya, Turkey, 2015
10.Çukurova Nöroloji Günleri, Attendee, Adana, Turkey, 2015
İnteraktif Multipl Skleroz ve Nörofizyoloji Sempozyumu, Attendee, Trabzon, Turkey, 2015
50.Ulusal Nöroloji Kongresi, Invited Speaker, Antalya, Turkey, 2014
ECTRIMS 2011, Attendee, Amsterdam, Netherlands, 2011
Uluslararası Nöroimmunoloji Sempozyumu, Attendee, Nevşehir, Turkey, 2011
1.Ulusal Alzheimer Kongresi, Attendee, İstanbul, Turkey, 2011
8.Nöropatik Ağrı Sempozyumu, Attendee, Antalya, Turkey, 2011
II.Ulusal Başağrısı Sempozyumu, Attendee, Lefkoşa, Cyprus (Kkct), 2011
6.Klinik Nöroimmunoloji Sempozyumu, Attendee, Antalya, Turkey, 2010
2.MS Bahar Sempozyumu, Invited Speaker, Antalya, Turkey, 2010
45.Ulusal Nöroloji Kongresi, Invited Speaker, Antalya, Turkey, 2009
45.Ulusal Nöroloji Kongresi, Invited Speaker, Antalya, Turkey, 2009
I.Kafkas Nörolojik Bilimler Kongresi, Invited Speaker, Erzurum, Turkey, 2009
1.MS Bahar Sempozyumu, Attendee, Antalya, Turkey, 2009
ECTRIMS 2007, Attendee, Praha, Czech Republic, 2007
5.Klinik Nöroimmunoloji Sempozyumu, Attendee, Antalya, Turkey, 2007
5.Klinik Nöroimmunoloji Sempozyumu, Attendee, Antalya, Turkey, 2007
4.Nöropatik Ağrı Sempozyumu, Attendee, Antalya, Turkey, 2007
4.Nöropatik Ağrı Sempozyumu, Attendee, Antalya, Turkey, 2007
42.Ulusal Nöroloji Kongresi, Attendee, Antalya, Turkey, 2006

ECTRIMS 2006, Attendee, Madrid, Spain, 2006
3.Nöroimmunoloji Okulu, Attendee, Antalya, Turkey, 2006
41.Ulusal Nöroloji Kongresi, Attendee, İstanbul, Turkey, 2005
ECTRIMS 2005, Attendee, Serrai, Greece, 2005
IV.Nöroimmunoloji Sempozyumu, Attendee, Bursa, Turkey, 2005
40.Ulusal Nöroloji Kongresi, Attendee, Antalya, Turkey, 2004
21.Ulusal Klinik Nörofizyoloji EEG-EMG Kongresi, Attendee, Samsun, Turkey, 2004
Temel ve Klinik Nöroimmunoloji Sempozyumu III, Attendee, Antalya, Turkey, 2004
1.Ulusal Kognitif Nöroloji Sempozyumu, Attendee, Antalya, Turkey, 2004
39.Ulusal Nöroloji Kongresi, Attendee, Antalya, Turkey, 2003
30.Ulusal Nöroloji Kongresi, Attendee, Antalya, Turkey, 2003
XVII. Ulusal İmmunoloji Kongresi, Attendee, Aydın, Turkey, 2003
20.Ulusal Klinik Nörofizyoloji EEG-EMG Kongresi, Attendee, Gaziantep, Turkey, 2003
II.Klinik Nöroimmunoloji Sempozyumu, Attendee, Denizli, Turkey, 2003
Klinik Nutrisyon Temel Eğitim Kursu, Attendee, Samsun, Turkey, 2003
38.Ulusal Nöroloji Kongresi, Attendee, Antalya, Turkey, 2002
3.Ulusal Epilepsi Kongresi, Attendee, Trabzon, Turkey, 2002
37.Ulusal Nöroloji Kongresi, Invited Speaker, Antalya, Turkey, 2001
Baş Ağrısına Multidisipliner Yaklaşım Sempozyumu, Attendee, Samsun, Turkey, 2001

Awards

Uzdil Z., Kaya S., Terzi M., Sökülmez Kaya P., Dündar E., Bilim - Sanat Ödülleri, Beslenme Eğitimi Ve Araştırma Vakfı , June 2022
Terzi M., Sözel İkincilik Ödülü, Türk Nöroloji Derneği, November 2021
Terzi M., Poster Birincilik Ödülü, Türk Nöroloji Derneği, November 2021
Terzi M., Klinik Nörolojik Bilimler Alanında Teşvik Ödülü, Türk Nöroloji Derneği, January 2014
Terzi M., Türk Nöroloji Derneği Yeterlilik, Türk Nöroloji Derneği, January 2011
Terzi M., Türk Nöroloji Derneği Yeterlilik Ödülü, Türk Nöroloji Derneği, January 2008
Terzi M., Nöroloji Yeterlik Belgesi (Board), Türk Nöroloji Derneği, January 2004